Method for determining skin stress or skin ageing in vitro

Abstract

The invention relates to a method for determining skin stress and/or skin ageing in humans or animals in vitro, test kits and biochips for determining skin stress and/or skin ageing, and the use of proteins, mRNA molecules or fragments of proteins or mRNA molecules as skin stress and/or ageing markers. The invention also relates to a test method for demonstrating the effectiveness of cosmetic or pharmaceutical active ingredients against skin stress and/or skin ageing, a screening method for identifying cosmetic or pharmaceutical active ingredients against skin stress and/or skin ageing, and a method for producing a cosmetic and/or pharmaceutical preparation against skin stress and/or skin ageing. The invention further relates to a cosmetic or pharmaceutical preparation against skin stress and/or skin ageing.

Description

[0001] This invention, relates to a process for the in vitro determination of skin stress and/or ageing of the skin in human beings or animals, to test kits and biochips for determining the skin stress and/or ageing of the skin and to the use of proteins, mRNA molecules or fragments of proteins or mRNA molecules as markers for skin stress and/or ageing of the skin; also to a test for demonstrating the effectiveness of cosmetic or pharmaceutical active substances against skin stress and/or ageing of the skin and to a screening process for identifying cosmetic or pharmaceutical active substances against skin stress and/or ageing of the skin and to a process for the production of a cosmetic or pharmaceutical preparation against skin stress and/or ageing of the skin.

[0002] Each living cell is capable of reacting to signals from its environment. The reactions of the cells are achieved through the ordered regulation of gene expression so that the metabolism of cells is not static but very dynamic. According to the most recent estimates, the human genome comprises ca. 140,000 genes. However, of this immense supply of information, each cell uses only a small part specific to it for the synthesis of proteins which is reflected in the gene expression pattern. Exogenous signals are received by cells and lead—partly through complex signal transduction cascades—to changes in the gene expression pattern. In this way, each cell reacts to signals from its environment by adaptation of its metabolism.

[0003] For example, the skin cells sense the high-energy radiation of the sun and react by reversing their RNA and protein synthesis rates. After a stress stimulus (for example sunlight), some molecules are synthesized to an increasing extent (for example MMP-1) while others are produced to a lesser extent (for example collagen α1 (I)). In addition, in many of the synthesis processes, no significant change will occur (for example TIMP-1).

[0004] The skin is the largest organ of the human body. It is an organ of very complex structure which consists of a large number of different cell types and which forms the interface between the body and the environment. It follows from this that the cells of the skin are particularly exposed to exogenous physical and chemical environmental signals and, accordingly, continuously regulate their gene expression. The analysis of gene expression in the skin is therefore crucially important to understanding reactions of the skin to exogenous stimuli.

[0005] The macroscopic phenomena of ageing skin are based on the one hand on intrinsic or chronological ageing (skin ageing) and, on the other hand, on extrinsic ageing by environmental stress (skin stress). The ability of living cells to react to their environment changes with time—ageing processes leading to senescence and ultimately to cell death take place. The visible signs of old skin should be interpreted as the integral of intrinsic and extrinsic ageing (for example by sunlight), the events of extrinsic ageing accumulating in the skin over a prolonged period.

[0006] A key feature of the skin is that, with increasing age, the cells lose their ability to maintain the homeostasis of the organ. Which molecular mechanisms are behind this development has hitherto been largely unclear.

[0007] Effective anti-ageing products show their effect on a broad spectrum of molecular phenomena of skin ageing. However, only a few molecular events of skin ageing have hitherto been described which could be used as a target for cosmetic anti-ageing products. The identification of new ageing markers makes it possible to understand the complex processes of intrinsic and extrinsic ageing of the skin and their causal relationships. Only with this knowledge can new concepts be developed for cosmetic anti-ageing products which exert their effect on the broad spectrum of extrinsic and intrinsic ageing processes in the skin.

[0008] Each cell type of the skin expresses ca. 15,000 different genes and synthesizes a corresponding number of proteins therefrom. However, which of these genes play a role in the ageing of the skin has hitherto been largely unclear.

[0009] The skin consists of several different cell types (fibroblasts, keratinocytes in various states of differentiation, melanocytes, Merkel cells, Langerhans cells, hair follicle cells, sweat gland cells, etc.) so that the complexity of genes expressed in the skin is immense. It has not yet been possible to describe this immense complexity. Nor has it yet been possible to identify from this complexity those genes which are relevant to ageing of the skin and which could serve as molecular markers for ageing of the skin.

[0010] In addition, a complicating factor is that, in living cells, mRNA molecules occur in concentrations between just a few and several hundred copies. Hitherto, the weakly expressed genes have only been accessible to analyses with great difficulty, if at all. However, these molecules can play a crucial role in ageing processes and in the homeostasis of the skin.

[0011] The totality of all the mRNA molecules which are synthesized at a certain time by a cell or a tissue is known as a “transcriptome”. Hitherto, it has not been possible to describe the complete transcriptome, i.e. the totality of all transcribed genes, of the human skin. Although gene expression can be analyzed by quantification of specific mRNA molecules (for example northern blot, RNase protection experiments), only a relatively limited number of genes can be measured by these techniques.

[0012] The anti-ageing products available on the market exert their effects on one of the few known markers of extrinsic skin ageing such as, for example, collagen synthesis, collagenase activity or collagenase inhibitors.

[0013] Understanding the complex ageing processes in the skin and identifying suitable marker proteins enables a search to be specifically made for substances or combinations of substances with a broad anti-ageing action spectrum. However, product concepts of this type have not yet been developed because many of the skin ageing markers were not known.

[0014] Previous efforts to identify ageing markers were carried out using artificial systems. WO 99/52929 (Lifespan Bioscience Inc.) and the work of Danit, L. et al. (2000), Science 287, pp. 2486-2492 describe the identification of ageing markers from isolated and then in vitro cultivated fibroblasts of the skin. The cells are no longer in their natural environment in which they divide extremely slowly, but divide relatively quickly and transpose their gene expression. Another key point is the fact that fibroblasts in the skin are exposed to the influence of adjacent skin cells which is no longer the case with isolated and in vitro cultivated cells.

[0015] Accordingly, there is a need to identify as many as possible and preferably all of the genes that are important to ageing of the skin.

[0016] Accordingly, the problem addressed by the present invention was to identify as large a number of the genes relevant to ageing of the skin and/or skin stress as possible and to provide processes for determining skin stress and/or ageing of the skin by means of the identified genes.

[0017] According to the invention, the solution to this first problem is provided by a process (1) for the in vitro identification of the genes relevant to ageing of the skin and/or to skin stress in human beings or animals which is characterized in that

[0018] a) a first mixture of genetically coded factors expressed, i.e. transcribed and optionally translated, in human or animal skin, i.e. a mixture of proteins, mRNA molecules or fragments of proteins or mRNA molecules, is isolated from young human or animal skin,

[0019] b) a second mixture of genetically coded factors expressed, i.e. transcribed and optionally translated, in human or animal skin, i.e. a mixture of proteins, mRNA molecules or fragments of proteins or mRNA molecules, is isolated from old human or animal skin,

[0020] c) the mixtures isolated in a) and b) are subjected to a serial analysis of gene expression (SAGE) so that the genes expressed to different extents (differentially) in old and young skin are identified.

[0021] The process according to the invention, like the other subjects of the invention, is preferably applied to human skin although it may also be applied to animal skin and to skin models based on human or animal skin.

[0022] The technique of “serial analysis of gene expression” (SAGE™) was used to determine the transcriptome of the skin. This technique enables all the genes expressed in the skin to be simultaneously identified and quantified. By comparing the transcriptome of young skin with the transcriptome of old skin, it is possible to differentiate between genes that are relevant and non-relevant to ageing of the skin.

[0023] Human skin from healthy female donors was used for the SAGE™ analysis. The SAGE™ analysis was carried out as described in EP-A-0 761 822 and in Velculescu, V. E. et al., 1995, Science 270, 484-487. Two SAGE™ libraries of human skin of different age groups were analyzed. The first library comes from a 29-year-old female volunteer (30048 tags) and the other library from a 69-year-old female volunteer (32840 tags). For further analysis, the two SAGE™ libraries were standardized to the average number of tags (31594 tags). The two libraries were compared with one another to identify genes with age-dependent regulation. As expected for two libraries of the same tissue type, the tag repertoire of the two skin libraries is largely similar.

[0024] The first feature to be noticed is that the library of young skin has a clear over-expression of collagens. Some collagens have several alternative poly-adenylations; the resulting tags show consistent results. For example, collagen (I) α1 is over-expressed by a factor of 4-5 in the young skin, collagen (I) α2 by a factor of 4 and collagen (III) α1 by a factor of 8. Other gene classes over-expressed in the young skin correspond to marker proteins, for example of the cytoskeleton. Thus, transgelin, desmin, actin, myosin, calponin and tropomyosin are over-represented by a factor of 6to 37.

[0025] By contrast, in the library of old skin, some keratins and other keratinocyte-specific genes are over-represented. The epidermal keratins 5, 10 and 14 strongly expressed in both libraries are represented more strongly in the old skin, for example by a factor of about 2, whereas the equally strongly expressed keratin 1 does not show this tendency. Stratifin, desmocollin, MMP2 (gelatinase) and CLSP (keratinocyte-specific calmodulin) are over-represented by a factor of 5 to 8.

[0026] Tables 1 to 4 contain a detailed list of the genes differentially expressed in old and young skin as determined by the process according to the invention, indicating

[0027] consecutive order numbers in column 1,

[0028] the tag sequence used in column 2,

[0029] the relative expression frequency determined in young skin in column 3,

[0030] the relative expression frequency determined in old skin in column 4,

[0031] the quotient of the frequencies (from column 3 and column 4) in column 5,

[0032] the significance in column 6,

[0033] the UniGene Accession Number in column 7 and

[0034] a brief description of the gene or gene product in column 8.

[0035] The quotient in column 5 indicates the strength of the differential expression, i.e. the factor by which the particular gene is expressed more strongly in young skin than in old skin or vice versa.

[0036] The particular genes or gene products are disclosed under their UniGene Accession Number in the databank of the National Center for Biotechnology Information (NCBI). This databank is accessible on-line at the following address: http://www.ncbi.nlm.nih.qov/.

[0037] In addition, the genes or gene products are directly accessible at the following internet addresses:

[0038] http://www.ncbi.nlm.nih.gov/UniGene/Hs.Home.html or

[0039] http://www.ncbi.nlm.nih.gov/qenome/quide.

[0040] All genes which are expressed differentially by a factor of at least 2 and less than 5 are listed in Table 1.

[0041] All genes which are expressed differentially by a factor of at least 5 and less than 7 are listed in Table 2.

[0042] All genes which are expressed differentially by a factor of at least 7 and less than 10 are listed in Table 3.

[0043] All genes which are expressed differentially by a factor of at least 10 are listed in Table 4.

[0044] Genes which are expressed differentially by a factor of at least 2 but to which no data bank entry could be assigned, so that they can only be identified by the tag sequence in column 2 are listed in Table 5.

[0045] Genes which are expressed differentially by a factor of at least 2 and which are defined in column 2 by their UniGene Accession Number or in column 3 by their Swissprot or TREMBL number or in column 4 by their EMBL/Genbank number are listed in Table 6.

[0046] Genes which are expressed differentially by a factor of 2.89 to 11.10 are listed in Table 7. The assignment of the tags to the genes defined by their Unigene Accession Number in column 6 was done by manual annotation.

[0047] The following data banks were used for the annotation:

[0048] 1. Unigene—30.10.01 version with the following data bank entries:

[0049] a. known genes from GenBank (12.10.01)

[0050] b. ESTs from dbEST (19.10.01)

[0051] 2. mRNA—version released on 17.10.01

[0052] The data banks were downloaded from the NCBI, formatted for a local version of the BLAST program (also NCBI) and compared for identical hits with the tags detected in the SAGE analysis.

[0053] The genes/clones found were checked for redundancy and finished as indicated below:

[0054] 1. tag sequences with several different hits: evaluation as non-annotatable

[0055] 2. tag sequences with double or several identical hits: elimination of the hits situated furthest away from the poly-A-tail.

[0056] The results from the Unigene databank were evaluated first and then compared with the results from the mRNA databank. The latter do not appear in Table 7 because they can also be called off via the Unigene entries.

[0057] All the links shown in the Results Table were tested on the 30.10.2001 database documented in the following (Unigene databank release: UniGene Build #143):

[0058] Sequences Included in Unigene

[0059] Known genes are from GenBank (Oct. 12, 2001)

[0060] ESTs are from dbEST through Oct. 19, 2001

[0061] 69367 mRNAs+gene CDSs

[0062] 1147828 EST, 3′reads

[0063] 1196006 EST, 5′reads

[0064] +598081 EST, other/unknown

[0065] 3011282 total sequences in clusters

[0066] Final Number of Clusters (Sets)

[0067] 96332 sets total

[0068] 20516 sets contain at least one known gene

[0069] 95171 sets contain at least one EST

[0070] 19355 sets contain both genes and ESTs

[0071] Release Notes

[0072] The genes or gene products defined by their Swissprot or TREMBL numbers are disclosed at the following internet addresses:

[0073] http://www.ebi.ac.uk/swissprot/ or http://www.ncbi.nlm.nih.gov/.

[0074] The genes or gene products defined by their EMBL/Genbank numbers are disclosed at the following internet address:

[0075] http://www.ncbi.nlm.nih.gov/.

[0076] According to the invention, the solution to the second problem addressed by the present invention is provided by a process (2) for the in vitro determination of skin stress and/or ageing of the skin in human beings or animals, more particularly in females, which is characterized in that

[0077] a) a mixture of proteins, mRNA molecules or fragments of proteins or mRNA molecules is isolated from human or animal skin,

[0078] b) the mixture isolated is tested for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules identified as expressed differentially in old and young skin by serial analysis of gene expression (SAGE),

[0079] c) the test results from b) are compared with the expression patterns identified by serial analysis of gene expression (SAGE) and

[0080] d) the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed more strongly in old or stressed skin than in young or unstressed skin or the mixture tested in b) is assigned to young or unstressed skin if it predominantly contains proteins, mRNA molecules or fragments,of proteins or mRNA molecules which are expressed more strongly in young or unstressed skin than in old or stressed skin.

[0081] It may be sufficient in step b) of the process for determining skin stress and/or ageing of the skin to test the isolated mixture for the presence of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules identified as differentially expressed in old and young skin by serial analysis of gene expression (SAGE) if they are expressed solely in old skin or solely in young skin. In all other cases, the quantity of differentially expressed molecules must also be determined, i.e. the expression must be quantified, in step b).

[0082] In step d) of the process for determining skin stress and/or ageing of the skin, the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed more strongly in old or stressed skin than in young or unstressed skin, i.e. the mixture either contains more different compounds typically expressed in old skin than those which are typically expressed in young skin (qualitative differentiation) or more copies of compounds typically expressed in old skin than typically present in young skin (quantitative differentiation). A complementary procedure is adopted for assignment to young or unstressed skin.

[0083] A preferred embodiment of the process according to the invention for determining skin stress and/or ageing of the skin is characterized in that, in step b), the mixture isolated is tested for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules defined by their UniGene Accession Number in Tables 1 to 4, column 7; in step c), the test results from b) are compared with the relative expression frequencies shown in Tables 1 to 4, columns 3 and 4, and the expression quotients indicated in column 5; and in step d), the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least twice as strongly in old or stressed skin as in young or unstressed skin or the mixture tested in b) is assigned to young or unstressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least twice as strongly in young or unstressed skin as in old or stressed skin.

[0084] Another preferred embodiment of the process according to the invention for determining skin stress and/or ageing of the skin is characterized in that, in step b), the mixture isolated is tested for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules defined by their UniGene Accession Number in Tables 2 to 4, column 7; in step c), the test results from b) are compared with the relative expression frequencies shown in Tables 2 to 4, columns 3 and 4, and the expression quotients indicated in column 5; and in step d), the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least five times as strongly in old or stressed skin as in young or unstressed skin or the mixture tested in b) is assigned to young or unstressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least five times as strongly in young or unstressed skin as in old or stressed skin.

[0085] Another preferred embodiment of the process according to the invention for determining skin stress and/or ageing of the skin is characterized in that, in step b), the mixture isolated is tested for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules defined by their UniGene Accession Number in Tables 3 and 4, column 7; in step c), the test results from b) are compared with the relative expression frequencies shown in Tables 3 and 4, columns 3 and 4, and the expression quotients indicated in column 5; and in step d), the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least seven times as strongly in old or stressed skin as in young or unstressed skin or the mixture tested in b) is assigned to young or unstressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least seven times as strongly in young or unstressed skin as in old or stressed skin.

[0086] Another preferred embodiment of the process according to the invention for determining skin stress and/or ageing of the skin is characterized in that, in step b), the mixture isolated is tested for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules defined by their UniGene Accession Number in Table 4, column 7; in step c), the test results from b) are compared with the relative expression frequencies shown in Table 4, columns 3 and 4, and the expression quotients indicated in column 5; and in step d), the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least ten times as strongly in old or stressed skin as in young or unstressed skin or the mixture tested in b) is assigned to young or unstressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least ten times as strongly in young or unstressed skin as in old or stressed skin.

[0087] Another preferred embodiment of the process according to the invention for determining skin stress and/or ageing of the skin is characterized in that, in step b), the mixture isolated is tested for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules defined by their 11-base tag sequence in Table 5 or in Table 7, column 2; in step c), the test results from b) are compared with the relative expression frequencies shown in Table 5 or in Table 7, columns 3 and 4, and the expression quotients indicated in column 5; and in step d), the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least twice, more particularly five times, preferably seven times and more preferably ten times as strongly in old or stressed skin as in young or unstressed skin or the mixture tested in b) is assigned to young or unstressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least twice, more particularly five times, preferably seven times and more preferably ten times as strongly in young or unstressed skin as in old or stressed skin.

[0088] The condition of the skin may also be described by quantifying several markers (expression products of the genes important to skin ageing and/or skin stress) which then have to be active in a characteristic ratio to one another in order to represent young skin or in a different characteristic ratio to represent old skin.

[0089] Accordingly, the present invention also relates to a process (3) for the in vitro determination of skin stress and/or ageing of the skin in human beings or animals, more particularly in females, which is characterized in that

[0090] a) a mixture of proteins, mRNA molecules or fragments of proteins or mRNA molecules is isolated from human or animal skin,

[0091] b) in the mixture isolated, at least two of the proteins, mRNA molecules or fragments of proteins or mRNA molecules identified as important to skin ageing and/or skin stress by process (1) are quantified,

[0092] c) the expression ratios of the at least two proteins, mRNA molecules or fragments of proteins or mRNA molecules to one another are determined,

[0093] d) the expression ratios from c) are compared with the expression ratios typically present in young skin or in old skin for the molecules quantified in b), more particularly with the expression ratios shown in Tables 1 to 5, columns 3 and 4 and

[0094] e) the mixture isolated in a) is assigned to old or stressed skin if the expression ratios of the skin under analysis correspond to the expression ratios in old skin or the mixture isolated in a) is assigned to young or unstressed skin if the expression ratios of the skin under analysis correspond to the expression ratios in young skin.

[0095] In step a) of the process according to the invention for determining skin stress and/or ageing of the skin, the mixture is preferably isolated from a skin sample, more particularly from a whole skin sample or from an epidermis sample. The whole skin sample offers more comprehensive possibilities for comparison with the SAGE libraries which are similarly obtained from whole skin. By contrast, the epidermis sample is easier to obtain, for example by applying an adhesive plaster to the skin and stripping it off, as described in WO 00/10579 to the whole of which reference is hereby made.

[0096] In another embodiment of the process according to the invention for determining skin stress and/or ageing of the skin, the mixture is isolated in step a) by microdialysis. The technique of microdialysis is described, for example, in “Microdialysis: A method for measurement of local tissue metabolism”, Nielsen, P. S., Winge, K., Petersen, L. M.; Ugeskr Laeger 1999, Mar. 22, 161:12 1735-8: and in “Cutaneous microdialysis for human in vivo dermal absorption studies”, Anderson, C. et al.; Drugs Pharm. Sci., 1998, 91, 231-244; and also on-line at http://www.microdialysis.se/techniqu.htm, to the whole of which reference is hereby made. In microdialysis, a probe is typically inserted into the skin and slowly rinsed with a suitable carrier solution. After the acute reactions have abated after insertion, microdialysis yields proteins, mRNA molecules or fragments of proteins or mRNA molecules which occur in the extracellular space and which can then be isolated in vitro, for example by fractionation of the carrier liquid, and analyzed. Microdialysis is less invasive than the removal of a whole skin sample but has the disadvantage that it is limited to the isolation of compounds occurring in the extracellular space.

[0097] Another preferred embodiment of the process according to the invention for determining skin stress and/or ageing of the skin is characterized in that, in step b) in process (2), testing for the presence and optionally the quantity of at least one of the proteins or protein fragments; or, in process (3), the quantification of at least two proteins or protein fragments is carried out by a method selected from

[0098] i. one- or two-dimensional gel electrophoresis

[0099] ii. affinity chromatography

[0100] iii. protein/protein complexing in solution

[0101] iv. mass spectrometry, more particularly Matrix Assisted Laser Desorption Ionization (MALDI) and, more particularly,

[0102] v. the use of protein chips,

[0103] or suitable combinations of these methods.

[0104] These methods suitable for use in accordance with the invention are described in the overview by Akhilesh Pandey and Matthias Mann: “Proteomics to study genes and genomes”, Nature, Volume 405, Number 6788, 837-846 (2000) and the references cited therein, to the whole of which reference is hereby made.

[0105] 2D gel electrophoresis is described, for example, in L. D. Adams, Two-dimensional Gel Electrophoresis using the Isodalt System or in L. D. Adams and S. R. Gallagher, Two-dimensional Gel Electrophoresis using the O'Farrell System; both in Current Protocols in Molecular Biology (1997), Eds. F. M. Ausubel et al.), Unit 10.3.1- 10.4.13; or in 2-D Electrophoresis Manual; T. Berkelman, T. Senstedt; Amersham Pharmacia Biotech, 1998 (Order No. 80-6429-60).

[0106] The mass spectrometric characterization of the proteins or protein fragments is conducted in known manner, for example as described in the following literature references:

[0107] Methods in Molecular Biology, 1999; Vol. 112; 2-D Proteome Analysis Protocols; Editor: A. J. Link; Humana Press; Totowa; N.J.; cf. in particular Courchesne, P. L. and Patterson, S. D.; pp. 487-512.

[0108] Carr S. A. and Annan, R. S.; 1997; in: Current Protocols in Molecular Biology; Editor: Ausubel, F. M. et al.; John Wiley and Sons, Inc. 10.2.1-10.21.27.

[0109] Another preferred embodiment of the process according to the invention for determining skin stress and/or ageing of the skin is characterized in that, in step b) in process (2), testing for the presence and optionally the quantity of at least one of the mRNA molecules or mRNA molecule fragments; or, in process (3), the quantification of at least two mRNA molecules or mRNA molecule fragments is carried out by a method selected from

[0110] i. northern blots,

[0111] ii. reverse transcriptase polymerase chain reaction (RT-PCR),

[0112] iii. RNase protection experiments,

[0113] iv. dot blots,

[0114] v. cDNA sequencing,

[0115] vi. clone hybridization,

[0116] vii. differential display,

[0117] viii. subtractive hybridization,

[0118] ix. cDNA fragment fingerprinting,

[0119] x. total gene expression analysis (TOGA)

[0120] xi. serial analysis of gene expression (SAGE) and, more particularly,

[0121] xii. the use of nucleic acid chips

[0122] or suitable combinations of these methods.

[0123] These methods suitable for use in accordance with the invention are described in the overviews by Akhilesh Pandey and Matthias Mann: “Proteomics to study genes and genomes”, Nature, Volume 405, Number 6788, 837-846 (2000) and “Genomics, gene expression and DNA arrays”, Nature, Volume 405, Number 6788, 827-836 (2000) and the references cited therein, to the whole of which reference is hereby made.

[0124] The TOGA process is described in “J. Gregor Sutcliffe et al., TOGA:An automated parsing technology for analyzing expression of nearly all genes, Proceedings of the National Academy of Sciences of the United States of America (PNAS), Vol. 97, No. 5, pp. 1976-1981 (2000)”, to the whole of which reference is hereby made.

[0125] According to the invention, however, other methods known to the expert may also be used to test for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules.

[0126] Another preferred embodiment of the process according to the invention for determining skin stress and/or ageing of the skin is characterized in that step b) comprises testing for the presence and optionally the quantity of 1 to about 5,000, preferably 1 to about 1,000, more preferably about 10 to about 500, most preferably about 10 to about 250, more particularly about 10 to about 100 and most particularly about 10 to about 50 of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are defined

[0127] i. by their Unigene Accession Number in Tables 1 to 4, column 7, or

[0128] ii. by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9 or

[0129] iii. by their 11-base tag sequence in Table 5 or in Table 7, column 2.

[0130] The present invention also relates to a test kit for the in vitro determination of skin stress and/or ageing of the skin in human beings or animals comprising means for carrying out the process according to the invention for determining skin stress and/or ageing of the skin.

[0131] The present invention also relates to a biochip for the in vitro determination of skin stress and/or ageing of the skin in human beings or animals comprising

[0132] i. a firm, i.e. rigid, or flexible support and,

[0133] ii. immobilized thereon, probes which are capable of binding specifically to at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are defined by their UniGene Accession Number in Tables 1 to 4, column 7, or by their 11-base tag sequence in Table 5 or in Table 7, column 2.

[0134] A biochip is a miniaturized functional element with molecules, more particularly biomolecules, immobilized on a surface which are capable of acting as specific interaction partners. The structure of these functional elements often comprise rows and columns. They are then known as chip arrays. Since thousands of biological or biochemical functional elements can be arranged on one chip, they generally have to be made by microtechnical methods. Biological and biochemical functional elements include in particular DNA, RNA, PNA (in the case of nucleic acids and chemical derivatives thereof, single strands, triplex structures or combinations thereof, for example, may be present), saccharides, peptides, proteins (for example antibodies, antigens, receptors) and derivatives of combinatorial chemistry (for example organic molecules). Biochips generally have a two-dimensional base for coating with biologically or biochemically active materials. The bases may also be formed, for example, by walls of one or more capillaries or by channels. The prior art is represented, for example, by the following publications: Nature Genetics, Vol. 21, Supplement (entire), January 1999 (Biochips); Nature Biotechnology, Vol. 16, pp. 981-983, October 1998 (Biochips); Trends in Biotechnology, Vol. 16, pp. 301-306, July 1998 (Biochips) and the already cited overviews by Akhilesh Pandey and Matthias Mann: “Proteomics to study genes and genomes”, Nature, Volume 405, Number 6788, 837-846 (2000) and “Genomics, gene expression and DNA arrays”, Nature, Volume 405, Number 6788, 827-836 (2000) and the references cited therein, to the whole of which reference is hereby made.

[0135] A synoptic portrayal of the practical methods of using DNA chip technology can be found in the books “DNA Microarrays: A Practical Approach” (Editor: Mark Schena, 1999, Oxford University Press) and “Microarray Biochip Technology” (Editor: Mark Schena, 2000, Eaton Publishing), to the whole of which reference is hereby made.

[0136] The particularly preferred DNA chip technology in the context of the present invention is based on the ability of nucleic acids to enter into complementary base pairings. This technical principle known as hybridization has been used for years in southern blot and northern blot analysis. By comparison with these conventional methods where only a few genes are analyzed, DNA chip technology enables a few hundred to several thousand genes to be analyzed at the same time. A DNA chip consists essentially of a support material (for example glass or plastic) on which single-stranded gene-specific probes are immobilized in high density at a particular spot. The technique of probe application and the chemistry of probe immobilization are rated as problematical.

[0137] In the present state of the art, probe immobilization can be carried out in several ways:

[0138] E. M. Southern (E. M. Southern et al. (1992), Nucleic Acid Research 20, 1679-1684 and E. M. Southern et al. (1997), Nucleic Acid Research 25, 1155-1161) describes the production of oligonucleotide arrangements by direct synthesis on a glass surface derivatized with 3-glycidoxypropyl trimethoxysilane and then with a glycol. A similar process achieves the in situ synthesis of oligonucleotides by photosensitive combinatorial chemistry which may be compared with photolithographic techniques (Pease, A. C. et al. (1994), Proc. Natl. Acad. Sci. USA 91, 5022-5026).

[0139] Besides these techniques based on the in situ synthesis of oligonucleotides, already present DNA molecules can also be immobilized on surfaces of support material.

[0140] P. O. Brown (DeRisi et al. (1997), Science 278, 680-686) describes the immobilization of DNA on glass surfaces coated with polylysine.

[0141] The Article by L. M. Smith (Guo, Z. et al. (1994), Nucleic Acid Research 22, 5456-5465) discloses a similar process: oligonucleotides carrying a 5′-terminal amino group can be immobilized on a glass surface treated with 3-aminopropyl trimethoxysilane and then with 1,4-phenyl diisothiocyanate.

[0142] The DNA probes may be applied to a support using a so-called pin spotter. To this end, thin metal needles, for example 250 μm in diameter, dip into probe solutions and then transfer the adhering sample material in defined volumes to the support material of the DNA chip.

[0143] However, the probes are preferably applied by means of a piezo-controlled nanodispenser which—similarly to an ink jet printer—applies probe solutions with a volume of 100 picoliters to the surface of the support material without any contact.

[0144] The probes are immobilized as described, for example, in EP-A-0 965 647. DNA probes are generated by PCR using a sequence-specific primer pair, one primer being modified at the 5′-end and carrying a linker with a free amino group. This ensures that a defined strand of the PCR products can be immobilized on a glass surface treated with 3-aminopropyl trimethoxysilane and then with 1,4-phenyl diisothiocyanate. Ideally, the gene-specific PCR products should comprise a defined nucleic acid sequence with a length of 200-400 bp and non-redundant sequences. After immobilization of the PCR products via the derivatized primer, the counter-strand of the PCR product is removed by incubation for 10 mins. at 96° C.

[0145] In one application typical of DNA chips, mRNA is isolated from two cell populations to be compared. The isolated mRNAs are converted into cDNA by reverse transcription using, for example, fluorescence-marked nucleotides. The samples to be compared are marked, for example, with red- or green-fluorescing nucleotides. The cDNAs are then hybridized with the gene probes immobilized on the DNA chip and the fixed fluorescences are then quantified.

[0146] The biochip according to the invention preferably comprises 1 to about 5,000, preferably 1 to about 1,000, more preferably about 10 to about 500, most preferably about 10 to about 250, more particularly about 10 to about 100 and most particularly about 10 to about 50 different probes. The different probes may be present as multiple copies on the chip.

[0147] The biochip according to the invention preferably comprises nucleic acid probes, more particularly RNA or PNA probes and most particularly DNA probes. The nucleic acid probes preferably have a length of about 10 to about 1,000, more preferably a length of about 10 to about 800, most preferably a length of about 100 to about 600 and, in one most particularly preferred embodiment, a length of about 200 to about 400 nucleotides.

[0148] In another preferred embodiment, the biochip according to the invention comprises peptide or protein probes, more particularly antibodies.

[0149] In another preferred form, the biochip according to the invention comprises probes which are capable of binding specifically to at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are identified by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9.

[0150] The present invention also relates to the use of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are defined

[0151] i. by their Unigene Accession Number in Tables 1 to 4, column 7, or

[0152] ii. by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9 or

[0153] iii. by their 11-base tag sequence in Table 5 or in Table 7, column 2,

[0154] as skin stress and/or skin ageing markers in human beings or animals.

[0155] The present invention also relates to a test for demonstrating the effectiveness of cosmetic or pharmaceutical active substances against skin stress and/or ageing of the skin in vitro, characterized in that

[0156] a) the status of the skin is determined by a process according to the invention for determining skin stress and/or ageing of the skin or with the aid of a test kit according to the invention for determining skin stress and/or ageing of the skin or with the aid of a biochip according to the invention,

[0157] b) an active substance against skin stress and/or ageing of the skin is applied one or more times to the skin,

[0158] c) the status of the skin is re-determined by a process according to the invention for determining skin stress and/or ageing of the skin or with the aid of a test kit according to the invention for determining skin stress and/or ageing of the skin or with the aid of a biochip according to the invention and

[0159] d) the effectiveness of the active substance is determined by comparing the results from a) and c).

[0160] In order to accelerate the test, various active substances or placebos may be simultaneously applied to different areas of the skin. For example, an active substance may be applied to the left forearm and a placebo to the right forearm or vice versa.

[0161] The present invention also relates to a test kit for demonstrating the effectiveness of cosmetic or pharmaceutical active substances against skin stress and/or ageing of the skin in vitro comprising means for carrying out the test according to the invention.

[0162] The present invention also relates to the use of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are defined

[0163] i. by their Unigene Accession Number in Tables 1 to 4, column 7, or

[0164] ii. by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9 or

[0165] iii. by their 11-base tag sequence in Table 5 or in Table 7, column 2,

[0166] for demonstrating the effectiveness of cosmetic or pharmaceutical active substances against skin stress and/or ageing of the skin.

[0167] The present invention also relates to a screening process for identifying cosmetic or pharmaceutical active substances against skin stress and/or ageing of the skin in vitro, characterized in that

[0168] a) the status of the skin is determined by a process according to the invention for determining skin stress and/or ageing of the skin or with the aid of a test kit according to the invention for determining skin stress and/or ageing of the skin or with the aid of a biochip according to the invention,

[0169] b) a potential active substance against skin stress and/or ageing of the skin is applied one or more times to the skin,

[0170] c) the status of the skin is re-determined by a process according to the invention for determining skin stress and/or ageing of the skin or with the aid of a test kit according to the invention for determining skin stress and/or ageing of the skin or with the aid of a biochip according to the invention and

[0171] d) effective active substances are determined by comparing the results from a) and c).

[0172] The present invention also relates to the use of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are defined

[0173] i. by their Unigene Accession Number in Tables 1 to 4, column 7, or

[0174] ii. by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9 or

[0175] iii. by their 11-base tag sequence in Table 5 or in Table 7, column 2,

[0176] for identifying cosmetic or pharmaceutical active substances against skin stress and/or ageing of the skin.

[0177] The present invention also relates to a process for the production of a cosmetic or pharmaceutical preparation against skin stress and/or ageing of the skin, characterized in that

[0178] a) active substances are determined by the screening process according to the invention or by the use for identifying cosmetic or pharmaceutical active substances skin stress and/or ageing of the skin and

[0179] b) active substances found to be effective are mixed with cosmetically and pharmacologically suitable and compatible carriers.

[0180] The present invention also relates to a cosmetic or pharmaceutical preparation against skin stress and/or ageing of the skin containing at least one nucleic acid construct which is capable of suppressing or reducing the activity of at least one of the proteins that are expressed more strongly in old or stressed skin than in young or unstressed skin or of inducing or strengthening the activity of at least one of the proteins that are expressed more strongly in young or unstressed skin than in old or stressed skin.

[0181] The proteins are preferably selected from those which are defined by their Unigene Accession Number in Tables 1 to 4, column 7, or by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9 or by their 11-base tag sequence in Table 5 or in Table 7, column 2.

[0182] The nucleic acid construct is preferably selected from DNA, RNA or PNA. However, linear combinations of these nucleic acids or hybrid molecules, for example RNA/DNA molecules, are also possible. In addition, the nucleic acid construct is preferably selected from protein-coding sequences, ribozymes, antisense nucleic acids, triple helix formers and rRNA.

[0183] The preparation according to the invention may contain about 1,000, more particularly about 10 to about 500, preferably about 10 to about 250, more preferably about 10 to about 100 and most preferably about 10 to about 50 different nucleic acid constructs.

[0184] In one particular embodiment, the nucleic acid construct is present in the preparation according to the invention encapsulated in lipid vesicles, for example in liposomes, niosomes or transfersomes, preferably in liposomes.

[0185] Nucleic acid constructs in the context of the invention include DNA and RNA sequences which code for one of the ageing markers and constructs of these polynucleotides.

[0186] After their transport into the cells of the skin, these constructs are transcribed and/or translated and lead to the strengthened expression of the proteins coded by them.

[0187] The invention also encompasses partial sequences of age genes and genes whose sequence has been modified in relation to the age genes by directed or other forms of mutagenesis. Various techniques for modifying closed genes are known and are described, for example, in “Current Protocols in Molecular Biology”, Vol. 1, Chapter 8, Ausubel et al. (Ed.), John Wiley & Sons, Inc. (2001). These modifications may be made in such a way that, after transcription and/or translation, the resulting protein has the identical amino acid sequence to the protein which would result without this mutation (redundancy of the genetic code). However, the modified gene may also lead to the expression of a protein with a modified amino acid sequence so that its biological activity is modified, for example strengthened or weakened.

[0188] In addition, polynucleotides suitable for channeling into the skin include DNA and RNA sequences which comprise part of the sequence of one or more of the genes mentioned and which even have the desired biological activity (for example antisense RNA, rRNA or short double-stranded DNA molecules).

[0189] Each gene suitable for use in accordance with the invention, but preferably those found to be weakly expressed in old skin, can be channeled into the cells of the skin with the object of strengthened expression.

[0190] Each construct of one of the genes usable in accordance with the invention—functionally linked to a eukaryotic promoter—may be used.

[0191] The constructs with one of the age genes may be any eukaryotic expression constructs. For example, bacterial plasmids, viral constructs or other DNA constructs may be genetically modified to form a recombinant DNA (or RNA) molecule which contains a sequence that codes for one of the age genes and expressed the required gene product in cells of the skin.

[0192] Constructs capable of replicating both in eukaryotic and in prokaryotic host cells are preferred. Such constructs are known and commercially available.

[0193] The preparation according to the invention is preferably applied to the skin. The DNA present in it may be either linear or circular, circular DNA molecules being preferred. The polynucleotide or the polynucleotide-containing construct may be multiplied and purified by known methods and is used either as a pure molecule or in one of the formulations mentioned below.

[0194] Constructs carrying a promoter that enables the DNA in question to be expressed are preferred. Various promoters may be used according to the nature of the gene and the purpose of its use. Strong constitutive promoters may be used, including for example the immediate early gene of cytomegalovirus (CMV) or the promoter of the long terminal repeat of Rous sarcoma virus (RSV).

[0195] Alternatively, tissue-specific promoters or cell-type-specific promoters may be used. For example, the promoter may be selected so that it effects the specific expression into skin cells or certain skin cell types. Examples of tissue-specific or cell-type-specific promoters are inter alia the keratin promoters (for example human keratin 14 promoter (Wang et al. 1997 Proc. Natl. Acd. Sci. US 94:219-226)) or tyrosinase promoters (specific to melanocytes). Alternatively, inducible promoters may be used.

[0196] Besides the promoters, the constructs may contain other elements which strengthen the transcriptional or translational expression of the gene product. For example, the construct may contain an internal ribosomal entry site (IRES) to strengthen the translation of the downstream sequence (cf. Murakami et al. 1997, Gene 202:23-29). Other components which may be present on the construct include markers (for example antibiotic resistance genes, such as the ampicillin resistance gene) for selecting cells which contain the construct, a replication source which effects the stable replication of the construct in prokaryotic cells, a nucleus locating signal or other elements which support the production of the DNA construct and/or of the coded protein. The constructs may also contain a polyadenylation signal. The sequence of such a signal may be selected from various known polyadenylation signals. A preferred example is the SV40 early polyadenylation signal.

[0197] The constructs may also contain one or more introns which can strengthen the expression of the DNA.

[0198] The present invention also encompasses constructs which code for fusion proteins of one of the age markers with a second protein or for a fusion protein of two age markers.

[0199] Preferred nucleic acid constructs are those with several expression cassettes on which two or more age markers are coded or which code one of the age genes and a gene for another protein.

[0200] Co-transfection with one or more other vectors which are capable of supporting the expression of the gene in question is also possible.

[0201] Vectors which bear one or more of the features mentioned and which, in addition, may contain other functional units have often been described in the literature and are commercially available. Examples of such vectors include pCI and pSI (Promega GmbH) or PDEST (Gibco BRL).

[0202] The sequences of the age genes and partial gene sequences determinable in accordance with the invention and in particular those of the age genes and partial gene sequences listed in Tables 1 to 9 may be used for selective inhibition of the expression of individual genes.

[0203] Preferred targets for expression inhibition are those which were found to be expressed more strongly in old skin. Oligo- and polynucleotides suitable for this purpose include antisense nucleotides, ribozyme nucleotides and double-stranded RNAs.

[0204] Antisense nucleotides are well known for their ability to hybridize with sense strands of mRNA and thus to interfere with the expression of mRNA (cf. for example Wingers et al., Laboratory Investigation 79, 1415-1424 (1999). An overview of the application of antisense nucleotides in the skin is presented by Wraight et al., Pharmacol. & Ther. 90, 89-104 (2001).

[0205] Ribozyme nucleic acids are also known as single-stranded RNA molecules which are capable of selectively cleaving ssRNA and ssDNA and thus selectively inhibiting the expression of the target molecules.

[0206] Post-transcriptional gene repression can also be produced by double-stranded RNAs. These dsRNAs interfere with the target RNA after cleavage into shorter segments by ribonuclease III. Duplexes of short RNA sequences may also be used for gene repression (S. M. Elbashir et al., Nature 411, 494-498 (2001). These double-stranded RNA molecules may also be used in accordance with the invention for repressing the age genes found.

[0207] Unmodified DNA or RNA molecules undergo rapid degradation in tissue or cells. In order to increase the resistance of oligo- or polynucleotides to degradation by nucleases, modifications involving either the backbone or the pyridine or pyrimidine bases of an oligonucleotide were developed. Correspondingly modified DNA or RNA sequences may also be used in accordance with the invention. Suitable modifications are, for example, phosphorthioates, methyl phosphonates or peptide linkages (PNAs) for the sugar backbone and C5-propynyl-dU, dC for the nucleoside bases.

[0208] The DNA or RNA molecules of the invention may be applied, for example, topically. The molecules may be used either without other penetration-influencing substances or in admixture or association with molecules which influence penetration through the stratum corneum and the transfection of the skin cells.

[0209] A preferred embodiment of the topical application of the age genes is a formulation containing lipids, optionally in admixture with surfactants, preferably in the form of liposomes.

[0210] This formulation contains ca. 0.1 μg -5 mg DNA or RNA per mg liposome. The constituents of the liposomes may be neutral or charged and may be present, for example, in the form of multilamellar vesicles or unilamellar vesicles.

[0211] Suitable lipids for the production of liposomes are, for example, phosphatidyl choline which may be obtained, for example, from eggs, soybeans, olives, coconuts, spermaceti, saffrons, linseeds, evening primroses or primulas. Other suitable lipids are, for example, natural and synthetic phosphatidyl ethanolamine, synthetic phosphatidyl choline, phosphatidic acids or esters thereof, phosphatidyl serine and phosphatidyl (poly)alcohols such as, for example, phosphatidyl inositol or phosphatidyl glycerol. Examples of the lipids mentioned are DPPC (dipalmitoyl phosphatidyl choline), DOPE (dioleyl phosphatidyl ethanolamine), DOTMA (N[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethyl ammonium chloride), DOTAB (N-1-(2,3-dioleoyloxy)propyl-N,N,N-trimethylammonium chloride), DPPA (dipalmitoylphosphatidic acid), DPPG (dipalmitoyl phosphatidyl glycerol).

[0212] Individual surface-active compounds used, for example as detergents or emulsifiers may also be used for the formation of liposomes. Examples of such surface-active compounds are DODAC (dioctadecyl ammonium chloride) and CTAC (cetyl trimethyl ammonium chloride). Suitable constituents of liposomes and production processes are described in the literature (cf. for example “Liposome Drug Delivery Systems”, G. Betageri (Ed.), Lancaster Techonomic Publishing Company (1993) or “Liposome Technology”, Gregoriadis (Ed.), CRC Press)). Besides liposomes, other lipid vesicles such as, for example, niosomes and transfersomes (cf. for example WO 98/17255) may also be used.

[0213] The penetrative power of the DNA and RNA molecules may be improved by the previous or simultaneous application of penetration enhancers. Chemical penetration enhancers have often been described in the literature (cf. for example M. Foldvari, PSTT 3, 417-425 (2000) or N. Kanikkannan, Curr Med. Chem. 7, 593-608 (2000)). Suitable penetration enhancers are inter alia organic solvents (for example ethanol), pyrrolidones, sulfoxides (for example DMSO), fatty acids (saturated or unsaturated, branched or unbranched with a preferred chain length of 8 to 18), terpenes (for example L-menthol or 1,8-cineol), surfactants (for example polysorbates (Tween), polyethylene alkylphenols (Brij), alkyl ether sulfates and betaines and amphoteric glycinates).

[0214] Invasive or minimal-invasive methods may also be used in accordance with the invention for improving the penetration of oligo- or polynucleotides. Conventional minimal-invasive methods include eletroporation and iontophoresis. In both methods, a voltage is applied to the surface of the skin with the aid of electrodes. Electroporation uses a brief high-voltage pulse to permeate the skin. In iontophoresis, a small voltage with constant current is used for this purpose. Low-frequency ultrasound may also be used to increase the permeability of the skin to DNA or RNA.

[0215] The following Examples are intended to illustrate the invention without limiting it in any way.

EXAMPLE 1

Preparation of Liposome/DNA Complexes

[0216] 18.6 μl (25 μmol) DOPE and 0.0175 g DOTAP (25 μmol) were dissolved together in 1 ml ethanol. The solution was dried overnight in an exsiccator and the lipid mixture was then rehydrated for 3-4 h in 3 ml PBS (58 mM NaHPO4, 17 mM NaH2PO4, 69 mM NaCl, pH 7.4) with occasional mixing in the absence of light. The lipid dispersion thus formed was ultrasonicated twice for 5 mins. with a 2-hour pause in between. 6.1 μl of the liposome dispersion formed were diluted with 1.5 ml PBS and mixed with 20 μg plasmid dissolved in 1.5 ml HBS (150 mM NaCl, 20 mM hepes, pH 7.4). The fairly intense clouding occurring during addition of the plasmid solution to the liposome solution is an indication of the formation of the DNA/liposome complexes.

EXAMPLE 2

Preparation of Liposome/DNA Complexes

[0217] 18.6 μl (25 μmol) DOPE and 0.0175 g DOTAP (25 μmol) were dissolved together in 1 ml ethanol. The solution was dried overnight in an exsiccator and the lipid mixture was then rehydrated for 3-4 h in 3 ml PBS (58 mM NaHPO4, 17 mM NaH2PO4, 69 mM NaCl, pH 7.4) with occasional mixing in the absence of light. The lipid dispersion thus formed was ultrasonicated twice for 5 mins. with a 2-hour pause in between. 50 μl of the liposome dispersion formed were mixed with 50 μg plasmid dissolved in 50 μl HBS (150 mM NaCl, 20 mM hepes, pH 7.4). The liposomes were identified by TEM micrographs of the liposome/DNA complexes (FIG. 1).

EXAMPLE 3

Preparation of Liposomes with Cationic Detergent and Complexing with DNA

[0218] 29.8 μl (40 μmol) DOPE and 4 mg CTAC (cetyl trimethyl ammonium chloride) (10 μmol) were dissolved together in 1 ml ethanol. The solvent ethanol was removed in a rotary evaporator and the mixture was then rehydrated for 3-4 h in 3 ml PBS (58 mM NaHPO4, 17 mM NaH2PO4, 69 mM NaCl, pH 7.4) with occasional mixing in the absence of light. The lipid dispersion thus formed was ultrasonicated twice for 5 mins. with a 2-hour pause in between. 6.7 μl of the liposome dispersion formed were diluted with 1.5 ml PBS and mixed with 20 μg plasmid dissolved in 1.5 ml HBS (150 mM NaCl, 20 mM hepes, pH 7.4).

LIST OF FIGURES

[0219] FIG. 1

[0220] TEM micrograph of the liposome/DNA complexes of Example 2 in cryomode. Magnification:×10,000

FIG. 1

[0221] Tables:

TABLE 4
No.	Tag sequence	Young	Old	Quotient	Significance	Annotation	Description
1	CCCCGGCCACC	43.72	0.00	43.72	13.39	Hs.279604	Desmin, muscle
							intermediate filament
							protein
2	AAACATTAAAA	20.82	0.96	21.69	5.35	Hs.77443	actin, gamma 2,
							smooth muscle,
							enteric
3	GGCTGTACCCA	20.82	0.96	21.69	5.35	Hs.108080	cysteine and glycine-
							rich protein 1
4	TTGAGGGGGTG	0.00	16.35	16.35	4.85	Hs.76549	reverse tag of AHNAK
5	CCACGGGATTC	14.57	0.00	14.57	4.48	Hs.119571	collagen, type III,
							alpha 1 (Ehlers-
							Danlos syndrome type
							IV)
6	AGCCACCGCAC	12.49	0.96	13.01	3.01	Hs.42612	ESTs
7	TCCTCCCTACT	1.04	12.51	12.03	2.88	Hs.70266	yeast Sec31p
							homolog
8	TCAAAAGACCT	11.45	0.96	11.93	2.73	Hs.25647	v-fos FBJ murine
							osteosarcoma viral
							oncogene homolog
9	TTAGTGTCGTA	11.45	0.00	11.45	3.52	Hs.74649	cytochrome c oxidase
							subunit VIc
10	TTTCTAGTTTG	11.45	0.00	11.45	3.52	Hs.111894	membrane nucleoside
							transporter
11	GACCAGGCCCT	20.82	1.92	10.84	4.59	Hs.180266	tropomyosin 2 (beta)
12	TTGAGCCAGCC	10.41	0.96	10.84	2.45	Hs.91142	KH-type splicing
							regulatory protein
							(FUSE binding protein 2)
13	AGATTCAAACT	10.41	0.96	10.84	2.45	Hs.14368	SH3 domain binding
							glutamic acid-rich
							protein like
14	ACAGGCTACGG	111.39	10.58	10.53	22.24	Hs.75777	transgelin
15	AATTGAAAAGG	10.41	0.00	10.41	3.20	Hs.78344	myosin, heavy
							polypeptide 11,
							smooth muscle
16	GTGGCGAATGA	1.04	10.58	10.17	2.38	Hs.69752	desmocollin 1
17	TGGCCCCACCC	1.04	10.58	10.17	2.38	Hs.198281	pyruvate kinase,
							muscle

[0222]

TABLE 3
No.	Tag sequence	Young	Old	Quotient	Significance	Annotation	Description
18	GAGACTCCTGC	0.00	9.62	9.62	2.86	Hs.169902	solute carrier family 2,
							member 1
19	TAGTCCCAGCT	1.04	9.62	9.25	2.14	Hs.274579	ancient conserved
							domain protein 1
20	CCCAGAGACCC	17.70	1.92	9.22	3.77	Hs.21223	calponin 1, basic,
							smooth muscle
21	AGGCTCAGGTC	8.33	0.96	8.68	1.90	Hs.78344	myosin, heavy
							polypeptide 11,
							smooth muscle
22	ATTTCTTCAAG	8.33	0.96	8.68	1.90	Hs.31386	ESTs, similar to
							JE0174 frizzled
							protein-2-human
23	TGTGAGCCCCT	8.33	0.96	8.68	1.90	Hs.102948	enigma (LIM domain
							protein)
24	CTGACTTGTGT	0.00	8.66	8.66	2.58	Hs.77961	major
							histocompatibility
							complex, class I, B
25	ACGGAACAATA	8.33	0.00	8.33	2.57	Hs.8272	prostaglandin D2
							synthase (21kD, brain)
26	CTGTTTGTTCA	8.33	0.00	8.33	2.57	Hs.211582	myosin, light
							polypeptide kinase
27	TGTGGCGTATA	8.33	0.00	8.33	2.57	Hs.211582	myosin, light
							polypeptide kinase
28	C1TTTTGTGCC	8.33	0.00	8.33	2.57	Hs.182238	GW128 protein
29	ATGGATACGGG	1.04	8.66	8.33	1.89	Hs.250722	Reverse tag of MUG
							(Myeloid-upregulated
							protein)
30	TAGGATGGGGG	0.00	7.70	7.70	2.29	Hs.76941	ATPase, Na+/K+
							transporting beta 3
							polypeptide
31	CCCCGCCAAGT	0.00	7.70	7.70	2.29	Hs.169718	calponin 2
32	TGCTGTGCATA	0.00	7.70	7.70	2.29	Hs.147916	DEAD/H (Asp-Glu-Ala-Asp/His)
							box
							polypeptide 3
33	CGTGGGACACT	0.00	7.70	7.70	2.29	Hs.110196	NICE-1 protein
34	CCCTCCTGGGG	7.29	0.96	7.59	1.63	Hs.95867	Homo sapiens
							EST00098 gene, last
							exon
35	GGGGTAAGAAA	7.29	0.96	7.59	1.63	Hs.80423	prostatic binding
							protein
36	GACCTATCTCT	7.29	0.96	7.59	1.63	Hs.194431	palladin
37	CAGGAGGAGTT	7.29	0.96	7.59	1.63	Hs.183760	glucose regulated
							protein, 58kD
38	CTGAGACAAAG	7.29	0.96	7.59	1.63	Hs.101025	basic transcription
							factor 3
39	CTCCCCTGCCC	1.04	7.70	7.40	1.66	Hs.82422	capping protein (actin
							filament(, gelsolin-like
40	TTCCAAGGCAG	1.04	7.70	7.40	1.66	Hs.317	topoisomerase (DNA)
							I
41	GTGGCCAGAGG	1.04	7.70	7.40	1.66	Hs.1420	fibroblast growth
							factor receptor 3
42	GGTTTGGCTTA	7.29	0.00	7.29	2.25	Hs.73818	ubiquinol-cytochrome
							c reductase hinge
							protein
43	CATCTAAACTG	7.29	0.00	7.29	2.25	Hs.180900	Williams-Beuren
							syndrome
							chromosome region 1
44	ACATAGACCGA	7.29	0.00	7.29	2.25	Hs.173594	pigment epithelium-derived
							factor
45	CCACAGGGGAT	13.53	1.92	7.05	2.71	Hs.119571	collagen, type III,
							alpha 1

[0223]

TABLE 2
No.	Tag sequence	Young	Old	Quotient	Significance	Annotation	Description
46	AGCCTGGACTG	0.00	6.73	6.73	2.01	Hs.90107	cell membrane
							glycoprotein
							110000M(r) (surface
							antigen)
47	TCTGTTTATCA	0.00	6.73	6.73	2.01	Hs.180394	signal recognition
							particle 14kD (Alu
							RNA-binding protein)
48	GAGCAGCGCCC	0.00	6.73	6.73	2.01	Hs.112408	S100 calcium-binding
							protein A7
							(psoriasin 1)
49	CCGGGGGAGCC	38.52	5.77	6.68	6.72	Hs.172928	collagen, type I,
							alpha 1
50	TCTGCTTACAG	6.25	0.96	6.51	1.37	Hs.74267	ribosomal protein
							L15
51	TTGGTGTGCTG	6.25	0.96	6.51	1.37	Hs.240399	EST
52	TTGCCCAGCAC	6.25	0.96	6.51	1.37	Hs.23954	cerebral cell
							adhesion molecule
53	CACCCCTGATG	6.25	0.96	6.51	1.37	Hs.173724	creatine kinase,
							brain
54	CCCTTGTCCGA	6.25	0.96	6.51	1.37	Hs.127824	ESTs, Weakly
							similar to weak
							similarity to
							collagens
							[C.elegans]
55	AAACAATAAAA	1.04	6.73	6.47	1.42	Hs.229971	EST
56	AAATAAAAGCT	1.04	6.73	6.47	1.42	Hs.155191	villin 2 (ezrin)
57	ACAAAACCCCA	1.04	6.73	6.47	1.42	Hs.140208	ESTs
58	GTACGTATTCT	6.25	0.00	6.25	1.93	Hs.76325	immunoglobulin J
							polypeptide
59	CCTATAATTCC	6.25	0.00	6.25	1.93	Hs.135491	ESTs
60	TTTCCTCTCAA	5.21	31.75	6.09	5.29	Hs.184510	stratifin
61	CGGCTGGTGAA	0.00	5.77	5.77	1.72	Hs.75748	proteasome
							(prosome,
							macropain) subunit,
							beta type, 1
62	TGCAGATGGTT	0.00	5.77	5.77	1.72	Hs.3628	mitogen-activated
							protein kinase
							kinase kinase kinase
							4
63	ACAACTTTTAT	0.00	5.77	5.77	1.72	Hs.283213	EST
64	GTGCGCTGAGC	0.00	5.77	5.77	1.72	Hs.277477	major
							histocompatibility
							complex, class I, C
65	CCACTGTATTC	0.00	5.77	5.77	1.72	Hs.235041	EST
66	AGGGAGGGGCC	0.00	5.77	5.77	1.72	Hs.172153	glutathione
							peroxidase 3
							(plasma)
67	TTGTAAATGCG	0.00	5.77	5.77	1.72	Hs.149436	kinesin family
							member 5B
68	CTTCTACTAAT	0.00	5.77	5.77	1.72	Hs.109857	Homo sapiens
							mRNA; cDNA
							DKFZp434H0820
69	AGCCTGCAGAA	0.00	5.77	5.77	1.72	Hs.10927	hypothetical protein
							R33729_1
70	GCAAAACCCTA	0.00	5.77	5.77	1.72	Hs.108740	DKFZP586A0522
							protein
71	GCCCAAGGACC	27.07	4.81	5.63	4.49	Hs.195464	filamin A, alpha
							(actin-binding
							protein-280)
72	CAAGAGGCAAA	1.04	5.77	5.55	1.20	Hs.5734	K1AA0679 protein
73	TGGGACGTGAG	1.04	5.77	5.55	1.20	Hs.3796	EphB6
74	CCTGTTATCCC	1.04	5.77	5.55	1.20	Hs.228142	EST
75	GGGGGACGGCT	1.04	5.77	5.55	1.20	Hs.21346	hypothetical protein
							LOC58481
76	CCAGGCACGCT	1.04	5.77	5.55	1.20	Hs.198427	hexokinase 2
77	TTTTTAATGTT	1.04	5.77	5.55	1.20	Hs.181307	H3 histone, family
							3A
78	TACAGTATGTT	1.04	5.77	5.55	1.20	Hs.170171	glutamate-ammonia
							ligase (glutamine
							synthase)
79	GTATTCCCCTT	1.04	5.77	5.55	1.20	Hs.117176	poly(A)-binding
							protein, nuclear 1
80	GCCTGGGCTGG	1.04	5.77	5.55	1.20	Hs.112184	DKFZP586J0619
							protein
81	GTGGGGGGGAG	1.04	5.77	5.55	1.20	Hs.10700	hypothetical protein
82	TCACCAAAAAA	5.21	0.96	5.43	1.12	Hs.84753	KIAA0246 protein
83	GACTTGTATAT	5.21	0.96	5.43	1.12	Hs.81328	NF of kappa light
							polypep.gene
							enhancer in B-cells
							inhibitor, alpha
84	ATCACACAGCT	5.21	0.96	5.43	1.12	Hs.79386	leiomodin 1 (smooth
							muscle)
85	CTGCTGAGTGA	5.21	0.96	5.43	1.12	Hs.79259	hypothetical protein
86	GAAACAAGATG	5.21	0.96	5.43	1.12	Hs.78771	phosphoglycerate
							kinase 1
87	TCTGTAGTCCC	5.21	0.96	5.43	1.12	Hs.7358	Homo sapiens
							mRNA; cDNA
							DKFZp566D1146
88	AACCCGGGGGG	5.21	0.96	5.43	1.12	Hs.6214	KIAA0731 protein
89	AATAAAGCCTT	5.21	0.96	5.43	1.12	Hs.3314	selenoprotein P,
							plasma, 1
90	AGCTGGTTTCC	5.21	0.96	5.43	1.12	Hs.286027	etoposide-induced
							mRNA
91	GTTGTCTTTGG	5.21	0.96	5.43	1.12	Hs.284394	complement
							component 3
92	GAAGCAATAAA	5.21	0.96	5.43	1.12	Hs.198253	major
							histocompatibility
							complex, class II,
							DQ alpha 1
93	GTGATGGTGTA	5.21	0.96	5.43	1.12	Hs.197345	thyroid autoantigen
							70kD (Ku antigen)
94	CTATTGCACTC	5.21	0.96	5.43	1.12	Hs.160483	erythrocyte
							membrane protein
							band 7.2 (stomatin)
95	TTACTAAATGG	5.21	0.96	5.43	1.12	Hs.155560	calnexin
96	TATTTCACCGT	5.21	0.96	5.43	1.12	Hs.138860	Rho GTPase
							activating protein 1
97	CAGGATCCAGA	5.21	0.96	5.43	1.12	Hs.119222	suppression of
							tumorigenicity 13
							(Hsp 70-interacting
							protein)
98	GCAGTCGCTTG	5.21	0.96	5.43	1.12	Hs.100002	HSPC162 protein
99	GTTCCACAGAA	10.41	1.92	5.42	1.95	Hs.179573	collagen, type I,
							alpha 2
100	ATGTCTTTTCT	15.62	2.89	5.40	2.74	Hs.1516	insulin-like growth
							factor-binding
							protein 4
101	CCAGGGCAACA	6.25	32.71	5.23	5.01	Hs.120980	ORF-less transcript
							in MEN1 region, long
							19 kB version
102	TCCCTGTACAT	5.21	0.00	5.21	1.61	Hs.89563	nuclear cap binding
							protein subunit 1,
							80kD
103	TTATGGATCTC	5.21	0.00	5.21	1.61	Hs.5662	G protein, beta
							polypeptide 2-like 1
104	GACCCTAGCTC	5.21	0.00	5.21	1.61	Hs.30570	polyglutamine
							binding protein 1
105	TACCCCATAAA	5.21	0.00	5.21	1.61	Hs.281083	ESTs
106	CTTAAAAAAAA	5.21	0.00	5.21	1.61	Hs.176626	hypothetical protein
							EDAG-1

[0224]

TABLE 1
No.	Tag sequence	Young	Old	Quotient	Significance	Annotation	Description
107	TTCTTGAACAA	9.37	1.92	4.88	1.71	Hs.76228	amplified in
							osteosarcoma
108	TCGGAGCTGTT	9.37	1.92	4.88	1.71	Hs.4055	chromosome 21 open
							reading fram 50
109	TTTGGTTTTCC	97.86	20.20	4.84	13.20	Hs.179573	collagen, type I, alpha
							2
110	TGTTGCTCCCA	0.00	4.81	4.81	1.44	Hs.82210	zinc finger protein
							220
111	GGTTATTTAGT	0.00	4.81	4.81	1.44	Hs.8110	adducin 3 (gamma)
112	GAGGTCCCTGG	0.00	4.81	4.81	1.44	Hs.74077	proteasome subunit,
							alpha type, 6
113	CAGCAGCAAAA	0.00	4.81	4.81	1.44	Hs.285090	ESTs
114	TTTCTTCCCTT	0.00	4.81	4.81	1.44	Hs.283009	tuftelin 1
115	AGTCTGCTGGG	0.00	4.81	4.81	1.44	Hs.259508	ESTs
116	GTGGCGGGCAT	0.00	4.81	4.81	1.44	Hs.230564	EST
117	TGTGCGGCTTC	0.00	4.81	4.81	1.44	Hs.162196	hypothetical protein
							FLJ20321
118	GAAGAGGACAA	0.00	4.81	4.81	1.44	Hs.120451	ESTs
119	GATCCCAACTG	0.00	4.81	4.81	1.44	Hs.118786	metallothionein 2A
120	ATGCTAAAAAA	0.00	4.81	4.81	1.44	Hs.116455	EST
121	TGATAATTCAA	0.00	4.81	4.81	1.44	Hs.100688	H, sapiens cDNA
							FLJ11279 fis, clone
							PLACE1009444
122	GATAGCACAGT	22.90	4.81	4.76	3.54	Hs.103391	Human IGFBP5
							mRNA
123	TGAAATAAAAG	2.08	9.62	4.63	1.68	Hs.48516	ESTs
124	CCACTGCGCTC	2.08	9.62	4.63	1.68	Hs.260287	ESTs
125	TCCTTGCTTCT	1.04	4.81	4.63	0.98	Hs.94491	hypothetical protein
							FLJ20297
126	CCCTCAATCCC	1.04	4.81	4.63	0.98	Hs.83077	interleukin 18
							(interferon-gamma-inducing
							factor)
127	TCCATCAAGAA	1.04	4.81	4.63	0.98	Hs.79387	proteasome 26S
							subunit, ATPase, 5
128	GAAATGAGCAG	1.04	4.81	4.63	0.98	Hs.77293	KIAA0127 gene
							product
129	AAGAAGACTTC	1.04	4.81	4.63	0.98	Hs.7719	GABA(A) receptor-associated
							protein
130	TGCAATATGCC	1.04	4.81	4.63	0.98	Hs.750	fibrillin 1 (Marfan
							syndrome)
131	GTGGCGGGAGC	1.04	4.81	4.63	0.98	Hs.68257	general TF IIF
							polypeptide 1 (74kD
							subunit)
132	TGTTCATCATC	1.04	4.81	4.63	0.98	Hs.65450	reticulon 4
133	CTGGATGGGCA	1.04	4.81	4.63	0.98	Hs.44017	SIR2-like
134	GGGAAACCCCG	1.04	4.81	4.63	0.98	Hs.254283	EST
135	TAAGTAGCAAA	1.04	4.81	4.63	0.98	Hs.239625	integral membrane
							protein 2B
136	CCTGTGGTCTC	1.04	4.81	4.63	0.98	Hs.236504	EST
137	CGGGCACCTTC	1.04	4.81	4.63	0.98	Hs.198249	gap junction protein,
							beta 5 (connexin
							31,1)
138	TTCAGTGCCTG	1.04	4.81	4.63	0.98	Hs.180933	CpG binding protein
139	ACAAACTTAGG	1.04	4.81	4.63	0.98	Hs.177656	calmodulin 1
							(phosphorylase
							kinase, delta)
140	GATTTGTGTTC	1.04	4.81	4.63	0.98	Hs.173125	peptidyiprolyl
							isomerase F
							(cyclophilin F)
141	TTGAATTCCCC	1.04	4.81	4.63	0.98	Hs.171921	semaphorin 3C
142	TAGTTGAAGTC	1.04	4.81	4.63	0.98	Hs.131255	ubiquinol-cytochrome
							c reductase binding
							protein
143	TTTGCACCTTT	17.70	3.85	4.60	2.79	Hs.75511	connective tissue
							growth factor
144	CCTGTAATCCA	8.33	1.92	4.34	1.48	Hs.253369	EST
145	TTAAATAGCAC	8.33	1.92	4.34	1.48	Hs.172928	collagen, type I, alpha
							1
146	AAGATCAAGAT	8.33	1.92	4.34	1.48	Hs.1288	actin, alpha 1,
							skeletal muscle
147	ACCTTGTGCCC	4.16	0.96	4.33	0.88	Hs.878	sorbitol
							dehydrogenase
148	GCTCCGAGCGT	4.16	0.96	4.33	0.88	Hs.80617	ribosomal protein S16
149	CCTTTGTAAGT	4.16	0.96	4.33	0.88	Hs.78465	v-jun avian sarcoma
							virus 17 oncogene
							homolog
150	TTCACTGCCGA	4.16	0.96	4.33	0.88	Hs.78089	ATPase, vacuolar, 14
							kD
151	TTCTGTGAATC	4.16	0.96	4.33	0.88	Hs.77870	ESTs
152	TTGCCGGTTAA	4.16	0.96	4.33	0.88	Hs.75925	proteasome inhibitor
							subunit 1 (P131)
153	TGCATCTGGTG	4.16	0.96	4.33	0.88	Hs.75410	heat shock 70kD
							protein 5 (GRP78,
							BiP)
154	TTTACAAAGAG	4.16	0.96	4.33	0.88	Hs.75360	carboxypeptidase E
155	CAGACTTTTGG	4.16	0.96	4.33	0.88	Hs.63348	DKFZP586M121
							protein
156	CTGTCCTTGTG	4.16	0.96	4.33	0.88	Hs.6101	Human DNA
							sequence from clone
							511E16
157	TCCGTGTATAA	4.16	0.96	4.33	0.88	Hs.3321	EST
158	ACCCTGCCAAA	4.16	0.96	4.33	0.88	Hs.284546	EST
159	CTCCCCCAAGC	4.16	0.96	4.33	0.88	Hs.283305	immunoglobulin
							heavy contant alpha
							1
160	CTTGCAGTCCT	4.16	0.96	4.33	0.88	Hs.27018	Ris
161	AACAGGGGCCA	4.16	0.96	4.33	0.88	Hs.262958	EST
162	CCTGGCCAGAA	4.16	0.96	4.33	0.88	Hs.261734	EST
163	AGGGAAAAAAA	4.16	0.96	4.33	0.88	Hs.215595	G protein, beta
							polypeptide 1
164	AAGAAAGGAGT	4.16	0.96	4.33	0.88	Hs.202097	procollagen C-endopeptidase
							enhancer
165	CCCGACGTGCC	4.16	0.96	4.33	0.88	Hs.198269	NADH
							dehydrogenase 1
							alpha subcomplex, 3
166	AAGGGAGGGTC	4.16	0.96	4.33	0.88	Hs.182248	sequestosome 1
167	CCCCAGGAGAA	4.16	0.96	4.33	0.88	Hs.169902	solute carrier family
							2, member 1
168	CTGGGCGTGTC	4.16	0.96	4.33	0.88	Hs.161554	hypothetical protein
							FLJ20159
169	TACTTGGGAGG	4.16	0.96	4.33	0.88	Hs.154103	LIM protein (similar to
							PKC-binding enigma)
170	AAAGAAAGTGG	4.16	0.96	4.33	0.88	Hs.151513	beta-1,2-N-acetylglucosaminyl-
							transferase
171	TATCTGTCTAC	4.16	0.96	4.33	0.88	Hs.145279	SET translocation
							(myeloid leukemia-associated)
172	GAATCACTGCC	4.16	0.96	4.33	0.88	Hs.14454	chromosome 2 open
							reading frame 1
173	ATTAACAAAGC	4.16	0.96	4.33	0.88	Hs.113368	neuroendocrine
							secretory protein 55
174	TTCTGCTCTTG	4.16	0.96	4.33	0.88	Hs.110802	von Willebrand factor
175	GACATAAATCC	4.16	0.96	4.33	0.88	Hs.109281	Nef-associated factor
							1
176	ACGGTGATGTC	4.16	0.96	4.33	0.88	Hs.10453	ESTs
177	GATCAGGCCAG	24.99	5.77	4.33	3.59	Hs.119571	collagen, type III,
							alpha 1
178	CTTTATTCCAG	41.64	9.62	4.33	5.59	Hs.172928	collagen, type I, alpha
							1
179	GTGTTAACCAG	12.49	2.89	4.32	2.03	Hs.74267	ribosomal protein L15
180	CCATTGTACTC	12.49	2.89	4.32	2.03	Hs.108740	DKFZP586A0522
							protein
181	GGAAATGTCAA	3.12	13.47	4.32	2.12	Hs.111301	matrix
							metalloproteinase 2
182	ACCAAAAACCA	100.98	24.05	4.20	12.20	Hs.172928	collagen, type I, alpha
							1
183	AGAAAGATGTC	2.08	8.66	4.16	1.47	Hs.78225	annexin A1
184	GAAGATGTGGG	2.08	8.66	4.16	1.47	Hs.250911	Homo sapiens clone
							23967 unknown
							mRNA
185	TCACCTTAGGT	2.08	8.66	4.16	1.47	Hs.239625	integral membrane
							protein 2B
186	TGGTTGGTGGT	2.08	8.66	4.16	1.47	Hs.12701	plasmolipin
187	TGCACACACAC	4.16	0.00	4.16	1.29	Hs.99816	beta-catenin-interacting
							protein
188	TTAAAGATTTA	4.16	0.00	4.16	1.29	Hs.77899	tropomyosin 1 (alpha)
189	GTGCTATTCTG	4.16	0.00 4.16	1.29	Hs.77873	mRNA full length
							insert cDNA
							(EUROIMAGE
							2176457)
190	TTTTCAAGAAG	4.16	0.00	4.16	1.29	Hs.75447	ralA binding protein 1
191	TACATTGCTTT	4.16	0.00	4.16	1.29	Hs.75104	RNA-binding protein
							S1, serine-rich
							domain
192	AGGCTGGATGC	4.16	0.00	4.16	1.29	Hs.5898	K1AA0668 protein
193	TGTCCACACAT	4.16	0.00	4.16	1.29	Hs.5897	Homo sapiens
							mRNA; cDNA
							DKFZp586P1622
194	TGATCTGCCTG	4.16	0.00	4.16	1.29	Hs.5723	EST
195	ATAGGTCAGAA	4.16	0.00	4.16	1.29	Hs.29665	KIAA0911 protein
196	GGTGAAACCCC	4.16	0.00	4.16	1.29	Hs.284878	EST
197	TCCATCTGTTG	4.16	0.00	4.16	1.29	Hs.252189	syndecan 4
							(amphiglycan,
							ryudocan)
198	ACTGGGCAGTG	4.16	0.00	4.16	1.29	Hs.241257	latent transforming
							growth factor beta
							binding protein 1
199	TAAAAACTTTC	4.16	0.00	4.16	1.29	Hs.204096	lipophilin B
							(uteroglobin family
							member), prostatein-like
200	TCCGGCCGCGA	4.16	0.00	4.16	1.29	Hs.171774	hypothetical protein
201	CATCTGTAATC	4.16	0.00	4.16	1.29	Hs.153290	EST
202	AGGTCAAAAAA	4.16	0.00	4.16	1.29	Hs.149570	actin related protein
							2/3 complex, subunit
							4 (20 kD)
203	CTCCCTGAACG	4.16	0.00	4.16	1.29	Hs.11006	ESTs
204	TGGAAATGACC	87.45	21.17	4.13	10.54	Hs.172928	collagen, type I, alpha
							1
205	GCCCCCAATAA	54.13	13.47	4.02	6.67	Hs.227751	lectin, galactoside-binding,
							soluble, 1
							(galectin 1)
206	AGAACCTTAAA	11.45	2.89	3.96	1.81	Hs.181244	major
							histocompatibility
							complex, class I, A
207	ATGTGAAGAGT	48.93	12.51	3.91	5.97	Hs.111779	secreted protein,
							acidic, cystein-rich
							(osteonectin)
208	GATGAGGAGAC	37.48	9.62	3.90	4.72	Hs.179573	collagen, type I, alpha
							2
209	ATAGCCAGGGA	0.00	3.85	3.85	1.15	Hs.95582	SRY (sex determining
							region Y)-box 20
210	AAAAGCAGAAA	0.00	3.85	3.85	1.15	Hs.84728	Kruppel-like factor 5
							(intestinal)
211	TAATTTGCGTT	0.00	3.85	3.85	1.15	Hs.79368	epithelial membrane
							protein 1
212	TGAGGCCAGGC	0.00	3.85	3.85	1.15	Hs.79162	structure specific
							recognition protein 1
213	GTTTTTGCTTC	0.00	3.85	3.85	1.15	Hs.79110	nucleolin
214	TAGGCCCAAGT	0.00	3.85	3.85	1.15	Hs.78880	iIvB (bacterial
							acetolactate
							synthase)-like
215	CAGTTACAAAG	0.00	3.85	3.85	1.15	Hs.77508	glutamate
							dehydrogenase 1
216	GACCACGAATA	0.00	3.85	3.85	1.15	Hs.76476	cathepsin H
217	CTGGGCCAGCC	0.00	3.85	3.85	1.15	Hs.74669	vesicle-associated
							membrane protein 5
							(myobrevin)
218	AATTACAGCCA	0.00	3.85	3.85	1.15	Hs.74471	gap junction protein,
							alpha 1, 43kD
							(connexin 43)
219	AGGATGACCAG	0.00	3.85	3.85	1.15	Hs.69554	hypothetical protein
							FLJ20552
220	GAAACCGAGGG	0.00	3.85	3.85	1.15	Hs.279813	hypothetical protein
221	AGCCGAGATCG	0.00	3.85	3.85	1.15	Hs.278053	EST
222	CCGGCCCTACC	0.00	3.85	3.85	1.15	Hs.271473	epithelial protein up-regulated
							in carcinoma
223	CTGTCTGTGGC	0.00	3.85	3.85	1.15	Hs.260150	hypothetical protein
							FLJ20552
224	AACGCTGCGAA	0.00	3.85	3.85	1.15	Hs.24174	K1AA0876 protein
225	CAAGCGCTCTA	0.00	3.85	3.85	1.15	Hs.23598	CREB binding protein
							(Rubinstein-Taybi
							syndrome)
226	CCTGTAGTTCT	0.00	3.85	3.85	1.15	Hs.231918	EST
227	GCAAAACACTG	0.00	3.85	3.85	1.15	Hs.198552	Homo sapiens
							mRNA; cDNA
							DKFZp566B193
228	CCTGCTCCCTG	0.00	3.85	3.85	1.15	Hs.184601	solute carrier family 7
							member 5
229	GAAGCTTTGCA	0.00	3.85	3.85	1.15	Hs.180532	heat shock 90kD
							protein 1, alpha
230	CCACTAATGGA	0.00	3.85	3.85	1.15	Hs.180139	SMT3 (suppressor of
							mif two 3, yeast)
							homolog 2
231	GGCCCCATTGC	0.00	3.85	3.85	1.15	Hs.173421	clone CE29 8,1
							(CAC)n/(GTG)n
							repeat-containing
232	GGATGCGCAGG	0.00	3.85	3.85	1.15	Hs.168541	H, sapiens mRNA full
							length (EUROIMAGE
							50374)
233	GCCGACGCCAG	0.00	3.85	3.85	1.15	Hs.165565	ESTs
234	CCTTGAGTACA	0.00	3.85	3.85	1.15	Hs.155247	aldolase C, fructose-bisphosphate
235	TGGAATTCCCT	0.00	3.85	3.85	1.15	Hs.154846	phosphatidylinositol
							4-kinase, catalytic,
							beta
236	AAGCGGGACCT	0.00	3.85	3.85	1.15	Hs.153436	N-acetyltransferase,
							homolog of S,
							cerevisiae ARD1
237	CCAGGCTGCGT	0.00	3.85	3.85	1.15	Hs.149846	integrin, beta 5
238	CCTCTAGTCCC	0.00	3.85	3.85	1.15	Hs.145501	ESTs
239	ACGGAAGTTTT	0.00	3.85	3.85	1.15	Hs.144974	ESTs
240	ATGGCACATTC	0.00	3.85	3.85	1.15	Hs.14328	Homo sapiens
							mRNA; cDNA
							DKFZp762O124
241	GAGCAAACGGA	0.00	3.85	3.85	1.15	Hs.108847	Homo sapiens
							chromosome 19,
							cosmid R26445
242	CAGCTGGCCAT	7.29	1.92	3.80	1.26	Hs.79732	fibulin 1
243	ATCAAATGCAA	7.29	1.92	3.80	1.26	Hs.79070	v-myc avian
							myelocytomatosis
							viral oncogene
							homolog
244	CACCAGCATTG	7.29	1.92	3.80	1.26	Hs.75847	chromosome 15 open
							reading frame 3
245	CAGTTACTTAG	7.29	1.92	3.80	1.26	Hs.279920	tyrosine 3-monoxygenase/tryptophan
							5-monooxygenase
							activation protein,
							beta polypeptide
246	ATGGCGGGTGC	7.29	1.92	3.80	1.26	Hs.172382	hypothetical protein
							FLJ20001
247	TTGCATATCAG	2.08	7.70	3.70	1.28	Hs.82237	ataxia-telangiectasia
							group D-associated
							protein
248	TCTGCTAAAGA	1.04	3.85	3.70	0.77	Hs.95958	solute carrier family
							2, member 4
249	TTGGACCTGGG	1.04	3.85	3.70	0.77	Hs.89761	ATP synthase, H+
							transporting, delta
							subunit
250	GCTTCCTCCTC	1.04	3.85	3.70	0.77	Hs.85289	CD34 antigen
251	TGTTTGTGTGT	1.04	3.85	3.70	0.77	Hs.85015	ESTs
252	CATTATAACTT	1.04	3.85	3.70	0.77	Hs.84359	hypothetical protein
253	AGATACATAGC	1.04	3.85	3.70	0.77	Hs.84045	Homo sapiens cDNA
							FLJ20288 fis, clone
							HEP04414
254	TGTGGTGGTGT	1.04	3.85	3.70	0.77	Hs.83422	MLN51 protein
255	GGAGATGAGGA	1.04	3.85	3.70	0.77	Hs.83419	KIAA0252 protein
256	GGCTGAGCTCA	1.04	3.85	3.70	0.77	Hs.83004	interleukin 14
257	GCCCGCCTTGT	1.04	3.85	3.70	0.77	Hs.80475	polymerase (RNA) II
							polypeptide J
							(13,3kD)
258	GGGTTTGTTTC	1.04	3.85	3.70	0.77	Hs.75969	proline-rich protein
							with nuclear targeting
							signal
259	CTATGGCTTCA	1.04	3.85	3.70	0.77	Hs.75618	RAB11A, member
							RAS oncogene family
260	CTGGCCGCAAG	1.04	3.85	3.70	0.77	Hs.74649	cytochrome c oxidase
							subunit Vic
261	GTGTATCTTTT	1.04	3.85	3.70	0.77	Hs.73965	splicing factor,
							arginine/serine-rich 2
262	CTCCATCGGCT	1.04	3.85	3.70	0.77	Hs.65238	95 kDa RB protein
							binding protein;
							(KIAA0661)
263	CACCACCACGC	1.04	3.85	3.70	0.77	Hs.5862	hypothetical protein
264	GCGACCAACAT	1.04	3.85	3.70	0.77	Hs.4055	chromosome 21 open
							reading frame 50
265	GCTAAGGAGAT	1.04	3.85	3.70	0.77	Hs.286250	ras-related C3 BTx
							substrate 1(G-Protein
							Rac1)
266	AGGCCTCGGCA	1.04	3.85	3.70	0.77	Hs.286202	H, sapiens cDNA
							FLJ11346 fis, clone
							PLACE1010900
267	TGCTGCTGCTT	1.04	3.85	3.70	0.77	Hs.283685	hypothetical protein
							FLJ20396
268	GCCCCGCCCTC	1.04	3.85	3.70	0.77	Hs.280666	Homo sapiens
							chromosome 19,
							cosmid R32184
269	AGCCGAGATCA	1.04	3.85	3.70	0.77	Hs.277663	EST
270	GTGGTATGTGC	1.04	3.85	3.70	0.77	Hs.277102	EST
271	CCCTGGCAATG	1.04	3.85	3.70	0.77	Hs.273369	hematopoietic
							stem/progenitor cells
							protein MDS027
272	GTGAAGCCTCA	1.04	3.85	3.70	0.77	Hs.271823	ESTs
273	CGAGGGCACTC	1.04	3.85	3.70	0.77	Hs.26915	spectrin, beta, non-erythrocytic 2
274	CTGAAATCTAT	1.04	3.85	3.70	0.77	Hs.253467	ESTs
275	CCTGTGATCCT	1.04	3.85	3.70	0.77	Hs.240395	potassium channel,
							subfamily K, member
							6 (TWIK-2)
276	TCACTGCATTC	1.04	3.85	3.70	0.77	Hs.235587	EST
277	ACAACACCCCA	1.04	3.85	3.70	0.77	Hs.21453	mRNA for inositol
							1,4,5-trisphosphate 3-kinase
278	ATTGCATCACT	1.04	3.85	3.70	0.77	Hs.209111	EST
279	TAGCTCCCTTG	1.04	3.85	3.70	0.77	Hs.199160	myeloid/lymphoid or
							mixed-lineage
							leukemia (trithorax
							(Drosophila)
							homolog)
280	AAGCTCTGTGT	1.04	3.85	3.70	0.77	Hs.19813	ESTs
281	GTGATGGATGG	1.04	3.85	3.70	0.77	Hs.181046	Homo sapiens
							mRNA; cDNA
							DKFZp586O1919
							(from clone
							DKFZp586O1919)
282	GACCAGAAAAA	1.04	3.85	3.70	0.77	Hs.180714	cytochrome c oxidase
							subunit Via
							polypeptide 1
283	GCCTGGTGACC	1.04	3.85	3.70	0.77	Hs.180224	death-associated
							protein 6
284	GTGCTCTGTAC	1.04	3.85	3.70	0.77	Hs.177556	melanoma antigen,
							family D, 1
285	CAGGAGGAAAG	1.04	3.85	3.70	0.77	Hs.177425	KIAA0964 protein
286	GACAATGCCAG	1.04	3.85	3.70	0.77	Hs.155433	ATP synthase, H+
							transporting
							mitochondrial F1
							complex, gamma
							polypeptide 1
287	AGCTTCCAGCC	1.04	3.85	3.70	0.77	Hs.144974	ESTs, Highly similar
							to unnamed protein
							produce [H,sapiens]
288	TGGGCCCGTGT	1.04	3.85	3.70	0.77	Hs.11607	ESTs
289	GATCTCTTGGG	1.04	3.85	3.70	0.77	Hs.115947	keratin 16 (focal non-epidermolytic
							palmoplantar
							keratoderma)
290	TGTGACCTCTC	1.04	3.85	3.70	0.77	Hs.108973	dolichyl-phosphate
							mannosyltransferase
							polypeptide 2,
							regulatory subunit
291	TGCTTCATCTG	1.04	3.85	3.70	0.77	Hs.10842	RAN, member RAS
							oncogene family
292	GTGCTCAAACC	1.04	3.85	3.70	0.77	Hs.103915	KIAA0346 protein
293	AGCAGGGCTCC	1.04	3.85	3.70	0.77	Hs.100623	phospholipase C,
							beta 3, neighbor
							pseudogene
294	TGCACTTCAAG	10.41	2.89	3.60	1.60	Hs.75445	SPARC-like 1 (mast9,
							hevin)
295	ACGCAGGGAGA	11.45	40.41	3.53	4.58	Hs.180532	heat shock 90kD
							protein 1, alpha
296	CAAGACGGGGG	4.16	14.43	3.47	1.97	Hs.106185	ral guanine
							nucleotide
							dissociation
							stimulator
297	TACTCTTGGCA	3.12	10.58	3.39	1.54	Hs.2730	heterogeneous
							nuclear
							ribonucleoprotein L
298	CTCTAAGAAGC	6.25	1.92	3.26	1.05	Hs.9641	complement
							component 1, q
							subcomponent, alpha
							polypeptide
299	GTGCGCTAGGG	6.25	1.92	3.26	1.05	Hs.9408	IKK-related kinase
							epsilon; inducible
							ikappaB kinase
300	TGATCTCCAAA	6.25	1.92	3.26	1.05	Hs.83190	fatty acid synthase
301	AGCACATTTGA	6.25	1.92	3.26	1.05	Hs.80562	gelsolin (amyloidosis,
							Finnish type)
302	TCTTGTGCATA	6.25	1.92	3.26	1.05	Hs.2795	lactate
							dehydrogenase A
303	GCCTATGGTCC	6.25	1.92	3.26	1.05	Hs.16561	HSPC141 protein
304	CCTGTAATCTT	6.25	1.92	3.26	1.05	Hs.120882	ESTs
305	ATCTCGAAAGG	6.25	1.92	3.26	1.05	Hs.10784	hypothetical protein
							FLJ20037
306	TGTCTTTGCTC	3.12	0.96	3.25	0.66	Hs.9589	ubiquilin 1
307	TTTTATTTCCA	3.12	0.96	3.25	0.66	Hs.93780	ESTs
308	CAGTACTGTAT	3.12	0.96	3.25	0.66	Hs.9295	elastin (supravalvular
							aortic stenosis
							Williams-Beuren
							syndrome)
309	GCCAAGATGCC	3.12	0.96	3.25	0.66	Hs.83135	p53-responsive gene
							6
310	CCAACAAGAAT	3.12	0.96	3.25	0.66	Hs.82749	transmembrane 4
							superfamily member
							2
311	TCCACGCACCA	3.12	0.96	3.25	0.66	Hs.82023	hypothetical protein
							similar to mouse
							Fbw5
312	GGGGGTCACCG	3.12	0.96	3.25	0.66	Hs.80986	ATP synthase, H+
							transporting,
							mitochondrial F0
							complex, subunit c
							(subunit 9), isoform 1
313	TAATAAAGAAT	3.12	0.96	3.25	0.66	Hs.80342	keratin 15
314	GC1TVTCAGAC	3.12	0.96	3.25	0.66	Hs.78781	vascular endothelial
							growth factor B
315	TTGTTATTGCC	3.12	0.96	3.25	0.66	Hs.78637	annexin A7
316	TAATCCTCAAG	3.12	0.96	3.25	0.66	Hs.78409	collagen, type XVIII,
							alpha 1
317	GAGCGGCCTCT	3.12	0.96	3.25	0.66	Hs.77868	ORF
318	AAACCAAAAAA	3.12	0.96	3.25	0.66	Hs.76753	endoglin (Osler-Rendu-Weber
							syndrome 1)
319	TTTCAGAGAGA	3.12	0.96	3.25	0.66	Hs.75975	signal recognition
							particle 9kD
320	TAGCCGCTGAG	3.12	0.96	3.25	0.66	Hs.75932	N-ethylmaleimide-sensitive
							factor
							attachment protein,
							alpha
321	ATCACTAAAGA	3.12	0.96	3.25	0.66	Hs.75888	phosphogluconate
							dehydrogenase
322	ATATGTATATT	3.12	0.96	3.25	0.66	Hs.75839	zinc finger protein 6
							(CMPX1)
323	TTTTCTCTGAA	3.12	0.96	3.25	0.66	Hs.75516	tyrosine kinase 2
324	TGGCCTCTCTG	3.12	0.96	3.25	0.66	Hs.75437	peroxisomal long-chain
							acyl-coA
							thioesterase;
							putative protein
325	CTGTTAGTGTG	3.12	0.96	3.25	0.66	Hs.75375	malate
							dehydrogenase 1,
							NAD (soluble)
326	GAGGAGGGTGA	3.12	0.96	3.25	0.66	Hs.75318	tubulin, alpha 1 (testis
							specific)
327	TCTACTTTTGT	3.12	0.96	3.25	0.66	Hs.74598	polymerase (DNA
							directed), delta 2,
							regulatory subunit
							(50kD)
328	CTGGGCCTGGC	3.12	0.96	3.25	0.66	Hs.74573	similar to vaccinia
							virus HINDIII K4L ORF
329	AAAATAAACCT	3.12	0.96	3.25	0.66	Hs.74304	periplakin
330	GATTTCGTTTT	3.12	0.96	3.25	0.66	Hs.738	early growth
							response 1
331	GCCACTACCCC	3.12	0.96	3.25	0.66	Hs.71475	hypothetical protein
332	ACCGCCGTGGT	3.12	0.96	3.25	0.66	Hs.68877	cytochrome b-245,
							alpha polypeptide
333	AGCTACCGGGC	3.12	0.96	3.25	0.66	Hs.6059	EGE-containing
							fibulin-like
							extracellular matrix
							protein 2
334	TGGGACTCCAG	3.12	0.96	3.25	0.66	Hs.59384	Homo sapiens
							mRNA; cDNA
							DKFZp586E2023
							(from clone
							DKFZp586E2023)
335	CTGTTCTCTTG	3.12	0.96	3.25	0.66	Hs.46824	ESTs
336	TGGAGAGCAAC	3.12	0.96	3.25	0.66	Hs.4113	S-adenosylhomocystein
							3 hydrolase-like 1
337	GCAAAGAAAAA	3.12	0.96	3.25	0.66	Hs.3844	LIM domain only 4
338	TGAGTGGACAG	3.12	0.96	3.25	0.66	Hs.3743	ESTs, Weakly similar
							to A28996 proline-rich
							protein M14
							precursor-mouse_[M,musculus]
339	TGGATCAACCA	3.12	0.96	3.25	0.66	Hs.286030	caveolin 1 caveolae
							protein, 22kD
340	AGCCGGATGCT	3.12	0.96	3.25	0.66	Hs.284232	KIAA0720 protein
341	GTGAAACCACA	3.12	0.96	3.25	0.66	Hs.283788	hypothetical protein
							DKFZp547A023
342	GTCCCTGCCTT	3.12	0.96	3.25	0.66	Hs.279837	glutathione S-transferase
							M2
							(muscle)
343	CTCCACAAATT	3.12	0.96	3.25	0.66	Hs.278426	PDGE associated
							protein
344	TGGCCCCAGGT	3.12	0.96	3.25	0.66	Hs.268571	apolipoprotein C-I
345	ATGGTGGGCGC	3.12	0.96	3.25	0.66	Hs.266417	EST
346	GGGAAGTCACC	3.12	0.96	3.25	0.66	Hs.264428	tissue specific
							transplantation
							antigen P35B
347	GTGGCGCGCAC	3.12	0.96	3.25	0.66	Hs.261403	ESTs
348	GTGGTAGGTGC	3.12	0.96	3.25	0.66	Hs.254237	EST
349	TGCCATCTGTA	3.12	0.96	3.25	0.66	Hs.23960	cyclin B1
350	GTGAAATTCCA	3.12	0.96	3.25	0.66	Hs.228168	ESTs
351	CCTGTGATTCC	3.12	0.96	3.25	0.66	Hs.227961	EST
352	GCGGGGTACCC	3.12	0.96	3.25	0.66	Hs.227823	pM5 protein
353	GGGATTAAAGC	3.12	0.96	3.25	0.66	Hs.211579	melanoma adhesion
							molecule
354	AATTCAATTAA	3.12	0.96	3.25	0.66	Hs.211568	eukaryotic translation
							initiation factor 4
							gamma, 1
355	AGGAACACAAA	3.12	0.96	3.25	0.66	Hs.211539	eukaryotic translation
							initiation factor 2,
							subunit 3 (gamma,
							52kD)
356	TTGGCCAGGGT	3.12	0.96	3.25	0.66	Hs.209396	ESTs, Weakly similar
							to plakophilin 2b
							[H,sapiens]
357	TTGCTGGAGAA	3.12	0.96	3.25	0.66	Hs.197114	RNA binding protein;
							AT-rich element
							binding factor
358	AGCAAACTGAA	3.12	0.96	3.25	0.66	Hs.182579	leucine
							aminopeptidase
359	GTGGCGGACGC	3.12	0.96	3.25	0.66	Hs.182577	inositol
							polyphosphate-5-phosphatase,
							75kD
360	TTTTTGATAAA	3.12	0.96	3.25	0.66	Hs.181165	eukaryotic translation
							elongation factor 1
							alpha 1
361	TAATGGTAACT	3.12	0.96	3.25	0.66	Hs.181028	cytochrome c oxidase
							subunit Va
362	TTTTTGTATTA	3.12	0.96	3.25	0.66	Hs.179526	upregulated by 1,25-dihydroxyvitamin
							D-3
363	GGATACAACCT	3.12	0.96	3.25	0.66	Hs.173993	RNA binding motif
							protein 6
364	CAAGGGTGACA	3.12	0.96	3.25	0.66	Hs.170222	solute carrier family 9
							(sodium/hydrogen
							exchanger), isoform 1
							(antiporter, Na+/H+,
							amiloride sensitive)
365	CGGAGTCCATT	3.12	0.96	3.25	0.66	Hs.155595	neural precursor cell
							expressed,
							developmentally
							down-regulated 5
366	TGCGCGCCCTG	3.12	0.96	3.25	0.66	Hs.15093	hypothetical protein
367	GGAAGCACGGA	3.12	0.96	3.25	0.66	Hs.148495	proteasome
							(prosome,
							macropain) 26S
							subunit, non-ATPase,
							4
368	GAGCCCCCGTG	3.12	0.96	3.25	0.66	Hs.12908	CDC42-binding
							protein kinase beta
							(DMPK-like)
369	CAGATGGAGGC	3.12	0.96	3.25	0.66	Hs.127273	hypothetical protein
							FLJ0044
370	GCTGGTGCCTG	3.12	0.96	3.25	0.66	Hs.125359	Thy-1 cell surface
							antigen
371	GCCTTTCCCTC	3.12	0.96	3.25	0.66	Hs.12064	ubiquitin specific
							protease 22
372	ACGAAACCCCA	3.12	0.96	3.25	0.66	Hs.117582	CGI-43 protein
373	ATTTAAAAAAA	3.12	0.96	3.25	0.66	Hs.1139	cold shock domain
							protein A
374	CATTTGGGAAG	3.12	0.96	3.25	0.66	Hs.111334	ferritin, light
							polypeptide
375	CCTTCCAAATT	3.12	0.96	3.25	0.66	Hs.111076	malate
							dehydrogenase 2,
							NAD (mitochondrial)
376	TTTCTGCTCCT	3.12	0.96	3.25	0.66	Hs.108124	ribosomal protein L41
377	AATATTGAGAA	3.12	0.96	3.25	0.66	Hs.106673	eukaryotic translation
							initiation factor 3,
							subunit 6 (48kD)
378	CTGAAACAGCT	3.12	0.96	3.25	0.66	Hs.106469	suppressor of var1
							(s,cerevisiae) 3-like 1
379	CACTGCCTTTG	3.12	0.96	3.25	0.66	Hs.106019	protein phosphatase
							1, regulatory subunit
							10
380	TTGCAACCAAA	3.12	0.96	3.25	0.66	Hs.10101	ESTs, Weakly similar
							to coded for by C,
							elegans cDNA
							yk27g3,5 [C,elegans]
381	ATCTCAGCTCA	9.37	2.89	3.24	1.39	Hs.246192	ESTs, Weakly similar
							to RMS1_HUMAN
							REGULATOR OF
							MITOTIC SPINDLE
							ASSEMBLY 1
							[H,sapiens]
382	GCTTTGATGAT	2.08	6.73	3.24	1.09	Hs.89649	epoxide hydrolase 1,
							microsomal
							(xenobiotic)
383	AAGCTAATAAA	2.08	6.73	3.24	1.09	Hs.88474	prostaglandin-endoperoxide
							synthase 1
							(prostaglandin G/H
							synthase and
							cyclooxygenase)
384	ATGATGATGAT	2.08	6.73	3.24	1.09	Hs.79172	solute carrier family
							25 (mitochondrial
							carrier; adenine
							nucleotide
							translocator),
							member 5
385	TAGAAAGGCAG	2.08	6.73	3.24	1.09	Hs.78909	butyrate response
							factor 2 (EGF-response
							factor 2)
386	TACCCCACCCT	2.08	6.73	3.24	1.09	Hs.7647	MYC-associated zinc
							finger protein (purine-binding
							transcription
							factor)
387	GGAATGTACGT	2.08	6.73	3.24	1.09	Hs.429	ATP synthase, H+
							transporting,
							mitochondrial F0
							complex, subunit c
							(subunit 9) isoform 3
388	GTGAAAACCTG	2.08	6.73	3.24	1.09	Hs.283606	ESTs
389	TGCCACCACAC	2.08	6.73	3.24	1.09	Hs.239993	ESTs
390	ATGTAGGTGCC	2.08	6.73	3.24	1.09	Hs.173717	phosphatidic acid
							phosphatase type 2B
391	AATCTAGTTCT	5.21	16.35	3.14	2.02	Hs.251440	Human profilaggrin
							gene exons 1-3, 5′
							end
392	TTGA1TGAGTG	3.12	0.00	3.12	0.97	Hs.9879	ESTs
393	AAGCTGCTGGA	3.12	0.00	3.12	0.97	Hs.9822	HCNP protein
394	AGTGTCTGTGA	3.12	0.00	3.12	0.97	Hs.8867	cysteine-rich,
							angiogenic inducer,
							61
395	ATTTTGTGCAA	3.12	0.00	3.12	0.97	Hs.8750	uncharacterized bone
							marrow protein
							BM045
396	CCTGCCCCCCT	3.12	0.00	3.12	0.97	Hs.861	mitogen-activated
							protein kinase 3
397	AAAAATAAAGC	3.12	0.00	3.12	0.97	Hs.85100	WD repeat domain 1
398	TGCTGGTGTGG	3.12	0.00	3.12	0.97	Hs.84883	KIAA0864 protein
399	TGAAGAGAATT	3.12	0.00	3.12	0.97	Hs.82306	destrin (actin
							depolymerizing
							factor)
400	ATGGCTAAGCT	3.12	0.00	3.12	0.97	Hs.82280	regulator of G-protein
							signalling 10
401	CATCACGGATC	3.12	0.00	3.12	0.97	Hs.82112	interleukin 1 receptor,
							type I
402	ACAAGAATTGT	3.12	0.00	3.12	0.97	Hs.80919	synaptophysin-like
							protein
403	TGTGAACACAT	3.12	0.00	3.12	0.97	Hs.80645	interferon regulatory
							factor 1
404	GGACCTTGGAG	3.12	0.00	3.12	0.97	Hs.78877	inositol 1,4,5-trisphosphate
							3-kinase B
405	CTTCTATGTAG	3.12	0.00	3.12	0.97	Hs.77225	ADP-ribosyltransferase
							(NAD+; poly (ADP-ribose)
							polymerase)-like 1
406	TTCTTATTTTA	3.12	0.00	3.12	0.97	Hs.75916	splicing factor 3b,
							subunit 2, 145kD
407	TTCTCCCAAAT	3.12	0.00	3.12	0.97	Hs.75617	collagen, type IV,
							alpha 2
408	TATTGACAACA	3.12	0.00	3.12	0.97	Hs.75608	tight junction protein
							2 (zona occludens 2)
409	AAAAAGCAGAT	3.12	0.00	3.12	0.97	Hs.75428	superoxide dismutase
							1, soluble
							(amyotrophic lateral
							sclerosis 1 (adult)
410	AGCTATTCCTC	3.12	0.00	3.12	0.97	Hs.75334	exostoses (multiple) 2
411	GTTCAAAGACT	3.12	0.00	3.12	0.97	Hs.75260	mitogen inducible 2
412	AGTTGTCACTT	3.12	0.00	3.12	0.97	Hs.74649	cytochrome c oxidase
							subunit Vlc
413	TGGTAGTTACC	3.12	0.00	3.12	0.97	Hs.66881	Homo sapiens
							mRNA; cDNA
							DKFZp564A026
							(from clone
							DKFZp434A1518);
							partial cds
414	TGTAACGTGGG	3.12	0.00	3.12	0.97	Hs.66762	Homo sapiens
							mRNA; cDNA
							DKFZp564A026
							(from clone
							DKFZp564A026)
415	CCCTTCTGCCA	3.12	0.00	3.12	0.97	Hs.6214	KIAA0731 protein
416	GACAGTCACTC	3.12	0.00	3.12	0.97	Hs.6066	Rho guanine
							nucleotide exchange
							factor (GEF) 4
417	CAGCTCAGCTG	3.12	0.00	3.12	0.97	Hs.58414	filamin C, gamma
							(actin-binding protein-280)
418	GCGAAACCCCT	3.12	0.00	3.12	0.97	Hs.46468	chemokine (C-C
							motif) receptor 6
419	CCATAATGTTG	3.12	0.00	3.12	0.97	Hs.39957	pleckstrin 2 (mouse)
							homolog
420	AAAGCATTTCT	3.12	0.00	3.12	0.97	Hs.36688	ESTs, Moderately
							similar to WAP four-disulfide
							core domain
							protein [R,norvegicus]
421	ATGACCCGCAG	3.12	0.00	3.12	0.97	Hs.286254	ESTs, Weakly similar
							to AF170723_1
							protein kinase STK10
							[H,sapiens]
422	GAGCTTACATT	3.12	0.00	3.12	0.97	Hs.285706	ESTs
423	TTGGTTTGCTG	3.12	0.00	3.12	0.97	Hs.284326	Human clone 23960
							mRNA sequence
424	GTTACCAGTTT	3.12	0.00	3.12	0.97	Hs.28264	Homo sapiens
							mRNA; cDNA
							DKFZp564L0822
							(from clone
							DKFZp564L0822)
425	TGGAACTGTGA	3.12	0.00	3.12	0.97	Hs.279751	sialic acid binding Ig-like
							lectin 8
426	AAACCCCGTCT	3.12	0.00	3.12	0.97	Hs.273464	ESTs
427	GAGGGTCTTGT	3.12	0.00	3.12	0.97	Hs.256310	SH3 domain-containing
							protein
							6511
428	GTGGTGCGCGC	3.12	0.00	3.12	0.97	Hs.252075	Homo sapiens
							mRNA; cDNA
							DKFZp434D179
							(from clone
							DKFZp434D179)
429	ATCCACCCGCC	3.12	0.00	3.12	0.97	Hs.251337	ESTs
430	TGGAGGCCAGG	3.12	0.00	3.12	0.97	Hs.250581	SWI/SNE related,
							matrix associated,
							actin dependent
							regulator of
							chromatin, subfamily
							d, member 2
431	GGGTGCAAAAA	3.12	0.00	3.12	0.97	Hs.249495	heterogeneous
							nuclear
							ribonucleoprotein A1
432	TACTGCAAAAA	3.12	0.00	3.12	0.97	Hs.24557	DKFZP434H018
							protein
433	TTATTTATGAA	3.12	0.00	3.12	0.97	Hs.245188	tissue inhibitor of
							metalloproteinase 3
							(Sorsby fundus
							dystrophy,
							pseudoinflammatory)
434	GTATAAACGTC	3.12	0.00	3.12	0.97	Hs.237356	stromal cell-derived
							factor 1
435	CGTGTTAATGG	3.12	0.00	3.12	0.97	Hs.2110	zinc finger protein 9
							(a cellular retroviral
							nucleic acid binding
							protein)
436	CCTGTAGGCCC	3.12	0.00	3.12	0.97	Hs.207938	EST
437	AACTGTCCTTC	3.12	0.00	3.12	0.97	Hs.194673	phosphoprotein
							enriched in astrocytes
							15
438	CCATTGCATTC	3.12	0.00	3.12	0.97	Hs.185156	ESTs
439	TTACTTCCCCA	3.12	0.00	3.12	0.97	Hs.184641	delta-6 fatty acid
							desaturase
440	TCTGGCCCAGC	3.12	0.00	3.12	0.97	Hs.183	Duffy blood group
441	CCTCTCCCATT	3.12	0.00	3.12	0.97	Hs.177533	Homo sapiens
							mRNA, chromosome
							1 specific transcript
							KIAA0503
442	TTGTGAGAATA	3.12	0.00	3.12	0.97	Hs.177425	KIAA0964 protein
443	AGCTAGGGAAG	3.12	0.00	3.12	0.97	Hs.172180	KIAA044O protein
444	GGGAGGTAGCA	3.12	0.00	3.12	0.97	Hs.171825	basic helix-loop-helix
							domain containing,
							classs B, 2
445	GAATGAGGACA	3.12	0.00	3.12	0.97	Hs.167791	reticulocalbin 1, EF-hand
							calcium binding
							domain
446	CAACTTAAGTG	3.12	0.00	3.12	0.97	Hs.16492	DKFZP564G2022
							protein
447	CCTAAACTCAA	3.12	0.00	3.12	0.97	Hs.16187	uncharacterized
							hematopoietic
							stem/progenitor cells
							protein MDS032
448	ATCGCACTACT	3.12	0.00	3.12	0.97	Hs.161721	ESTs
449	CCTGTAATCTG	3.12	0.00	3.12	0.97	Hs.159975	ESTs
450	CTTGTAGTTCC	3.12	0.00	3.12	0.97	Hs.155983	KIAA0677 gene
							product
451	ATACAATAAAA	3.12	0.00	3.12	0.97	Hs.151734	nuclear transport
							factor 2 (placental
							protein 15)
452	TGATTCTGTTT	3.12	0.00	3.12	0.97	Hs.146428	collagen, type V,
							alpha 1
453	ATTTGTCCCAG	3.12	0.00	3.12	0.97	Hs.139800	high-mobility group
							(nonhistone
							chromosomal) protein
							isoforms I and Y
454	AGCTGGGTTGG	3.12	0.00	3.12	0.97	Hs.131731	hypothetical protein
							FLJ11099
455	GGGCTACGTCC	3.12	0.00	3.12	0.97	Hs.123107	kallikrein 1,
							renal/pancreas/salivary
456	TGCTGCCTGTT	3.12	0.00	3.12	0.97	Hs.118110	bone marrow stromal
							cell antigen 2
457	CCCCCAATGCT	3.12	0.00	3.12	0.97	Hs.115232	splicing factor 3a,
							subunit 2, 66kD
458	AAAGCAGCACA	3.12	0.00	3.12	0.97	Hs.108802	N-ethylmaleimide-sensitive
							factor
459	TGGTAACTGGC	3.12	0.00	3.12	0.97	Hs.108741	ESTs
460	GCGAGTCTCCG	3.12	0.00	3.12	0.97	Hs.10632	hypothetical protein
							DKFZp762M136
461	TGCCCCTTGCC	3.12	0.00	3.12	0.97	Hs.105700	secreted frizzled-related
							protein 4
462	GCAGGGCCTCA	3.12	9.62	3.08	1.36	Hs.92323	FXYD domain-containing
							ion
							transport regulator 3
463	GCGAAACCCAG	3.12	9.62	3.08	1.36	Hs.142442	HP1-BP74
464	ACAGCGGCAAT	16.66	50.99	3.06	4.90	Hs.74316	desmoplakin (DPI,
							DPII)
465	CCCTACCCTGT	22.90	7.70	2.97	2.53	Hs.75736	apolipoprotein D
466	CACACGGGCGA	19.78	6.73	2.94	2.24	Hs.194679	WNT1 inducible
							signaling pathway
							protein 2
467	CCCCAGGCTGC	0.00	2.89	2.89	0.87	Hs.9645	ESTs
468	ACAAACTGTGG	0.00	2.89	2.89	0.87	Hs.90370	actin related protein
							2/3 complex, subunit
							1A (41 kD)
469	GACCACCTTTA	0.00	2.89	2.89	0.87	Hs.83551	microfibrillar-associated
							protein 2
470	GCAGCTAATTT	0.00	2.89	2.89	0.87	Hs.8207	GK001 protein
471	GAATCGGTTAT	0.00	2.89	2.89	0.87	Hs.80595	NADH
							dehydrogenase
							(ubiquinone) Fe-S
							protein 5 (15kD)
							(NADH-coenzyme aspartyl
							reductase)
472	GCAGCTCAGGC	0.00	2.89	2.89	0.87	Hs.79572	cathepsin D
							(lysosomal aspartyl
							protease)
473	GCAGGTCAGCC	0.00	2.89	2.89	0.87	Hs.78950	branched chain keto
							acid dehydrogenase
							E1, alpha polypeptide
							(maple syrup urine
							disease)
474	TAAACTATTGG	0.00	2.89	2.89	0.87	Hs.78851	KIAA0217 protein
475	AGAGCAAGTAC	0.00	2.89	2.89	0.87	Hs.78050	small acidic protein
476	GTGAGCAAGAC	0.00	2.89	2.89	0.87	Hs.78040	KDEL (Lys-Asp-Glu-Leu)
							endoplasmic
							reticulum protein
							retention receptor 1
477	CGGCTGAATTC	0.00	2.89	2.89	0.87	Hs.75888	phosphogluconate
							dehydrogenase
478	GCTCCACTGGA	0.00	2.89	2.89	0.87	Hs.75709	mannose-6-phosphate
							receptor
							(cation dependent)
479	CAAAATCTTGA	0.00	2.89	2.89	0.87	Hs.75431	fibrinogen, gamma
							polypeptide
480	GGACAGATGTA	0.00	2.89	2.89	0.87	Hs.75356	transcription factor 4
481	GGGGGTGGATG	0.00	2.89	2.89	0.87	Hs.75087	Fas-activated
							serine/threonine
							kinase
482	AGTATGACCTA	0.00	2.89	2.89	0.87	Hs.74649	cytochrome c oxidase
							subunit Vic
483	ACAAAGGGCCC	0.00	2.89	2.89	0.87	Hs.7416	KIAA0397 gene
							product
484	GGCCAGTAACA	0.00	2.89	2.89	0.87	Hs.69559	KIAA1096 protein
485	TACATCAGTAA	0.00	2.89	2.89	0.87	Hs.65029	growth arrest-specific
							1
486	CGGCTGCCCAC	0.00	2.89	2.89	0.87	Hs.63236	synuclein, gamma
							(breast cancer-specific
							protein 1)
487	TGGCAGTCTGC	0.00	2.89	2.89	0.87	Hs.6179	DEAD/H (Asp-Glu-Ala-Asp/His)
							box
							polypeptide 17
							(72kD)
488	GAGCTGGTGAA	0.00	2.89	2.89	0.87	Hs.6163	ESTs, Weakly similar
							to myotonic dystrophy
							kinase [H,sapiens]
489	TGGCAGCTTTT	0.00	2.89	2.89	0.87	Hs.6153	CGI-48 protein
490	AAGCTGGAGGA	0.00	2.89	2.89	0.87	Hs.55682	eukaryotic translation
							initiation factore 3,
							subunit 7 (zeta,
							66/67kD)
491	GCTTCCATCTT	0.00	2.89	2.89	0.87	Hs.55296	HLA-B associated
							transcript-1
492	GAGTGCAACCC	0.00	2.89	2.89	0.87	Hs.54680	ESTs
493	TGGATCCTAGA	0.00	2.89	2.89	0.87	Hs.5273	NADH
							dehydrogenase
							(ubiquinone) Fe-S
							protein 3 (30kD)
							(NADH-coenzyme Q
							reductase)
494	TATGTGATTTG	0.00	2.89	2.89	0.87	Hs.5216	HSPC028 protein
495	GGGACGAGTGA	0.00	2.89	2.89	0.87	Hs.3337	transmembrane 4
							superfamily member
							1
496	ATTGTTTCAAG	0.00	2.89	2.89	0.87	Hs.32366	ESTs, Moderately
							similar to
							TWST_HUMAN
							TWIST RELATED
							PROTEIN [H,sapiens]
497	TTTCAGTGGGT	0.00	2.89	2.89	0.87	Hs.31218	secretory carrier
							membrane protein 1
498	GTGAAACTCTT	0.00	2.89	2.89	0.87	Hs.29759	RNA POLYMERASE
							I AND TRANSCRIPT
							RELEASE FACTOR
499	CTGGTGGCCAC	0.00	2.89	2.89	0.87	Hs.286028	Human alpha-2
							collagen type VI
							mRNA, 3′end
500	TAAACGTGGCA	0.00	2.89	2.89	0.87	Hs.284146	hypothetical protein
							DKFZp762N0610
501	GTGGCTCATAC	0.00	2.89	2.89	0.87	Hs.281094	ESTs
502	CPAACTCAAAA	0.00	2.89	2.89	0.87	Hs.279809	hypothetical protein
							PRO1741
503	GTGAGACCCCT	0.00	2.89	2.89	0.87	Hs.269952	ESTs
504	CCTGTAGTCAC	0.00	2.89	2.89	0.87	Hs.268900	ESTs
505	CACTTGTAATC	0.00	2.89	2.89	0.87	Hs.268488	KIAA1185 protein
506	TTCAGTTGCTT	0.00	2.89	2.89	0.87	Hs.26700	Homo sapiens cDNA
							FLJ10309 fis, clone
							NT2RM2000287
507	TTGACACTTTC	0.00	2.89	2.89	0.87	Hs.26136	ESTs
508	GAGTAGCTGAG	0.00	2.89	2.89	0.87	Hs.260039	sarcospan (Kras
							oncogene-associated
							gene)
509	TCCTGACCACC	0.00	2.89	2.89	0.87	Hs.26002	LIM domain binding 1
510	CCACTGGACTC	0.00	2.89	2.89	0.87	Hs.253913	ESTs
511	GTGCGGTACCT	0.00	2.89	2.89	0.87	Hs.25313	microspherule protein
							1
512	GTGAGAACTCG	0.00	2.89	2.89	0.87	Hs.250639	ESTs
513	AGACCCTGTCT	0.00	2.89	2.89	0.87	Hs.239283	ESTs
514	GCGGCTGACAG	0.00	2.89	2.89	0.87	Hs.236511	ESTs, Moderately
							similar to RNA
							splicing-related
							protein [R,norvegicus]
515	AGCGAGAGAGG	0.00	2.89	2.89	0.87	Hs.232146	ESTs, Weakly similar
							to bromodomain
							containing protein
							[H,sapiens]
516	AGCCACCACCC	0.00	2.89	2.89	0.87	Hs.232045	ESTs
517	TTAAACTCTAA	0.00	2.89	2.89	0.87	Hs.226213	cytochrome P450, 51
							(lanosterol 14-alpha-demethylase)
518	AACACAGGAGG	0.00	2.89	2.89	0.87	Hs.222874	ESTs, Moderately
							similar to zinc
							transporter 4
							[H,sapiens]
519	AGATCAGTTGA	0.00	2.89	2.89	0.87	Hs.191805	ESTs
520	AATCATTGAGG	0.00	2.89	2.89	0.87	Hs.19150	Homo sapiens
							mRNA; cDNA
							DKFZp564A2164
							(from clone
							DKFZp564A2164)
521	TAACTTAAGCA	0.00	2.89	2.89	0.87	Hs.184542	CGI-127 protein
522	CGACTGCACTC	0.00	2.89	2.89	0.87	Hs.182061	Novel human gene
							mapping to
							chomosome 22
523	AGGAGTCGACA	0.00	2.89	2.89	0.87	Hs.181369	ubiquitin fusion
							degradation 1-like
524	AAATATGAGCT	0.00	2.89	2.89	0.87	Hs.181368	US snRNP-specific
							protein (220 kD),
							ortholog of S,cerevisiae
							Prp8p
525	AAGTGATTCTG	0.00	2.89	2.89	0.87	Hs.180677	zinc finger protein
							162
526	GAGCTTTTGAA	0.00	2.89	2.89	0.87	Hs.180638	Homo sapiens cDNA
							FLJ11066 fis,clone
							PLACE1004885
527	GACTGTTGCTG	0.00	2.89	2.89	0.87	Hs.179902	Homo sapiens CTL1
							gene
528	ACCATTCTGCT	0.00	2.89	2.89	0.87	Hs.174195	interferon induced
							transmembrane
							protein 2 (1-8D)
529	TGGACCCCCCG	0.00	2.89	2.89	0.87	Hs.173501	ESTs, Moderately
							similar to
							AF151825_1 CGI-67
530	GTGCCAAACAC	0.00	2.89	2.89	0.87	Hs.172216	chromogranin A
							(parathyroid secretory
							protein 1)
531	CACTTTACCAG	0.00	2.89	2.89	0.87	Hs.170019	runt-related
							transcription factor 3
532	TGTTCTGATTT	0.00	2.89	2.89	0.87	Hs.167835	acyl-Coenzyme A
							oxidase 1, palmitoyl
533	TCTAAAAAGGC	0.00	2.89	2.89	0.87	Hs.16622	zinc finger protein
							185 (LIM domain)
534	CCTCTGTCTCC	0.00	2.89	2.89	0.87	Hs.161031	Homo sapiens
							mRNA; cDNA
							DKFZp434K0322
							(from clone
							DKFZp434K0322);
							partial cds
535	GCTCAGATCGG	0.00	2.89	2.89	0.87	Hs.158286	KIAA0446 gene
							product
536	GCCAACAGCAT	0.00	2.89	2.89	0.87	Hs.155606	paired mesoderm
							homeo box 1
537	CGGAACACCGT	0.00	2.89	2.89	0.87	Hs.155191	villin 2 (ezrin)
538	GAAACAAAATG	0.00	2.89	2.89	0.87	Hs.14896	DHHC1 protein
539	CACTCGTGTGA	0.00	2.89	2.89	0.87	Hs.146409	wingless-type MMTV
							integration site family,
							member 4
540	CCCGGCCCAAA	0.00	2.89	2.89	0.87	Hs.133207	PTPRF interacting
							protein, binding
							protein 1 (liprin beta
							1)
541	GTGCCTAGGGA	0.00	2.89	2.89	0.87	Hs.12854	ATRAP protein
542	CTGCTGCTGGT	0.00	2.89	2.89	0.87	Hs.12289	Cdc42 effector
							protein 2
543	GCTCGTGGTCA	0.00	2.89	2.89	0.87	Hs.119475	cold inducible RNA-binding
							protein
544	GTGGCTCATTC	0.00	2.89	2.89	0.87	Hs.116577	prostate
							differentiation factor
545	CCTGTGTGCAT	0.00	2.89	2.89	0.87	Hs.11611	KIAA1424 protein
546	TGTAAAAAAAA	0.00	2.89	2.89	0.87	Hs.112743	synaptonemal
							complex protein 1
547	GAAAATAAAGT	0.00	2.89	2.89	0.87	Hs.111334	ferritin, light
							polypeptide
548	CAGAGTTGTAT	0.00	2.89	2.89	0.87	Hs.109144	ESTs
549	GGTAGCCTGGG	0.00	2.89	2.89	0.87	Hs.108327	damage-specific DNA
							binding protein 1
							(127kD)
550	GCGGAACCTCA	0.00	2.89	2.89	0.87	Hs.10700	hypothetical protein
551	GGAGGTGGGAG	0.00	2.89	2.89	0.87	Hs.105097	thymidine kinase 1,
							soluble
552	GGCCCTAGGCA	8.33	24.05	2.89	2.53	Hs.78909	butyrate response
							factor 2 (EGF-response
							factor 2)
553	GTGACCTCCTT	8.33	2.89	2.88	1.20	Hs.81097	cytochrome c oxidase
							subunit VIII
554	CAACTAATTCA	8.33	2.89	2.88	1.20	Hs.75106	clusterin
							(complement lysis
							inhibitor, SP-40, 40,
							sulfated glycoprotein
							2, testosterone-repressed
							prostate
							message 2,
							apolipoprotein J)
555	CCCTTAGCTTT	8.33	2.89	2.88	1.20	Hs.233936	myosin, light
							polypeptide
							regulatory, non-sacrcomeric
							(20kD)
556	AGGGAGCAGAG	8.33	2.89	2.88	1.20	Hs.118223	microfibrillar-associated
							protein 4
557	GGAGTGTGCTC	21.86	7.70	2.84	2.35	Hs.9615	myosin regulatory
							light chain 2, smooth
							muscle isoform
558	CGGCAGAGCTG	1.04	2.89	2.78	0.59	Hs.9610	purinergic receptor
							P2X, ligand-gated ion
							channel, 4
559	GTACAAAAGTA	1.04	2.89	2.78	0.59	Hs.9552	binder of Arl Two
560	CGTGGGGTGGC	1.04	2.89	2.78	0.59	Hs.92679	ESTs, Weakly similar
							to microtubule-based
							motor [H,sapiens]
561	TTTACAAGTTA	1.04	2.89	2.78	0.59	Hs.91246	hypothetical protein
							DKFZp547O146
562	AGGAGCTGCTG	1.04	2.89	2.78	0.59	Hs.90443	NADH
							dehydrogenase
							(ubiquinone) Fe-S
							protein 8 (23kD)
							(NADH-coenzyme Q
							reductase)
563	GGTGACCACCA	1.04	2.89	2.78	0.59	Hs.83623	nuclear receptor
							subfamily 1, group I,
							member 3
564	CCACTCCTCCA	1.04	2.89	2.78	0.59	Hs.82890	defender against cell
							death 1
565	TAAAATACTCC	1.04	2.89	2.78	0.59	Hs.8125	Homo sapiens
							mRNA; cDNA
							DKFZp586E1521
							(from clone
							DKFZp586E1521);
							partial cds
566	TTTTGAAGCAG	1.04	2.89	2.78	0.59	Hs.80464	hepatitis B virus x-interacting
							protein
							(9,6kD)
567	CTGCCTCCTTA	1.04	2.89	2.78	0.59	Hs.7918	uncharacterized
							hypothalamus protein
							HSMNP1
568	GTGTCCTCCTC	1.04	2.89	2.78	0.59	Hs.78979	Golgi apparatus
							protein 1
569	CGCAAGCTGGT	1.04	2.89	2.78	0.59	Hs.77886	lamin A/C
570	AGGGGCCGGGG	1.04	2.89	2.78	0.59	Hs.77448	aldehyde
							dehydrogenase 4
571	CTCACTTTTTT	1.04	2.89	2.78	0.59	Hs.76722	CCAAT/enhancer
							binding protein
							(C/EBP), delta
572	TGGCTCCTCCC	1.04	2.89	2.78	0.59	Hs.76506	lymphocyte cytosolic
							protein 1 (L-plastin)
573	TTTTCTGAAAA	1.04	2.89	2.78	0.59	Hs.76136	thioredoxin
574	GTGGCAGAGAC	1.04	2.89	2.78	0.59	Hs.75813	polycystic kidney
							disease 1 (autosomal
							dominant
575	TGGTTTTGGCA	1.04	2.89	2.78	0.59	Hs.75721	profilin 1
576	TACCCCACCTT	1.04	2.89	2.78	0.59	Hs.75258	H2A histone family,
							member Y
577	TCTGTCCTCAG	1.04	2.89	2.78	0.59	Hs.75216	protein tyrosine
							phosphatase,
							receptor type, F
578	CACAGAGTCCT	1.04	2.89	2.78	0.59	Hs.75140	low density
							lipoprotein-related
							protein-associated
							protein 1
579	GGCCCTGAGCG	1.04	2.89	2.78	0.59	Hs.71618	polymerase (RNA) II
							(DNA directed)
							polypeptide L (7,6kD)
580	GAGGCCATCCC	1.04	2.89	2.78	0.59	Hs.70830	U6 snRNA-associated
							Sm-like
							protein LSm7
581	TTGTGATGTAA	1.04	2.89	2.78	0.59	Hs.6975	PRO1073 protein
582	GAGTCCCTGGT	1.04	2.89	2.78	0.59	Hs.68398	period (Drosophila)
							homolog 1
583	CACACACACAC	1.04	2.89	2.78	0.59	Hs.63984	cadherin 13, H-cadherin
							(heart)
584	GCTCACACCTG	1.04	2.89	2.78	0.59	Hs.60617	sialyltransferase 4A
							(beta-galactosidase
							alpha-2,3-sialytransferase)
585	TGATTGATTTG	1.04	2.89	2.78	0.59	Hs.5912	F-box only protein 7
586	AAATGCGAACA	1.04	2.89	2.78	0.59	Hs.5672	ESTs, Weakly similar
							to Similarity to Yeast
							D-lactate
							dehydrogenase
							[C,elegans]
587	TAGTTGTAGGG	1.04	2.89	2.78	0.59	Hs.5324	hypothetical protein
588	GGCCCCGGACC	1.04	2.89	2.78	0.59	Hs.4742	anchor attachment
							protein 1 (Gaa1p,
							yeast) homolog
589	GGGCCCAGGGG	1.04	2.89	2.78	0.59	Hs.3803	reticulon 2
590	TAAACTGAAAA	1.04	2.89	2.78	0.59	Hs.3491	ribosomal protein S14
591	GCTTTTATTCA	1.04	2.89	2.78	0.59	Hs.31819	HT014
592	TACTGGTTTAT	1.04	2.89	2.78	0.59	Hs.30299	IGF-II mRNA-binding
							protein 2
593	GCAGTTGGATC	1.04	2.89	2.78	0.59	Hs.284932	Homo sapiens clone
							24650 ubiquitin
							hydrolase mRNA,
							partial cds
594	ACCTTCAAAAA	1.04	2.89	2.78	0.59	Hs.28444	hypothetical protein
							FLJ10567
595	GACAGTGTGGG	1.04	2.89	2.78	0.59	Hs.279863	nuclear mitotic
							apparatus protein 1
596	AAACCAGGGCC	1.04	2.89	2.78	0.59	Hs.279836	HSPC166 protein
597	CTGAGGGTGGT	1.04	2.89	2.78	0.59	Hs.279761	HSPC134 protein
598	CTCGGAGGCCT	1.04	2.89	2.78	0.59	Hs.279623	selenoprotein X
599	TGAATGATACG	1.04	2.89	2.78	0.59	Hs.278614	protease, serine, 15
600	GCTGCCCTTGA	1.04	2.89	2.78	0.59	Hs.278242	tubulin, alpha,
							ubiquitous
601	TGATGTTCCAC	1.04	2.89	2.78	0.59	Hs.277401	bromodomain
							adjacent to zinc finger
							domain, 2A
602	GTGTCGGCTGT	1.04	2.89	2.78	0.59	Hs.275959	eukaryotic translation
							elongation factor 1
							beta 2
603	AAGTCATTCAG	1.04	2.89	2.78	0.59	Hs.274416	NADH
							dehydrogenase
							(ubiquinone) 1 alpha
							subcomplex, 6 (14kD,
							B14)
604	GCGAAAACCCC	1.04	2.89	2.78	0.59	Hs.272837	ESTs
605	GTGGCACTTGC	1.04	2.89	2.78	0.59	Hs.272322	Homo sapiens
							mRNA; cDNA
							DKFZp434L092 (from
							clone
							DKFZp434L092)
606	CCTGTATCCCA	1.04	2.89	2.78	0.59	Hs.270072	ESTs
607	CCTCCCCCGTC	1.04	2.89	2.78	0.59	Hs.268763	Breakpoint cluster
							region protein, uterine
							leiomyoma, 1; barrier
							to autointegration
							factor
608	GCCCCTGCGCA	1.04	2.89	2.78	0.59	Hs.267200	ESTs, Moderately
							similar to T20D3,3
							[C,elegans]
609	GTGGCTCAGGC	1.04	2.89	2.78	0.59	Hs.259047	ESTs
610	GGGCCCTGGCC	1.04	2.89	2.78	0.59	Hs.25895	ESTs, Weakly similar
							to PI-3 kinase
							[H,sapiens]
611	GAGTTGGCAGT	1.04	2.89	2.78	0.59	Hs.258730	heme-regulated
							initiation factor 2-alpha
							kinase
612	TGGCTGTGTGG	1.04	2.89	2.78	0.59	Hs.25709	ESTs, Weakly similar
							to PSF_HUMAN
							PTB-ASSOCIATED
							SPLICING FACTOR
							[H,sapiens]
613	TTCTTTTTCTT	1.04	2.89	2.78	0.59	Hs.250722	(Manual assignment)
							MUG, Myeloid-upregulated
							protein
614	GTTCCAGCAGC	1.04	2.89	2.78	0.59	Hs.23918	Homo sapiens clone
							25116 mRNA
							sequence
615	TCTCCAGGAAC	1.04	2.89	2.78	0.59	Hs.237924	CGI-69 protein
616	TAATCCCAGCA	1.04	2.89	2.78	0.59	Hs.236710	EST
617	CCTCTAATCCC	1.04	2.89	2.78	0.59	Hs.236150	ESTs, Weakly similar
							to AF090942_1
							PRO657 [H,sapiens]
618	AGTTCGAGACC	1.04	2.89	2.78	0.59	Hs.232540	ESTs
619	AAGTGAGGAGA	1.04	2.89	2.78	0.59	Hs.231840	WW domain binding
							protein 2
620	GCTGGGAGGGG	1.04	2.89	2.78	0.59	Hs.20733	ESTs
621	GTGGCTGACAC	1.04	2.89	2.78	0.59	Hs.202234	ESTs
622	TTACAGTCTTA	1.04	2.89	2.78	0.59	Hs.194110	Homo sapiens
							mRNA; cDNA
							DKFZp434C0814
							(from clone
							DKFZp434C0814)
623	TAGCTCTATGG	1.04	2.89	2.78	0.59	Hs.190703	ATPase, Na+/K+
							transporting, alpha 1
							polypeptide
624	GGGGCCCCCTC	1.04	2.89	2.78	0.59	Hs.18528	Sjogren's syndrome
							nuclear autoantigen 1
625	CCGCTGATCCA	1.04	2.89	2.78	0.59	Hs.184161	exostoses (multiple) 1
626	GGGAAACAGGT	1.04	2.89	2.78	0.59	Hs.18368	DKFZP564B0769
							protein
627	AAATACAGCAG	1.04	2.89	2.78	0.59	Hs.182429	protein disulfide
							isomerase-related
							protein
628	AAAAAAAAAAG	1.04	2.89	2.78	0.59	Hs.180842	ribosomal protein L13
629	CTGGGTCTCCA	1.04	2.89	2.78	0.59	Hs.180842	ribosomal protein L13
630	AGGAAGGAACA	1.04	2.89	2.78	0.59	Hs.173664	v-erb-b2 avian
							erythroblastic
							leukemia viral
							oncogene homolog 2
							(neuro/glioblastoma
							derived oncogene
							homolog)
631	GCACGCGTAAC	1.04	2.89	2.78	0.59	Hs.169552	ESTs, Weakly similar
							to BRDT [H,sapiens]
632	ATTTCAAGATG	1.04	2.89	2.78	0.59	Hs.155097	carbonic anhydrase II
633	GCTGGCAGGCC	1.04	2.89	2.78	0.59	Hs.154886	choline kinase-like
634	TCAATAAAACC	1.04	2.89	2.78	0.59	Hs.151411	KIAA0916 protein
635	TCTTCCCCAGT	1.04	2.89	2.78	0.59	Hs.14231	selenoprotein W, 1
636	ATGGTGGGCAC	1.04	2.89	2.78	0.59	Hs.132390	zinc finger protein 36
							(KOX 18)
637	GTTTCTATCAA	1.04	2.89	2.78	0.59	Hs.12540	lysophospholipase I
638	GTGGCACCTGC	1.04	2.89	2.78	0.59	Hs.1244	CD9 antigen (p24)
639	ACTGCAGAGCG	1.04	2.89	2.78	0.59	Hs.12186	Homo sapiens cDNA
							FLJ20792 fis, clone
							COL01292
640	CTCTGCCCTCC	1.04	2.89	2.78	0.59	Hs.115412	ESTs,Weakly similar
							to dJ68O2.2
							[H,sapiens]
641	GACCGCGGCTT	1.04	2.89	2.78	0.59	Hs.110903	claudin 5
							(transmembrane
							protein deleted in
							velocardiofacial
							syndrome)
642	TTTGGTGTTTG	1.04	2.89	2.78	0.59	Hs.11050	F-box only protein 9
643	GGAAGGACAGA	1.04	2.89	2.78	0.59	Hs.106876	Vacuolar proton-ATPase,
							subunit D;
							V-ATPase, subunit D
644	AAGATAATGCC	1.04	2.89	2.78	0.59	Hs.102696	MCT-1 protein
645	GATGCTGCCAA	3.12	8.66	2.78	1.19	Hs.99914	ribosomal protein L22
646	ACTGCCCGCTG	3.12	8.66	2.78	1.19	Hs.81071	extracellular matrix
							protein 1
647	GTGAAACCCGG	3.12	8.66	2.78	1.19	Hs.229170	ESTs
648	ATGTACTCTGG	2.08	5.77	2.77	0.91	Hs.75432	IMP (inosine
							monophosphate)
							dehydrogenase 2
649	TTCTTGTTTTG	2.08	5.77	2.77	0.91	Hs.74621	prion protein (p27-30)
							(Creutzfeld-Jakob
							disease, Gerstmann-Strausler-
							Scheinker syndrome, fatal
							familial insomnia)
650	GCGAGACCCTG	2.08	5.77	2.77	0.91	Hs.278531	Homo sapiens
							mRNA; cDNA
							DKFZp434A1014
							(from clone
							DKFZp434A1014);
							partial cds
651	GGGTCAAAAGG	2.08	5.77	2.77	0.91	Hs.181307	H3 histone, family 3A
652	TGGAGAAGAGC	2.08	5.77	2.77	0.91	Hs.179526	upregulated by 1,25-dihydroxyvitamin
							D-3
653	AAATCAATACA	5.21	1.92	2.71	0.86	Hs.94953	ESTs, Highly similar
							to C1QC_HUMAN
							COMPLEMENT C1Q
							SUBCOMPONENT,
							C CHAIN
							PRECURSOR−[H,sapiens]
654	TGCTTTGGGAT	5.21	1.92	2.71	0.86	Hs.84344	CGI-135 protein
655	TCCGTGGTTGG	5.21	1.92	2.71	0.86	Hs.79516	brain acid-soluble
							protein 1
656	CAAGGGTAAGA	5.21	1.92	2.71	0.86	Hs.76224	EGF-containing
							fibulin-like
							extracellular matrix
							protein 1
657	TTTGCACTTGT	5.21	1.92	2.71	0.86	Hs.75188	wee1+ (S, pombe)
							homolog
658	CAGCCCAACCG	5.21	1.92	2.71	0.86	Hs.28081	eukaryotic translation
							initiation factor 3,
							subunit 4 (delta,
							44kD)
659	ATGAACCGCAG	5.21	1.92	2.71	0.86	Hs.252259	ribosomal protein S3
660	GCCCAGCGGCC	5.21	1.92	2.71	0.86	Hs.194385	hypothetical protein
							FLJ20234
661	ATGGCACGTGC	5.21	1.92	2.71	0.86	Hs.179999	stromal cell protein
662	TCTCTTTTTCT	5.21	1.92	2.71	0.86	Hs.119529	epididymal secretory
							protein (19,5kD)
663	CCTGTCCTGCA	5.21	1.92	2.71	0.86	Hs.11417	Rab acceptor 1
							(prenylated)
664	CTGAGAGCTGG	10.41	3.85	2.70	1.34	Hs.78501	growth arrest-specific
							6
665	AGTCTGATGTT	10.41	3.85	2.70	1.34	Hs.173255	small nuclear
							ribonucleoprotein
							polypeptide A
666	CTAAAAAAAAA	22.90	8.66	2.64	2.28	Hs.23740	KIAA1598 protein
667	TGTGCTAAATG	7.29	19.24	2.64	1.98	Hs.250895	ribosomal protein L34
668	TACCATCAATA	30.19	11.54	2.62	2.77	Hs.169476	glyceraldehyde-3-phosphate
							dehydrogenase
669	CCCGTAATCCC	12.49	4.81	2.60	1.47	Hs.274168	Homo sapiens
							mRNA; cDNA
							DKFZp761P0212
							(from clone
							DKFZp761P0212);
							partial cds
670	AGAACCTTCCA	12.49	4.81	2.60	1.47	Hs.181244	major
							histocompatibility
							complex, class I, A
671	GTGGCGCACAC	4.16	10.58	2.54	1.28	Hs.246717	ESTs
672	GCCTACCCGAG	4.16	10.58	2.54	1.28	Hs.23582	tumor-associated
							calcium signal
							transducer 2
673	GTGGCGTGTGC	8.33	21.17	2.54	2.05	Hs.278627	prenylcysteine lyase
674	CTAACCAGACA	7.29	2.89	2.52	1.02	Hs.76368	capping protein (actin
							filament) muscle Z-line,
							beta
675	ACTGGGTCTAT	7.29	2.89	2.52	1.02	Hs.275163	non-metastatic cells
							2, protein (NM23B)
							expressed in
676	GCCAGCCAGTG	7.29	2.89	2.52	1.02	Hs.149098	smoothelin
677	GCCCCTGCTGA	41.64	104.86	2.52	7.23	Hs.195850	keratin 5
							(epidermolysis
							bullosa simplex,
							Dowling-Meara/Kobner/Weber-Cockayne
							types)
678	GGCGACAGAGC	3.12	7.70	2.47	1.03	Hs.92254	hypothetical protein
							FLJ20163
679	TAACAGCCAGG	3.12	7.70	2.47	1.03	Hs.81328	nuclear factor of
							kappa light
							polypeptide gene
							enhancer in B-cells
							inhibitor, alpha
680	GGCCCCTCACC	3.12	7.70	2.47	1.03	Hs.274313	insulin-like growth
							factor binding protein
							6
681	GTTCTGGTTTA	3.12	7.70	2.47	1.03	Hs.241336	Homo sapiens
							mRNA; cDNA
							DKFZp564G0422
							(from clone
							DKFZp564G0422)
682	TCAAAAAAAAA	3.12	7.70	2.47	1.03	Hs.200188	deleted in lung and
							esophageal cancer 1
683	CACTTGCCCTA	3.12	7.70	2.47	1.03	Hs.15977	NADH
							dehydrogenase
							(ubiquinone) 1 beta
							subcomplex, 9 (22kD,
							B22)
684	CAATAAACTGA	3.12	7.70	2.47	1.03	Hs.150580	putative translation
							initiation factor
685	CCATTGCACTG	3.12	7.70	2.47	1.03	Hs.142457	ESTs, Moderately
							similar to alternatively
							spliced product using
							exon 13A [H,sapiens]
686	TAAACCTGCTG	31.23	76.96	2.46	5.39	Hs.99923	lectin, galactoside
							binding, soluble, 7
							(galectin 7)
687	CCACCGCACTC	6.25	15.39	2.46	1.60	Hs.222669	EST
688	AGCCTTTGTTG	18.74	7.70	2.43	1.83	Hs.9930	collagen-binding
							protein 2 (colligen 2)
689	CGCAGTGTCCT	9.37	3.85	2.43	1.17	Hs.76159	ATPase, H+
							transporting,
							lysosomal (vacuolar
							proton pump) 16kD
690	GTGGAGGGCAC	5.21	12.51	2.40	1.37	Hs.83393	cystatin E/M
691	TTTGCTCTCCC	11.45	4.81	2.38	1.30	Hs.75350	vinculin
692	CAGGCCCCACC	11.45	4.81	2.38	1.30	Hs.256290	S100 calcium-binding
							protein A11
							(calgizzarin)
693	TGGCCAGCTCC	13.53	5.77	2.34	1.43	Hs.170121	protein tyrosine
							phosphatase
							receptor type, C
694	CCGTGACTCTG	13.53	5.77	2.34	1.43	Hs.155712	Homo sapiens
							mRNA; cDNA
							DKFZp586O2223
							(from clone
							DKFZp586O2223)
695	AATAAATTCCT	4.16	9.62	2.31	1.13	Hs.76307	neuroblastoma,
							suppression of
							tumorigenicity 1
696	CATCTGTACTC	4.16	9.62	2.31	1.13	Hs.180255	major
							histocompatibility
							complex, class II, DR
							beta 1
697	ATCGCTTTCTA	4.16	9.62	2.31	1.13	Hs.177486	amyloid beta (A4)
							precursor protein
							(protease nexin-II,
							Alzheimer disease)
698	CAAAAAAAAAA	4.16	9.62	2.31	1.13	Hs.112272	histone deacetylase 8
699	TCTGCAATGAA	2.08	4.81	2.31	0.75	Hs.8170	hypothetical protein
700	GCTTAACCTGG	2.08	4.81	2.31	0.75	Hs.77508	glutamate
							dehydrogenase 1
701	ATGAGCTGACC	2.08	4.81	2.31	0.75	Hs.695	cystatin B (stefin B)
702	ACTACCATAAC	2.08	4.81	2.31	0.75	Hs.57929	slit (Drosophila)
							homolog 3
703	CATTGTAAATA	2.08	4.81	2.31	0.75	Hs.57929	protease inhibitor 5
							(maspin)
704	CGGATAACCAG	2.08	4.81	2.31	0.75	Hs.5181	proliferation-associated
							2G4,
							38kD
705	GCTCCCAGACT	2.08	4.81	2.31	0.75	Hs.5097	synaptogyrin 2
706	GCCTGCAGTCT	2.08	4.81	2.31	0.75	Hs.31439	serine protease
							inhibitor, Kunitz type,
							2
707	CCTGTAGCCCC	2.08	4.81	2.31	0.75	Hs.277320	EST
708	CCGGTAATCCC	2.08	4.81	2.31	0.75	Hs.272813	dual oxidase 1
709	CTTCCTGTGAT	2.08	4.81	2.31	0.75	Hs.2533	aldehyde
							dehydrogenase 9
							(gamma-aminobutyraldehyde
							dehydrogenase, E3
							isozyme)
710	CCAGTAATCCC	2.08	4.81	2.31	0.75	Hs.237078	ESTs
711	ACACTGCACTC	2.08	4.81	2.31	0.75	Hs.200454	ESTs
712	GTGGGTTGGCT	2.08	4.81	2.31	0.75	Hs.195432	aldehyde
							dehydrogenase 2,
							mitochondrial
713	AACGCGAACAC	2.08	4.81	2.31	0.75	Hs.18946	squamous cell
							carcinoma antigen
							recognised by T cells
714	GCCAGGAGCTA	2.08	4.81	2.31	0.75	Hs.18141	ladinin 1
715	GGAAAAAAAAA	2.08	4.81	2.31	0.75	Hs.177530	ATP synthase, H+
							transporting,
							mitochondrial F1
							complex, epsilon
							subunit
716	TATGACTTAAT	2.08	4.81	2.31	0.75	Hs.173737	Homo sapiens
							mRNA,
							clone:PO2ST9
717	GCCAAGGGGCC	2.08	4.81	2.31	0.75	Hs.168669	oxoglutarate
							dehydrogenase
							(lipoamide)
718	AAAAATAAAGG	2.08	4.81	2.31	0.75	Hs.155101	ATP synthase, H+
							transporting,
							mitochondrial F1
							complex, alpha
							subunit, isoform 1,
							cardiac muscle
719	ATTATTTTTCT	2.08	4.81	2.31	0.75	Hs.153	ribosomal protein L7
720	GCGAAACTCCA	2.08	4.81	2.31	0.75	Hs.112860	KIAA1353 protein
721	GCGCTGGAGTG	2.08	4.81	2.31	0.75	Hs.110695	ESTs, Weakly similar
							to B0495,6
							[C,elegans]
722	CTGACCTGTGT	19.78	8.66	2.28	1.79	Hs.77961	major
							histocompatibility
							complex, class I, B
723	ATCCGCGAGGC	13.53	30.79	2.28	2.39	Hs.180142	(Manual assignment)
							CLSP Calmodulin-like
							skin protein
724	ACCTCCACTGG	42.68	95.24	2.23	5.58	Hs.1 12457	ESTs
725	TACCCTAGAAC	8.33	18.28	2.19	1.62	Hs.252588	Homo sapiens
							mRNA; cDNA
							DKFZp564F172 (from
							clone
							DKFZp564F172)
726	ATCATAGCTCA	4.16	1.92	2.17	0.68	Hs.97876	ESTs
727	TCTATAATCCC	4.16	1.92	2.17	0.68	Hs.96866	ESTs
728	GAATAAATGTT	4.16	1.92	2.17	0.68	Hs.8762	FK506-binding
							protein 9 (63 kD)
729	CTTGAGCAATA	4.16	1.92	2.17	0.68	Hs.848	FK506-binding
							protein 4 (59kD)
730	AGCCCTCCCTG	4.16	1.92	2.17	0.68	Hs.74111	RNA-binding protein
							(autoantigenic)
731	CTACCAGGCCT	4.16	1.92	2.17	0.68	Hs.54457	CD81 antigen (target
							of antiproliferative
							antibody 1)
732	GCGAAACCTCA	4.16	1.92	2.17	0.68	Hs.42644	thioredoxin-like
733	GACTCTGAAAA	4.16	1.92	2.17	0.68	Hs.2953	ribosomal protein
							S15a
734	GTTTGGCAGTG	4.16	1.92	2.17	0.68	Hs.283690	hypothetical protein
735	AGACCTCCTTC	4.16	1.92	2.17	0.68	Hs.281706	sortilin 1
736	GGAAGGGAGGC	4.16	1.92	2.17	0.68	Hs.279581	hypothetical protein
							FLJ20568
737	TTTGTGACTGT	4.16	1.92	2.17	0.68	Hs.239737	C-terminal binding
							protein 1
738	AGTGGTGGCTA	4.16	1.92	2.17	0.68	Hs.230	fibromodulin
739	AGAACAAAACC	4.16	1.92	2.17	0.68	Hs.180909	peroxiredoxin 1
740	GCTGGATGCGG	4.16	1.92	2.17	0.68	Hs.18075	chromosome 9 open
							reading frame 3
741	CCAGGAGGAAT	4.16	1.92	2.17	0.68	Hs.180414	heat shock 70kd
							protein 10 (HSC71)
742	CACCACAACAA	4.16	1.92	2.17	0.68	Hs.174139	chloride channel 3
743	GTCTGACCCCA	4.16	1.92	2.17	0.68	Hs.173902	protein phosphatase
							2 (formerly 2A),
							regulatory subunit A
							(PR 65), alpha
							isoform
744	AAGCGCTCTCG	4.16	1.92	2.17	0.68	Hs.168913	serine/threonine
							kinase 24 (Ste20,
							yeast homolog)
745	ATCCGCCTGCC	4.16	1.92	2.17	0.68	Hs.167956	ESTs, Weakly similar
							to KIAA0309
							[H,sapiens]
746	CTTGTGTGTAG	4.16	1.92	2.17	0.68	Hs.158203	actin binding LIM
							protein 1
747	TGCTAAAAAAA	4.16	1.92	2.17	0.68	Hs.146550	myosin, heavy
							polypeptide 9, non-muscle
748	ATCCGTGCCCT	4.16	1.92	2.17	0.68	Hs.141011	calmodulin 3
							(phosphorylase
							kinase, delta)
749	GTGGCGTGCGC	4.16	1.92	2.17	0.68	Hs.117582	CGI-43 protein
750	CCTTTGTCTTT	2.08	0.96	2.17	0.46	Hs.99654	protein-O-mannosyltransferase
							1
751	GCAACAGCAAT	2.08	0.96	2.17	0.46	Hs.9950	Sec61 gamma
752	GCCTGGGACTC	2.08	0.96	2.17	0.46	Hs.98057	ESTs, Weakly similar
							to I68667
							transcription factor
							ZFM, splice from
							ABCDF-human_[H,sapiens]
753	CTCTAGAGAAA	2.08	0.96	2.17	0.46	Hs.97925	hypothetical protein
754	CCCTCCTGCTC	2.08	0.96	2.17	0.46	Hs.96731	huntingtin interacting
							protein-1-related
755	AAGGTGGAGTG	2.08	0.96	2.17	0.46	Hs.9573	ATP-binding
							cassette, sub-family F
							(GCN20), member 1
756	AACAAGGTGAG	2.08	0.96	2.17	0.46	Hs.94952	ESTs, Highly similar
							to transcription
							elongation factor
							TFIIS,h [H,sapiens]
757	ACTGAAGGCGC	2.08	0.96	2.17	0.46	Hs.92208	a disintegrin and
							metalloproteinase
							domain 15
							(metargidin)
758	CTAATTTAACT	2.08	0.96	2.17	0.46	Hs.9194	putative glialblastoma
							cell differentiation-related
759	GCCTTGATCTC	2.08	0.96	2.17	0.46	Hs.91146	DKFZP586E0820
							protein
760	CCTCCCTGCTC	2.08	0.96	2.17	0.46	Hs.90790	ESTs
761	GAGCCTGGATA	2.08	0.96	2.17	0.46	Hs.9004	chondroitin sulfate
							proteoglycan 4
							(melanoma-associated)
762	TTTACAGCTGG	2.08	0.96	2.17	0.46	Hs.89981	diacylglycerol kinase,
							zeta (104kD)
763	GCTTTACTTTG	2.08	0.96	2.17	0.46	Hs.8966	integral membrane
							protein 1
764	ACCTAGCCACT	2.08	0.96	2.17	0.46	Hs.89463	potassium large
							conductance calcium-activated
							channel,
							subfamily M, alpha
							member 1
765	GACCTCCTGCC	2.08	0.96	2.17	0.46	Hs.89449	mitogen-activated
							protein kinase kinase
							kinase 11
766	CTCATATGTTA	2.08	0.96	2.17	0.46	Hs.8939	yes-associated
							protein 65 kDa
767	TTATACAAAAA	2.08	0.96	2.17	0.46	Hs.88558	ESTs
768	GCCCCCCCGTG	2.08	0.96	2.17	0.46	Hs.85573	Homo sapiens
							mRNA; cDNA
							DKFZp566N034
							(from clone
							DKFZp566N034);
							partial cds
769	CTTTGATGTTC	2.08	0.96	2.17	0.46	Hs.85100	WO repeat domain 1
770	CGGACTCACTG	2.08	0.96	2.17	0.46	Hs.84700	similar to
							phosphatidylcholine
							transfer protein 2
771	CATTTGTAAAA	2.08	0.96	2.17	0.46	Hs.84429	KIAA0971 protei
772	CTTCTCACCGT	2.08	0.96	2.17	0.46	Hs.84285	ubiquitin-conjugating
							enzyme E2I
							(homologous to yeast
							UBC9)
773	ACCAGCTGTCC	2.08	0.96	2.17	0.46	Hs.84153	dynamitin (dynactin
							complex 50 kD
							subunit)
774	ACAAAATAAAA	2.08	0.96	2.17	0.46	Hs.83469	nuclear factor
							(erythroid-derived 2)-like 1
775	AAACATTAGCC	2.08	0.96	2.17	0.46	Hs.82911	protein tyrosine
							phosphatase type
							IVA, member 2
776	TAAATGAAAAA	2.08	0.96	2.17	0.46	Hs.82120	nuclear receptor
							subfamily 4, group A,
							member 2
777	GAGACCCTGGA	2.08	0.96	2.17	0.46	Hs.8088	similar to S,
							cerevisiae Sec6p and
							R, norvegicus rsec6
778	TTCCCTCGTGA	2.08	0.96	2.17	0.46	Hs.80758	aspartyl-tRNA
							synthetase
779	AGGATAAAAAA	2.08	0.96	2.17	0.46	Hs.79404	neuron-specific
							protein
780	GCAAATCCTGT	2.08	0.96	2.17	0.46	Hs.79059	transforming growth
							factor, beta receptor
							III (betaglycan,
							300kD)
781	GTCTCAGTCAT	2.08	0.96	2.17	0.46	Hs.78943	bleomycin hydrolase
782	ACCAGACAGAC	2.08	0.96	2.17	0.46	Hs.7882	ESTs
783	GTTGTAAAATA	2.08	0.96	2.17	0.46	Hs.7869	lysophosphatidic acid
							acyltransferase-delta
784	CTCACTAGTGG	2.08	0.96	2.17	0.46	Hs.78683	ubiquitin specific
							protease 7 (herpes
							virus-associated)
785	AAACGAAGTTG	2.08	0.96	2.17	0.46	Hs.78353	SFRS protein kinase
							2
786	AGCTCTTGGAG	2.08	0.96	2.17	0.46	Hs.7833	selenium binding
							protein 1
787	AGTCGCCTTCA	2.08	0.96	2.17	0.46	Hs.7811	eukaryotic translation
							initiation factor 3,
							subunit 5 (epsilon,
							47kD)
788	CGATGGTCCCC	2.08	0.96	2.17	0.46	Hs.7771	B-cell associated
							protein
789	ACTGCTTGCCC	2.08	0.96	2.17	0.46	Hs.77502	methionine
							adenosyltransferase
							II, alpha
790	TAAAAGACAAA	2.08	0.96	2.17	0.46	Hs.77196	spectrin, alpha, non-erythrocytic
							1 (alpha-fodrin)
791	GACTCGCCCAC	2.08	0.96	2.17	0.46	Hs.77171	minichromosome
							maintenance deficient
							(S, cerevisiae) 5 (cell
							division cycle 46)
792	TATATTGATTG	2.08	0.96	2.17	0.46	Hs.77054	B-cell translocation
							gene 1, anti-proliferative
793	CTGGGACTGAC	2.08	0.96	2.17	0.46	Hs.76719	U6 snRNA-associated
							Sm-like
							protein
794	CTCTTCGAGAA	2.08	0.96	2.17	0.46	Hs.76686	glutathione
							peroxidase 1
795	TCTGTCAAGAC	2.08	0.96	2.17	0.46	Hs.76572	ATP synthase, H+
							transporting,
							mitochondrial F1
							complex, O subunit
							(oligomycin sensitivity
							conferring protein)
796	ATGAAAAGAAA	2.08	0.96	2.17	0.46	Hs.76550	Homo sapiens
							mRNA; cDNA
							DKFZp564B1264
							(from clone
							DKFZp564B1264)
797	AACACATCAGC	2.08	0.96	2.17	0.46	Hs.76253	spinocerebellar ataxia 2
							(olivopontocerebellar
							ataxia 2, autosomal
							dominant, ataxin 2)
798	AAAACCTGTAA	2.08	0.96	2.17	0.46	Hs.75914	coated vesicle
							membrane protein
799	CCTTGG1TTTG	2.08	0.96	2.17	0.46	Hs.75875	ubiquitin-conjugating
							enzyme E2 variant 1
800	AGTTTCCCAAT	2.08	0.96	2.17	0.46	Hs.75854	sulfotransferase
							family, cytosolic, 1C,
							member 2
801	GATTTTTAAAA	2.08	0.96	2.17	0.46	Hs.75447	raIA binding protein 1
802	AGGGGATTCCC	2.08	0.96	2.17	0.46	Hs.75412	Arginine-rich protein
803	ACAAATCCTTG	2.08	0.96	2.17	0.46	Hs.752	FK506-binding
							protein 1A (12kD)
804	GTGACAGACAT	2.08	0.96	2.17	0.46	Hs.75117	interleukin enhancer
							binding factor 2, 45kD
805	CAGACTTTTTT	2.08	0.96	2.17	0.46	Hs.74649	cytochrome c oxidase
							subunit Vic
806	TGCGGCTGGTT	2.08	0.96	2.17	0.46	Hs.74617	dynactin 1 (p150,
							Glued (Drosophila)
							homolog)
807	GGCTGCCCTGG	2.08	0.96	2.17	0.46	Hs.74566	dihydropyrimidinase-like
							3
808	CCTGTAACACC	2.08	0.96	2.17	0.46	Hs.74304	periplakin
809	GTTTCAGTTAC	2.08	0.96	2.17	0.46	Hs.7016	RAB7, member RAS
							oncogene family
810	CTGGAAATAAA	2.08	0.96	2.17	0.46	Hs.69745	ferredoxin reductase
811	GTGATGTACGG	2.08	0.96	2.17	0.46	Hs.6639	Homo sapiens cDNA
							FLJ20818 fis, clone
							ADSE00627
812	CAGCCTTGGAC	2.08	0.96	2.17	0.46	Hs.65648	RNA binding motif
							protein 8
813	GTGGATGGACT	2.08	0.96	2.17	0.46	Hs.6418	seven
							transmembrane
							domain orphan
							receptor
814	TGCCAGAAATG	2.08	0.96	2.17	0.46	Hs.63510	KIAA0141 gene
							product
815	AATAATCCTGG	2.08	0.96	2.17	0.46	Hs.62908	ESTs
816	GGAGGGATCAG	2.08	0.96	2.17	0.46	Hs.6196	integrin-linked kinase
817	GGATTCCAGTT	2.08	0.96	2.17	0.46	Hs.5321	ARP3 (actin-related
							protein 3, yeast)
							homolog
818	TAATTTCTCAA	2.08	0.96	2.17	0.46	Hs.5306	Homo sapiens
							mRNA; cDNA
							DKFZp586F1122
							(from clone
							DKFZp586F1122)
819	CCTGTAGACCC	2.08	0.96	2.17	0.46	Hs.5123	inorganic
							pyrophosphatase
820	CTGCAACCTAA	2.08	0.96	2.17	0.46	Hs.50785	SEC22, vesicle
							trafficking protein (S,
							cerevisiae)-like 1
821	GACGGCTGCAA	2.08	0.96	2.17	0.46	Hs.4909	dickkopf (Xenopus
							laevis) homolog 3
822	CATTGCAGGAT	2.08	0.96	2.17	0.46	Hs.4288	hypothetical protein
							DKFZp434K046
823	GCAGAGATGGG	2.08	0.96	2.17	0.46	Hs.39850	hypothetical protein
							FLJ20517
824	TCAGTTTGGAG	2.08	0.96	2.17	0.46	Hs.3873	palmitoyl-protein
							thioesterase 1
							(ceroid-lipofuscinosis,
							neuronal 1, infantile)
825	ATAGCTGGGGC	2.08	0.96	2.17	0.46	Hs.3446	mitogen-activated
							protein kinase kinase
							1
826	CGTACAGCCCC	2.08	0.96	2.17	0.46	Hs.32580	KIAA1448 protein
827	GTGAAACCGTC	2.08	0.96	2.17	0.46	Hs.30596	Homo sapiens mRNA
							full length insert
							cDNA clone
							EUROIMAGE 43465
828	ATTACAAACCT	2.08	0.96	2.17	0.46	Hs.30376	hypothetical protein
829	AGGATCACTTG	2.08	0.96	2.17	0.46	Hs.287355	ESTs
830	CAGATTAGTTA	2.08	0.96	2.17	0.46	Hs.286195	Homo sapiens clone
							25244 DEAD-box
							protein p72 mRNA
							sequence, complete
							cds
831	AGGGGGGAGGG	2.08	0.96	2.17	0.46	Hs.284181	hypothetical protein
							DKFZp434P0531
832	ATTTCCATTAA	2.08	0.96	2.17	0.46	Hs.284126	hairless (mouse)
							homolog
833	TCATTGTAATG	2.08	0.96	2.17	0.46	Hs.283722	GTT1 protein
834	GTAACAAGCTC	2.08	0.96	2.17	0.46	Hs.279849	KIAA0438 gene
							product
835	CTAATAAACTT	2.08	0.96	2.17	0.46	Hs.279583	CGI-81 protein
836	ACATCCTCACC	2.08	0.96	2.17	0.46	Hs.279554	proteasome
							(prosome
							macropain) 26S
							subunit, non-ATPase,
							13
837	CTCCAATAAAA	2.08	0.96	2.17	0.46	Hs.278559	talin
838	CCACTGCATTG	2.08	0.96	2.17	0.46	Hs.278551	ESTs
839	ATTTTTTTCAG	2.08	0.96	2.17	0.46	Hs.278004	EST
840	TTCTCTCAACT	2.08	0.96	2.17	0.46	Hs.27445	unknown
841	GTGGCGAGCAC	2.08	0.96	2.17	0.46	Hs.261831	EST
842	CACCTTCTGCC	2.08	0.96	2.17	0.46	Hs.25511	transforming growth
							factor beta 1 induced
							transcript 1
843	TCTCTGCAAAA	2.08	0.96	2.17	0.46	Hs.25489	hypothetical protein
							FLJ20640
844	AAAGGGGGCAG	2.08	0.96	2.17	0.46	Hs.249247	heterogeneous
							nuclear protein
							similar to rat helix
							destabilizing protein
845	CGGAGGTGGGA	2.08	0.96	2.17	0.46	Hs.2491	DiGeorge syndrome
							critical region gene 2
846	TAACTCCAAAG	2.08	0.96	2.17	0.46	Hs.24743	hypothetical protein
							FLJ20171
847	ATGTCCAATTT	2.08	0.96	2.17	0.46	Hs.247309	succinate-CoA ligase,
							GDP-forming, beta
							subunit
848	CATCCAAAACA	2.08	0.96	2.17	0.46	Hs.245710	heterogeneous
							nuclear
							ribonucleoprotein H1
							(H)
849	GGAGTCTAACT	2.08	0.96	2.17	0.46	Hs.240170	ESTs, Moderately
							similar to alternatively
							spliced product using
							exon 13A [H,sapiens]
850	TGCTAGATTGG	2.08	0.96	2.17	0.46	Hs.239663	myeloid/lymphoid or
							mixed-lineage
							leukemia
851	GCCCCAGCGAG	2.08	0.96	2.17	0.46	Hs.238296	ADP-ribosylation
							factor binding protein
							GGA1
852	CTGTGAAATGC	2.08	0.96	2.17	0.46	Hs.23618	hypothetical protein
							FLJ10704
853	GATCACAGTTT	2.08	0.96	2.17	0.46	Hs.234489	lactate
							dehydrogenase B
854	GTGAAACACCA	2.08	0.96	2.17	0.46	Hs.231777	EST
855	ATCCACCTGCC	2.08	0.96	2.17	0.46	Hs.231656	EST
856	GAGGCCAGTGA	2.08	0.96	2.17	0.46	Hs.2280	ribophorin I
857	AAGTACGAGGA	2.08	0.96	2.17	0.46	Hs.22660	ESTs
858	CCTACTGCACT	2.08	0.96	2.17	0.46	Hs.225641	ESTs, Moderately
							similar to KIAA0680
							protein [H,sapiens]
859	TTCTCTGCTCA	2.08	0.96	2.17	0.46	Hs.21907	histone
							acetyltransferase
860	TACGTTGCAGC	2.08	0.96	2.17	0.46	Hs.21756	translation factor sui1
							homolog
861	TACCAAGGATT	2.08	0.96	2.17	0.46	Hs.21729	splicing factor 3a,
							subunit 1, 120kD
862	CTGTAGAAATG	2.08	0.96	2.17	0.46	Hs.215595	guanine nucleotide
							binding protein (G
							protein), beta
							polypeptide 1
863	GTGAAACCCTT	2.08	0.96	2.17	0.46	Hs.206955	ESTs
864	ACTGCTGAACC	2.08	0.96	2.17	0.46	Hs.200600	secretory carrier
							membrane protein 3
865	TTGCGGAGCCC	2.08	0.96	2.17	0.46	Hs.199695	hypothetical protein
866	TGCCGTAAATG	2.08	0.96	2.17	0.46	Hs.199067	v-erb-b2 avian
							erythroblastic
							leukemia viral
							oncogene homolog 3
867	ATCAGTGTGCA	2.08	0.96	2.17	0.46	Hs.194662	calponin 3, acidic
868	ACCAGCCAAAG	2.08	0.96	2.17	0.46	Hs.193090	ESTs, Highly similar
							to AF161437_1
							HSPC319 [H,sapiens]
869	AACAGATATTG	2.08	0.96	2.17	0.46	Hs.190161	LR8 protein
870	TTGGCAAGGCT	2.08	0.96	2.17	0.46	Hs.184720	ESTs
871	TCTGGGGAACA	2.08	0.96	2.17	0.46	Hs.184390	similar to aspartate
							beta hydroxylase
							(ASPH)
872	GCTCTCGGCGG	2.08	0.96	2.17	0.46	Hs.183994	protein phosphatase
							1, catalytic subunit,
							alpha isoform
873	GGACTGAGTCA	2.08	0.96	2.17	0.46	Hs.18387	transcription factor
							AP-2 alpha
							(activating enhancer-binding
							protein 2
							alpha)
874	GAGCACTTGGG	2.08	0.96	2.17	0.46	Hs.182937	peptidylprolyl
							isomerase A
							(cyclophilin A)
875	TTTTGTGTGAA	2.08	0.96	2.17	0.46	Hs.182698	hypothetical protein
							FLJ10024
876	CCTGTAATTGC	2.08	0.96	2.17	0.46	Hs.181464	ESTs
877	ACCCCCTTCCT	2.08	0.96	2.17	0.46	Hs.181392	major
							histocompatibility
							complex, class I, E
878	GCCTGGGACCT	2.08	0.96	2.17	0.46	Hs.180871	protein kinase C,
							alpha binding protein
879	AGGAAAAAAAA	2.08	0.96	2.17	0.46	Hs.180639	EST
880	GTTTGGAGCTG	2.08	0.96	2.17	0.46	Hs.180533	mitogen-activated
							protein kinase kinase
							3
881	GGCAACAAAAG	2.08	0.96	2.17	0.46	Hs.180446	karyopherin (importin)
							beta 1
882	TTCCATACCCC	2.08	0.96	2.17	0.46	Hs.180398	LIM domain-containing
							preferred
							translocation partner
							in lipoma
883	CAACTTAGTTT	2.08	0.96	2.17	0.46	Hs.180224	death-associated
							protein 6
884	GCATATTAAAA	2.08	0.96	2.17	0.46	Hs.178658	RAD23 (S,
							cerevisiae) homolog
							B
885	GACTCTCTCAG	2.08	0.96	2.17	0.46	Hs.178576	similar to Bos taurus
							P14 protein
886	TATCCCAGAAT	2.08	0.96	2.17	0.46	Hs.175819	EST
887	TGAACTTTCCT	2.08	0.96	2.17	0.46	Hs.17567	ESTs
888	GAAATGGGGAA	2.08	0.96	2.17	0.46	Hs.173933	Homo sapiens mRNA
							for KIAA1439 protein,
							partial cds
889	TACTAAAAAAG	2.08	0.96	2.17	0.46	Hs.173611	NADH
							dehydrogenase
							(ubiquinone) Fe-S
							protein 2 (49kD)
890	AACTGGCTGCT	2.08	0.96	2.17	0.46	Hs.173381	dihydropyrimidinase-like
							2
891	TGGAAATGAAA	2.08	0.96	2.17	0.46	Hs.172928	collagen, type I, alpha
							1
892	TGAGGGATGGA	2.08	0.96	2.17	0.46	Hs.172740	microtubule-associated
							protein,
							RP/EB family,
							member 3
893	CAGTGGGGTTA	2.08	0.96	2.17	0.46	Hs.17138	hypothetical protein
							FLJ20303
894	GAGGGTTCCAG	2.08	0.96	2.17	0.46	Hs.167835	acyl-Coenzyme A
							oxidate 1, palmitoyl
895	ACCCATCGCCT	2.08	0.96	2.17	0.46	Hs.165428	ESTs
896	CACTGTGTGTA	2.08	0.96	2.17	0.46	Hs.164207	ESTs
897	AGGCAGAGGTT	2.08	0.96	2.17	0.46	Hs.164129	ESTs
898	TTCTGGACCCA	2.08	0.96	2.17	0.46	Hs.155543	proteasome
							(prosome,
							macropain) 26S
							subunit, non-ATPase,
							7 (Mov34 homolog)
899	ATGGCCATAGA	2.08	0.96	2.17	0.46	Hs.155206	serine/threonine
							kinase 25 (Ste20,
							yeast homolog)
900	GCGGGAGGGCT	2.08	0.96	2.17	0.46	Hs.154162	ADP-ribosylation
							factor-like 2
901	AGGCATTGAAA	2.08	0.96	2.17	0.46	Hs.151734	nuclear transport
							factor 2 (placental
							protein 15)
902	GTCTTTCTTGG	2.08	0.96	2.17	0.46	Hs.151536	RAB13, member RAS
							oncogene family
903	GCAAAACCAGC	2.08	0.96	2.17	0.46	Hs.15071	chaperonin
							containing TCP1,
							subunit 8 (theta)
904	TGAAGTAACAA	2.08	0.96	2.17	0.46	Hs.150580	putative translation
							initiation factor
905	CAATTAAAAGG	2.08	0.96	2.17	0.46	Hs.149923	X-box binding protein
							1
906	TTTGAGGATTG	2.08	0.96	2.17	0.46	Hs.147916	DEAD/H (Asp-Glu-Ala-Asp/His)
							box
							polypeptide 3
907	GAGTAGAGAAA	2.08	0.96	2.17	0.46	Hs.145279	SET translocation
							(myeloid leukemia-associated)
908	AAGCCAGCCCC	2.08	0.96	2.17	0.46	Hs.1432	protein kinase C
							substrate 80K-H
909	TATCTGGTCTT	2.08	0.96	2.17	0.46	Hs.142258	signal transducer and
							activator of
							transcription 3 (acute-phase
							response
							factor)
910	GTTCTCCCACT	2.08	0.96	2.17	0.46	Hs.14038	sec61 homolog
911	CCGAGTTTTTG	2.08	0.96	2.17	0.46	Hs.139709	ESTs
912	TGGAAGGGCAC	2.08	0.96	2.17	0.46	Hs.132785	EAP30 subunit of
							ELL complex
913	AAGGCGTTTCC	2.08	0.96	2.17	0.46	Hs.13255	KIAA0930 protein
914	TGCCTTAGTAA	2.08	0.96	2.17	0.46	Hs.13015	ESTs, Highly similar
							to MTJ1_MOUSE
							DNAJPROTEIN
							HOMOLOG MTJ1_[M,musculus]
915	TTTCTGGAGGT	2.08	0.96	2.17	0.46	Hs.129943	KIAA0545 protein
916	CCTGGCCAAAA	2.08	0.96	2.17	0.46	Hs.126824	EST
917	CAGAATAATGT	2.08	0.96	2.17	0.46	Hs.125031	choline/ethanolamine
							phosphotransferase
918	CGGGGACGAGG	2.08	0.96	2.17	0.46	Hs.124942	protein phosphatase
							2A 48 kDa regulatory
							subunit
919	ACAGCCGTGGG	2.08	0.96	2.17	0.46	Hs.123090	SWI/SNE related,
							matrix associated,
							actin dependent
							regulator of
							chromatin, subfamily
							f, member 1
920	AGTCTCCCCTA	2.08	0.96	2.17	0.46	Hs.12303	suppressor of Ty
							(S,cerevisiae) 6
							homolog
921	TGATGTGATCA	2.08	0.96	2.17	0.46	Hs.12272	beclin 1 (coiled-coil,
							myosin-like BCL2-interacting
							protein)
922	ACCAGGCCACC	2.08	0.96	2.17	0.46	Hs.12068	carnitine
							acetyltransferase
923	TCCTTCTCCAC	2.08	0.96	2.17	0.46	Hs.119000	actinin, alpha
924	AATGAATAAAA	2.08	0.96	2.17	0.46	Hs.118797	ubiquitin-conjugating
							enzyme E2D 3
							(homologous to yeast
							UBC4/5)
925	GATGGGGACAA	2.08	0.96	2.17	0.46	Hs.118724	DR1-associated
							protein 1 (negative
							cofactor 2 alpha)
926	TTGGGAGGCTG	2.08	0.96	2.17	0.46	Hs.118269	ESTs, Weakly similar
							to A46010 X-linked
							retinopathy protein
							[H,sapiens]
927	CCTTATATTTG	2.08	0.96	2.17	0.46	Hs.118174	tetratricopeptide
							repeat domain 3
928	CAGCAGAACTG	2.08	0.96	2.17	0.46	Hs.117582	CGI-43 protein
929	CCACCACACCC	2.08	0.96	2.17	0.46	Hs.117582	CGI-43 protein
930	ACTCGCTCTGT	2.08	0.96	2.17	0.46	Hs.11669	laminin, alpha 5
931	AGTATCTGGGA	2.08	0.96	2.17	0.46	Hs.11538	actin related protein
							2/3 complex, subunit
							1A (41 kD)
932	AATGAAAAAAA	2.08	0.96	2.17	0.46	Hs.11393	RAD51 (S,
							cerevisiae ) homolog
							C
933	TAGTTGGAACT	2.08	0.96	2.17	0.46	Hs.1119	nuclear receptor
							subfamily 4, group A,
							member 1
934	AACCCAAACTC	2.08	0.96	2.17	0.46	Hs.11184	hypothetical protein
							FLJ20419
935	GAGGCCTCAGC	2.08	0.96	2.17	0.46	Hs.11184	hypothetical protein
							FLJ20419
936	TTTGTTAAAAC	2.08	0.96	2.17	0.46	Hs.111244	hypothetical protein
937	TTCAGCGTTCT	2.08	0.96	2.17	0.46	Hs.109929	hypothetical protein
							MPMGp800B12492Q
							3
938	GCCAGACCCCT	2.08	0.96	2.17	0.46	Hs.108945	KIAA0515 protein
939	GCTGGCTGGCT	2.08	0.96	2.17	0.46	Hs.108809	chaperonin
							containing TCP1,
							subunit 7 (eta)
940	GTTGGGAGTCC	2.08		0.96	2.17	0.46	Hs.108504	hypothetical protein
							FLJ20113
941	TCTTCTAAAAA	2.08	0.96	2.17	0.46	Hs.108112	histone fold protein
							CHRAC17; DNA
							polymerase epsilon
							p17 subunit
942	AGAAAGAATCT	2.08	0.96	2.17	0.46	Hs.107979	small membrane
							protein 1
943	CCCATCTAGCT	2.08	0.96	2.17	0.46	Hs.106070	cyclin-dependent
							kinase inhibitor 1C
							(p57, Kip2)
944	TCTGCAAGCAG	2.08	0.96	2.17	0.46	Hs.105598	ESTs, Weakly similar
							to neural variant
							mena++ protein
							[M,musculus]
945	AAAGAACATAG	2.08	0.96	2.17	0.46	Hs.104558	ESTs
946	GGCAAACTTTA	2.08	0.96	2.17	0.46	Hs.102497	paxillin
947	AGGGACATAAA	2.08	0.96	2.17	0.46	Hs.101516	BAl1-associated
							protein 3
948	TAAAGATCCTC	2.08	0.96	2.17	0.46	Hs.100407	Homo sapiens
							mRNA; cDNA
							DKFZp564H2416
							(from clone
							DKFZp564H2416)
949	TCAAGCCATCA	24.99	11.54	2.17	1.97	Hs.738	early growth
							response 1
950	CCTGGCTAATT	20.82	9.62	2.16	1.75	Hs.25661	ESTs
951	GCTGTAATCCC	10.41	4.81	2.16	1.15	Hs.184019	Homo sapiens clone
							23551 mRNA
							sequence
952	AAGCACAAAAA	8.33	3.85	2.16	1.01	Hs.9963	TYRO protein
							tyrosine kinase
953	CCCACTTGTAA	8.33	3.85	2.16	1.01	Hs.75922	brain protein 13
954	GCTTGGATCTC	8.33	3.85	2.16	1.01	Hs.250723	FK506 binding
							protein 12-rapamycin
							associated protein 1
955	CCACTGCTCTC	8.33	3.85	2.16	1.01	Hs.23510	Kruppel-like factor 12
956	TTGGCCAGACT	6.25	2.89	2.16	0.86	Hs.91728	polymyositis/sclerode
							rma autoantigen 1
							(75kD)
957	AGGTCCTAGCC	6.25	2.89	2.16	0.86	Hs.226795	glutathione S-transferase
							pi
958	GTGGTGTACGC	6.25	2.89	2.16	0.86	Hs.182225	RNA binding motif
							protein 3
959	AGCCCAGGAGG	6.25	2.89	2.16	0.86	Hs.136340	ESTs, Weakly similar
							to unnamed protein
							product [H,sapiens]
960	CAGATCTTTGT	6.25	2.89	2.16	0.86	Hs.119502	ubiquitin A-52 residue
							ribosomal protein
							fusion product 1
961	CCGTGGTCGTG	3.12	6.73	2.16	0.88	Hs.99853	fibrillarin
962	AGACCAAAGTG	3.12	6.73	2.16	0.88	Hs.82646	heat shock 40kD
							protein 1
963	TGAGTCTGGCT	3.12	6.73	2.16	0.88	Hs.4055	chromosome 21 open
							reading frame 50
964	GCAAAACTCTG	3.12	6.73	2.16	0.88	Hs.278746	ESTs
965	CCAGCTGCCAA	3.12	6.73	2.16	0.88	Hs.2055	ubiquitin-activating
							enzyme E1
966	GCGAAATCCCG	3.12	6.73	2.16	0.88	Hs.194251	ESTs
967	AAGGATGCCAA	3.12	6.73	2.16	0.88	Hs.169946	GATA-binding protein
							3
968	CAGCTATTTCA	3.12	6.73	2.16	0.88	Hs.153179	fatty acid binding
							protein 5 (psoriasis-associated)
969	GAATTATACTT	3.12	6.73	2.16	0.88	Hs.104800	hypothetical protein
							FLJ10134
970	GGAGGGGGCTT	9.37	20.20	2.16	1.70	Hs.77886	lamin A/C
971	AAGGAGATGGG	7.29	15.39	2.11	1.41	Hs.184014	ribosomal protein L31
972	GGAGGTGGGGC	7.29	15.39	2.11	1.41	Hs.180577	granulin
973	GAAAACAAAGT	153.04	319.40	2.09	14.34	Hs.99936	keratin 10
							(epidermolytic
							hyperkeratosis;
							keratosis palmaris et
							plantaris)
974	TTGGCTTTTCT	4.16	8.66	2.08	1.00	Hs.218329	hypothetical protein
975	GTGAAGCCCCA	4.16	8.66	2.08	1.00	Hs.171501	ubiquitin specific
							protease 11
976	ATGGCAACAGA	4.16	8.66	2.08	1.00	Hs.149609	integrin, alpha 5
							(fibronectin receptor,
							alpha polypeptide)
977	CGGGAGCGCTA	4.16	8.66	2.08	1.00	Hs.148590	ESTs, Weakly similar
							to AF208846_1 BM-004
							[H,sapiens]
978	TGTGATCAGAC	4.16	8.66	2.08	1.00	Hs.107476	ATP synthase, H+
							transporting,
							mitochondrial F1F0,
							subunit g
979	CTTCTCCAAAA	2.08	0.00	2.08	0.65	Hs.99949	prolactin-induced
							protein
980	CAGTTTTTTTC	2.08	0.00	2.08	0.65	Hs.99597	ESTs
981	TCAGAGAATAA	2.08	0.00	2.08	0.65	Hs.99486	ESTs
982	TGGGTCATTTG	2.08	0.00	2.08	0.65	Hs.98073	ESTs
983	AGGTTTCCTCC	2.08	0.00	2.08	0.65	Hs.9736	proteasome
							(prosome,
							macropain) 26S
							subunit, non-ATPase,
							3
984	AACGGGGCCCT	2.08	0.00	2.08	0.65	Hs.97203	small inducible
							cytokine subfamily A
							(Cys-Cys), member
							22
985	CTTAGCCCCAG	2.08	0.00	2.08	0.65	Hs.96908	ESTs
986	CCTGGTCAAGA	2.08	0.00	2.08	0.65	Hs.95972	silver (mouse
							homolog) like
987	TACCCCTTGAA	2.08	0.00	2.08	0.65	Hs.95834	ESTs
988	TTTTGTTTTGT	2.08	0.00	2.08	0.65	Hs.95583	transmembrane 4
							superfamily member
							(tetraspan NET-7)
989	TTTGCCTGGAT	2.08	0.00	2.08	0.65	Hs.95260	Autosomal Highly
							Conserved Protein
990	TTATTCCACAA	2.08	0.00	2.08	0.65	Hs.93765	lipoma HMGIC fusion
							partner
991	GTCTCATTTGA	2.08	0.00	2.08	0.65	Hs.92381	nudix (nucleoside
							diphosphate linked
							moiety X)-type motif 4
992	GTGGTCAAGTT	2.08	0.00	2.08	0.65	Hs.92127	ESTs
993	CACACCCCTGA	2.08	0.00	2.08	0.65	Hs.90061	progesterone binding
							protein
994	AATGAATGAAA	2.08	0.00	2.08	0.65	Hs.8986	complement
							component 1, q
							subcomponent, beta
							polypeptide
995	ATGCGAAAGGC	2.08	0.00	2.08	0.65	Hs.89466	dodecenoyl-Coenzyme
							A delta
							isomerase (3,2 transenoyl-Coenzyme A
							isomerase)
996	AGCACGACCCG	2.08	0.00	2.08	0.65	Hs.89434	drebrin 1
997	GCAATAAATGG	2.08	0.00	2.08	0.65	Hs.89434	drebrin 1
998	GGGGCTTAGGA	2.08	0.00	2.08	0.65	Hs.89135	KIAA1528 protein
999	GTTAAATCCTG	2.08	0.00	2.08	0.65	Hs.8881	ESTs, Weakly similar
							to RMS1_HUMAN
							REGULATOR OF
							MITOTIC SPINDLE
							ASSEMBLY 1
							[H,sapiens]
1000	GACTTCTGTCC	2.08	0.00	2.08	0.65	Hs.87539	aldehyde
							dehydrogenase 8
1001	GCACAATGGGA	2.08	0.00	2.08	0.65	Hs.85838	solute carrier family
							16 (monocarboxylic
							acid transporters),
							member 3
1002	GAGCGCAGCGA	2.08	0.00	2.08	0.65	Hs.83727	cleavage and
							polyadenylation
							specific factor 1,
							160kD subunit
1003	CAGGCTTTTTG	2.08	0.00	2.08	0.65	Hs.83484	SRY (sex determining
							region Y)-box 4
1004	ACACTTCTTTC	2.08	0.00	2.08	0.65	Hs.83381	guanine nucleotide
							binding protein 11
1005	TACAGTATTTT	2.08	0.00	2.08	0.65	Hs.82921	solute carrier family
							35 (CMP-sialic acid
							transporter), member
							1
1006	CAGCCCCTCTT	2.08	0.00	2.08	0.65	Hs.82503	H,sapiens mRNA for
							3′UTR of unknown
							protein
1007	AAAAGGCACTT	2.08	0.00	2.08	0.65	Hs.82425	actin related protein
							2/3 complex, subunit
							5 (16 kD)
1008	ACCATAATGTG	2.08	0.00	2.08	0.65	Hs.821	zinc finger protein
							homologous to Zfp92
							in mouse
1009	GGGCCCCCTGG	2.08	0.00	2.08	0.65	Hs.81994	glycophorin C
							(Gerbich blood group)
1010	TCAGAAAAAAA	2.08	0.00	2.08	0.65	Hs.8118	KIAA0650 protein
1011	AAAACATTATG	2.08	0.00	2.08	0.65	Hs.80917	adaptor-related
							protein complex 3,
							sigma 1 subunit
1012	GCTCCGTAAGG	2.08	0.00	2.08	0.65	Hs.80712	KIAA0202 protein
1013	AGTAAACCATC	2.08	0.00	2.08	0.65	Hs.80285	Homo sapiens
							mRNA; cDNA
							DKFZp586C1723
							(from clone
							DKFZp586C1723)
1014	GAAATTTGAAA	2.08	0.00	2.08	0.65	Hs.79457	hypothetical protein
							FLJ20519
1015	CACTCAATAAA	2.08	0.00	2.08	0.65	Hs.79361	Kalikrein 6 (neurosin,
							zyme)
1016	ATACTTTAATC	2.08	0.00	2.08	0.65	Hs.79274	annexin A5
1017	CAGGTTGAAGT	2.08	0.00	2.08	0.65	Hs.79219	RalGDS-like gene;
							KIAA0959 protein
1018	CTGCTTCCTGA	2.08	0.00	2.08	0.65	Hs.78921	A kinase (PRKA)
							anchor protein 1
1019	CTTTGCACTCT	2.08	0.00	2.08	0.65	Hs.78869	transcription
							elongation factor A
							(SII), 1
1020	TGGGCGCCTTT	2.08	0.00	2.08	0.65	Hs.78601	uroporphyrinogen
							decarboxylase
1021	TTTTCCTTTTG	2.08	0.00	2.08	0.65	Hs.78546	ATPase, Ca++
							transporting, plasma
							membrane 1
1022	CTGGGGGGAAG	2.08	0.00	2.08	0.65	Hs.77864	KIAA0638 protein
1023	GATTGTGCAAG	2.08	0.00	2.08	0.65	Hs.76666	C9orf10 protein
1024	GCCCTGTAGTT	2.08	0.00	2.08	0.65	Hs.76578	protein inhibitor of
							activated STAT3
1025	TGACAATTTTG	2.08	0.00	2.08	0.65	Hs.75912	KIAA0257 protein
1026	GATGTATTCTA	2.08	0.00	2.08	0.65	Hs.75844	ESTs, Highly similar
							to AF151903_1 CGI-145
							protein
							[H,sapiens]
1027	TATTTTTCTAG	2.08	0.00	2.08	0.65	Hs.7579	hypothetical protein
							FLJ10402
1028	CTGGATCTGGG	2.08	0.00	2.08	0.65	Hs.75658	phosphorylase,
							glycogen; brain
1029	TATTTTGTGAG	2.08	0.00	2.08	0.65	Hs.75607	myristoylated alanine-rich
							rich protein kinase C
							substrate (MARCKS,
							80K-L)
1030	TTGTTTAATTT	2.08	0.00	2.08	0.65	Hs.75546	capping protein (actin
							filament) muscle Z-line,
							alpha 2
1031	CGTTCCTGCGG	2.08	0.00	2.08	0.65	Hs.75424	inhibitor of DNA
							binding 1, dominant
							negtive helix-loop-helix
							protein
1032	CACTCAGTGTG	2.08	0.00	2.08	0.65	Hs.75379	solute carrier family 1
							(glial high affinity
							glutamate
							transporter), member
							3
1033	GCTAGGTCTGG	2.08	0.00	2.08	0.65	Hs.75354	GCN1 (general
							control of amino-acid
							synthesis 1, yeast)-like
							1
1034	GGAAGAGCACT	2.08	0.00	2.08	0.65	Hs.75268	sialyltransferase 4C
							(beta-galactosidase
							alpha-2,3-sialytransferase)
1035	ATGCAGCCATA	2.08	0.00	2.08	0.65	Hs.75212	ornithine
							decarboxylase 1
1036	CATCTGTGAGC	2.08	0.00	2.08	0.65	Hs.75189	death-associated
							protein
1037	CACTTTTGGGC	2.08	0.00	2.08	0.65	Hs.75080	LIM and SH3 protein
							1
1038	ATTTTGTGTCA	2.08	0.00	2.08	0.65	Hs.75056	adaptor-related
							protein complex 3,
							delta 1 subunit
1039	GCCGGGTGGGC	2.08	0.00	2.08	0.65	Hs.74631	basigin
1040	CATCCTGCTGC	2.08	0.00	2.08	0.65	Hs.74619	proteasome
							(prosome,
							macropain) 26S
							subunit, non-ATPase,
							2
1041	GCTGTATAATT	2.08	0.00	2.08	0.65	Hs.74170	metallothionein 1E
							(functional)
1042	GGAACCAGGTC	2.08	0.00	2.08	0.65	Hs.7404	ESTs
1043	AAAAAGAAACT	2.08	0.00	2.08	0.65	Hs.73287	KIAA1235 protein
1044	TCTGTATCCCC	2.08	0.00	2.08	0.65	Hs.724	thyroid hormone
							receptor, alpha (avian
							erythroblastic
							leukemia viral (v-erb-a)
							oncogene
							homolog)
1045	CACTGGACGAG	2.08	0.00	2.08	0.65	Hs.71574	ESTs
1046	CAAATAAAATG	2.08	0.00	2.08	0.65	Hs.71465	squalene epoxidase
1047	TGTCAAAAAAA	2.08	0.00	2.08	0.65	Hs.7120	cytokine receptor-like
							molecule 9
1048	ATGTCGTGGTC	2.08	0.00	2.08	0.65	Hs.6900	ring finger protein 13
1049	TCTTTACTTGA	2.08	0.00	2.08	0.65	Hs.6895	actin related protein
							2/3 complex, subunit
							3 (21 kD)
1050	TGCCTGGAACT	2.08	0.00	2.08	0.65	Hs.6820	ESTs, Weakly similar
							to putative
							[C,elegans]
1051	GGGCTCTGAGC	2.08	0.00	2.08	0.65	Hs.6770	LCAT-like
							lysophospholipase
1052	TTGGACTGAGC	2.08	0.00	2.08	0.65	Hs.6518	ganglioside
							expression factor 2
1053	ATGCAGTTCAA	2.08	0.00	2.08	0.65	Hs.65135	Homo sapiens
							mRNA; cDNA
							DKFZp434E0121
							(from clone
							DKFZp434E0121)
1054	ATTGAGCCACA	2.08	0.00	2.08	0.65	Hs.63290	2-hydroxyphytanoyl-CoA
							lyase
1055	TGTTTCAGGAT	2.08	0.00	2.08	0.65	Hs.6216	tumorous imaginal
							discs (Drosophila)
							homolog
1056	CCTGCCTCGTA	2.08	0.00	2.08	0.65	Hs.61490	schwannomin
							interacting protein 1
1057	AATAGGGGAAA	2.08	0.00	2.08	0.65	Hs.6147	KIAA1075 protein
1058	GCCGAGACCAA	2.08	0.00	2.08	0.65	Hs.61258	argininosuccinate
							lyase
1059	TTCAGGAGGGG	2.08	0.00	2.08	0.65	Hs.5890	ESTs, Weakly similar
							to A49134 Ig kappa
							chain V-I region
							[H,sapiens]
1060	TTGTTATATTG	2.08	0.00	2.08	0.65	Hs.5862	hypothetical protein
1061	TGAGTTTTACA	2.08	0.00	2.08	0.65	Hs.58373	ESTs
1062	TGCTTATTGAA	2.08	0.00	2.08	0.65	Hs.5822	lectin, mannose-binding,
							1
1063	AGTCAAGCCCC	2.08	0.00	2.08	0.65	Hs.57687	four and a half LIM
							domains 3
1064	GTATTCCTAAA	2.08	0.00	2.08	0.65	Hs.5724	ESTs, Weakly similar
							to multi PDZ domain
							protein MUPP1
							[H,sapiens]
1065	AGCCGGGCTTT	2.08	0.00	2.08	0.65	Hs.57079	ESTs
1066	CCTCTCTGGTC	2.08	0.00	2.08	0.65	Hs.56874	heat shock 27kD
							protein family,
							member 7
							(cardiovascular)
1067	AGTGTGTTGCA	2.08	0.00	2.08	0.65	Hs.56105	ESTs, Weakly similar
							to WDNM_RAT
							WDNM1 PROTEIN
							PRECURSOR_[R,norvegicus]
1068	TCAGGCATTTT	2.08	0.00	2.08	0.65	Hs.5566	gap junction protein,
							beta 2, 26kD
							(connexin 26)
1069	TGTGTGTGACA	2.08	0.00	2.08	0.65	Hs.55148	ESTs
1070	TGCAGACCCAT	2.08	0.00	2.08	0.65	Hs.5437	Taxi (human T-cell
							leukemia virus type I)
							binding protein 1
1071	TAATTTTTACT	2.08	0.00	2.08	0.65	Hs.52256	hypothetical protein
							FLJ20624
1072	ATTGTTTCTTG	2.08	0.00	2.08	0.65	Hs.52081	KIAA0867 protein
1073	CTTTTGTTTGG	2.08	0.00	2.08	0.65	Hs.5094	ring finger protein 10
1074	GTCTTAACTCA	2.08	0.00	2.08	0.65	Hs.5074	similar to S. pombe
							dim1+
1075	TAATAAAGCAT	2.08	0.00	2.08	0.65	Hs.4888	seryl-tRNA
							synthetase
1076	CCACGCACTGT	2.08	0.00	2.08	0.65	Hs.48778	Homo sapiens
							mRNA; cDNA
							DKFZp586O0221
							(from clone
							DKFZp586O0221)
1077	ACTCACGATTG	2.08	0.00	2.08	0.65	Hs.4814	mannosidase, alpha,
							class 1B, member 1
1078	TAACCAATCAG	2.08	0.00	2.08	0.65	Hs.479	RAB5C, member
							RAS oncogene family
1079	GGCCTCTGATG	2.08	0.00	2.08	0.65	Hs.46670	PRO1575 protein
1080	CCCAATTTTCA	2.08	0.00	2.08	0.65	Hs.46405	polymerase (RNA) II
							(DNA directed)
							polypeptide F
1081	TTTGTTGAATG	2.08	0.00	2.08	0.65	Hs.44856	ESTs
1082	TCTTTGCTCTT	2.08	0.00	2.08	0.65	Hs.44077	hypothetical protein
							FLJ10793
1083	AGGACTTCTGA	2.08	0.00	2.08	0.65	Hs.43847	ESTs, Weakly similar
							to SFR7_HUMAN
							SPLICING FACTOR,
							ARGININE/SERINE-RICH
							7 [H,sapiens]
1084	ATAATAAAGCT	2.08	0.00	2.08	0.65	Hs.37682	retinoic acid receptor
							responder
							(tazarotene induced)
							2
1085	CTTTTCATCAT	2.08	0.00	2.08	0.65	Hs.3726	x 003 protein
1086	TGGTCCCTCTC	2.08	0.00	2.08	0.65	Hs.36587	protein phosphatase
							1, regulatory subunit
							7
1087	TCTAGTCACTG	2.08	0.00	2.08	0.65	Hs.36565	ESTs
1088	GACTGCTCTGG	2.08	0.00	2.08	0.65	Hs.36475	ESTs
1089	GGGAAAGAGGG	2.08	0.00	2.08	0.65	Hs.35096	KIAA1538 protein
1090	GAGCTCCACAG	2.08	0.00	2.08	0.65	Hs.3407	protein kinase
							(cAMP-dependent,
							catalytic) inhibitor
							gamma
1091	TATGAAAACAT	2.08	0.00	2.08	0.65	Hs.3337	transmembrane 4
							superfamily member
							1
1092	GCCACGTTGTC	2.08	0.00	2.08	0.65	Hs.32352	hypothetical protein
							DKFZp434K1210
1093	TCCTCTACCTG	2.08	0.00	2.08	0.65	Hs.32018	SNARE associated
							protein snapin
1094	GGAGCAGACGC	2.08	0.00	2.08	0.65	Hs.31718	Homo sapiens cDNA
							FLJ11034 fis, clone
							PLACE1004258
1095	AATATTTTTAT	2.08	0.00	2.08	0.65	Hs.31386	ESTs, Highly similar
							to JE0174 frizzled
							protein-2-human
							[H,sapiens]
1096	GAGAGCCTGCC	2.08	0.00	2.08	0.65	Hs.31305	transducin-like
							enhancer of split 3,
							homolog of
							Drosophila E(sp1)
1097	GGCATTGTTCA	2.08	0.00	2.08	0.65	Hs.3128	polymerase (RNA) II
							(DNA directed)
							polypeptide H
1098	GAAATGGCAGT	2.08	0.00	2.08	0.65	Hs.30853	ESTs
1099	TTACCAAAGCA	2.08	0.00	2.08	0.65	Hs.30246	solute carrier family
							19 (thiamine
							transporter), member
							2
1100	GTATTGGCCTT	2.08	0.00	2.08	0.65	Hs.28757	transmembrane 9
							superfamily member
							2
1101	GTGTAAATGGA	2.08	0.00	2.08	0.65	Hs.286131	CGI-101 protein
1102	TTCACATTGTC	2.08	0.00	2.08	0.65	Hs.285804	ESTs
1103	CAGCTCATCTA	2.08	0.00	2.08	0.65	Hs.285634	Homo sapiens
							HSPC222 mRNA,
							complete cds
1104	AAACCCCAATA	2.08	0.00	2.08	0.65	Hs.285501	Human rearranged
							immunoglobulin
							lambda light chain
							mRNA
1105	TCATTTGGTGT	2.08	0.00	2.08	0.65	Hs.285439	ESTs
1106	ACTGTGGACTG	2.08	0.00	2.08	0.65	Hs.285122	ESTs, Weakly similar
							to S53869 laminin
							beta-2 chain
							precursor [H,sapiens]
1107	ACTGAGGTGCC	2.08	0.00	2.08	0.65	Hs.284159	FIBP-1 protein
1108	AGAGAAGAATG	2.08	0.00	2.08	0.65	Hs.2841	neuromedin U
1109	CTGGAGGCACA	2.08	0.00	2.08	0.65	Hs.283976	Homo sapiens clone
							TCBA00888 mRNA
							sequence
1110	GAGCCAACAAT	2.08	0.00	2.08	0.65	Hs.283680	hypothetical protein
1111	AGGATTGTTTG	2.08	0.00	2.08	0.65	Hs.283545	ESTs
1112	ATGTATGGGGA	2.08	0.00	2.08	0.65	Hs.283429	SMC (mouse)
							homolog, X
							chromosome
1113	TTGTAATAAAA	2.08	0.00	2.08	0.65	Hs.283429	SMC (mouse)
							homolog, X
							chromosome
1114	ATGAAACCCTA	2.08	0.00	2.08	0.65	Hs.282671	EST
1115	ACGTGGTGATG	2.08	0.00	2.08	0.65	Hs.279945	HSPC023 protein
1116	GAAATCCGCAC	2.08	0.00	2.08	0.65	Hs.279854	mannosidase, alpha,
							class 2B, member 1
1117	CTTTACTGTGT	2.08	0.00	2.08	0.65	Hs.279853	HSPC018 protein
1118	TGTGTTGTGTC	2.08	0.00	2.08	0.65	Hs.279806	Homo sapiens
							mRNA; cDNA
							DKFZp434E109
							(from clone
							DKFZp434E109)
1119	TGAGATTTCTT	2.08	0.00	2.08	0.65	Hs.279061	CGI-150 protein
1120	GTAAAGATTTG	2.08	0.00	2.08	0.65	Hs.278629	ESTs
1121	GTCGGACACTG	2.08	0.00	2.08	0.65	Hs.278559	talin
1122	GCTGGGCGCGG	2.08	0.00	2.08	0.65	Hs.278070	EST
1123	CTTGTAATCTC	2.08	0.00	2.08	0.65	Hs.278002	EST
1124	GTGGGTGTCCT	2.08	0.00	2.08	0.65	Hs.27633	DKFZP586B0519
							protein
1125	GGCAATGCAGT	2.08	0.00	2.08	0.65	Hs.275505	ESTs
1126	GTATAAAAAAA	2.08	0.00	2.08	0.65	Hs.27337	hypothetical protein
							FLJ20623
1127	ACACCTCTAAA	2.08	0.00	2.08	0.65	Hs.273230	hypothetical protein
							FLJ10830
1128	CACCTGTAGTT	2.08	0.00	2.08	0.65	Hs.271053	ESTs, Weakly similar
							to A46010 X-linked
							retinopathy protein
							[H,sapiens]
1129	TCACTCCAGCC	2.08	0.00	2.08	0.65	Hs.270497	ESTs
1130	TGTACATATGT	2.08	0.00	2.08	0.65	Hs.268384	homolog of yeast
							CDH1/HCT1
1131	GCTCTGTAAGC	2.08	0.00	2.08	0.65	Hs.268149	putative
							methyltransferase
1132	AATGTCCAGTA	2.08	0.00	2.08	0.65	Hs.26373	ESTs
1133	TTGTTAAGCCT	2.08	0.00	2.08	0.65	Hs.26243	Homo sapiens cDNA
							FLJ11177 fis, clone
							PLACE1007402
1134	TCTGGCTAATT	2.08	0.00	2.08	0.65	Hs.262198	ESTs
1135	TGTTAATGTTA	2.08	0.00	2.08	0.65	Hs.261828	Homo sapiens
							mRNA; cDNA
							DKFZp434N0211
							(from clone
							DKFZp434N0211)
1136	TCTGTAACACC	2.08	0.00	2.08	0.65	Hs.260622	butyrate-induced
							transcript 1
1137	GGGGTTTGTTT	2.08	0.00	2.08	0.65	Hs.258455	EST
1138	ACATAGTCTGA	2.08	0.00	2.08	0.65	Hs.25766	ESTs
1139	CGGATAAGGCC	2.08	0.00	2.08	0.65	Hs.256526	nuclear prelamin A
							recognition factor
1140	ATCTGAAGCAA	2.08	0.00	2.08	0.65	Hs.256311	granin-like
							neuroendocrine
							peptide precursor
1141	AAAGGCATCAG	2.08	0.00	2.08	0.65	Hs.256297	integrin, alpha 11
1142	CCCGCCAGTGC	2.08	0.00	2.08	0.65	Hs.256297	integrin, alpha 11
1143	TATGCTGAAAT	2.08	0.00	2.08	0.65	Hs.255277	ESTs
1144	AGGAGCGGGGT	2.08	0.00	2.08	0.65	Hs.252189	syndecan 4
							(amphiglycan,
							ryudocan)
1145	TTCACTTCAAC	2.08	0.00	2.08	0.65	Hs.250911	Homo sapiens clone
							23967 unknown
							mRNA, partial cds
1146	TTGTATCAGAA	2.08	0.00	2.08	0.65	Hs.250723	FK506 binding
							protein 12-rapamycin
							associated protein 1
1147	AGGTATATATC	2.08	0.00	2.08	0.65	Hs.24715	Homo sapiens
							mRNA; cDNA
							DKFZp434D0215
							(from clone
							DKFZp434D0215);
							partial cds
1148	ATGGAAAGGAA	2.08	0.00	2.08	0.65	Hs.243901	Homo sapiens cDNA
							FLJ20738 fis, clone
							HEP08257
1149	CCTCCAGCTAC	2.08	0.00	2.08	0.65	Hs.242463	keratin 8
1150	TATCTAGCTGC	2.08	0.00	2.08	0.65	Hs.241545	hypothetical protein
1151	GCTGTAATCCT	2.08	0.00	2.08	0.65	Hs.241382	tumor necrosis factor
							(ligand) superfamily,
							member 15
1152	TGAAGAGACTT	2.08	0.00	2.08	0.65	Hs.240767	Human DNA
							sequence from clone
							RP1-12G14 on
							chromosome 6q24, 1-25,2.
1153	GGACCACCCAA	2.08	0.00	2.08	0.65	Hs.239298	microtubule
							associated protein 4
1154	ATCCTACTGTT	2.08	0.00	2.08	0.65	Hs.239218	uncharacterized
							hypothalamus protein
							HCDASE
1155	CTTAGGAGTCA	2.08	0.00	2.08	0.65	Hs.23853	ESTs
1156	GGTGACAGAAC	2.08	0.00	2.08	0.65	Hs.234890	EST
1157	TGCCACCACGC	2.08	0.00	2.08	0.65	Hs.233480	EST
1158	GGCTTGTCTAT	2.08	0.00	2.08	0.65	Hs.23294	ESTs, Weakly similar
							to weak similarity to
							HSP90 [C,elegans]
1159	AAACTGGGAGG	2.08	0.00	2.08	0.65	Hs.231722	ESTs
1160	AACCCGGGGAG	2.08	0.00	2.08	0.65	Hs.228009	EST
1161	TTCTCCTCTTT	2.08	0.00	2.08	0.65	Hs.22451	hypothetical protein
							FLJ10357
1162	CCAATGTTGTT	2.08	0.00	2.08	0.65	Hs.22209	EST
1163	CAGCTCTTAGG	2.08	0.00	2.08	0.65	Hs.22208	Homo sapiens mRNA
							full length insert
							cDNA clone
							EUROIMAGE 30872
1164	GAAGTGCTGCT	2.08	0.00	2.08	0.65	Hs.21812	ESTs
1165	GAATGTTTTTT	2.08	0.00	2.08	0.65	Hs.21432	SEX gen
1166	TACATCCGAAT	2.08	0.00	2.08	0.65	Hs.21321	Homo sapiens
							mRNA; cDNA
							DKFZp564E1363
							(from clone
							DKFZp564E1363)
1167	GCGAACCCCCC	2.08	0.00	2.08	0.65	Hs.211862	EST
1168	CCCTCACTCCT	2.08	0.00	2.08	0.65	Hs.21143	(Manual assignment)
							MEMOREC PSL4
							presenilin-like protein,
							primary tag
1169	TGCAGGTGTGT	2.08	0.00	2.08	0.65	Hs.20993	high-glucose-regulated
							protein 8
1170	GCTAACTTAAA	2.08	0.00	2.08	0.65	Hs.20787	ESTs
1171	AAGTTTATAGA	2.08	0.00	2.08	0.65	Hs.206097	oncogene TC21
1172	AGACGCTTCTG	2.08	0.00	2.08	0.65	Hs.203772	FSHD region gene 1
1173	CCACTGCACGC	2.08	0.00	2.08	0.65	Hs.202669	thiopurine S-methyltransferase
1174	TAACCAAATAC	2.08	0.00	2.08	0.65	Hs.201623	ESTs
1175	TATTCCCCACC	2.08	0.00	2.08	0.65	Hs.199316	ESTs
1176	TGACTGTATTA	2.08	0.00	2.08	0.65	Hs.198241	amine oxidase,
							copper containing 3
							(vascular adhesion
							protein 1)
1177	TTTTTCTTAAA	2.08	0.00	2.08	0.65	Hs.197955	KIAA0704 protein
1178	CACTGCATATG	2.08	0.00	2.08	0.65	Hs.196177	phosphorylase
							kinase, gamma 2
							(testis)
1179	CCCTGAATGAA	2.08	0.00	2.08	0.65	Hs.19545	frizzled (Drosophila)
							homolog 4
1180	TTGGCCAAGAT	2.08	0.00	2.08	0.65	Hs.19522	hypothetical protein
							PRO2849
1181	TACAAAAGTGG	2.08	0.00	2.08	0.65	Hs.194662	calponin 3, acidic
1182	TGCTCAGTGGT	2.08	0.00	2.08	0.65	Hs.194625	dynein, cytoplasmic,
							light intermediate
							polypeptide 2
1183	CCCCCAATTCT	2.08	0.00	2.08	0.65	Hs.194534	vesicle-associated
							membrane protein 2
							(synaptobrevin 2)
1184	TGAGCACATAA	2.08	0.00	2.08	0.65	Hs.194208	suc1-associated
							neurotrophic factor
							target 2 (FGFR
							signalling adaptor)
1185	TTCCAGCTGCT	2.08	0.00	2.08	0.65	Hs.19121	adaptor-related
							protein complex 2,
							alpha 2 subunit
1186	CCACTCCACTC	2.08	0.00	2.08	0.65	Hs.190452	KIAA0365 gene
							product
1187	CAATTGTAAAT	2.08	0.00	2.08	0.65	Hs.18792	thioredoxin-like, 32kD
1188	AAGAACTAAAA	2.08	0.00	2.08	0.65	Hs.18778	hypothetical protein
1189	GGGGTACCCCT	2.08	0.00	2.08	0.65	Hs.187520	ESTs, Weakly similar
							to dJ353E16,2
							[H,sapiens]
1190	CCCTGAATCCC	2.08	0.00	2.08	0.65	Hs.184592	Human clone
							A9A2BRB5
							(CAC)n/(GTG)n
							repeat-containing
							mRNA
1191	AAAACAGTGGC	2.08	0.00	2.08	0.65	Hs.184109	ribosomal protein
							L37a
1192	CAGCATCTAAT	2.08	0.00	2.08	0.65	Hs.184062	putative Rab5-interacting
							protein
1193	CCACTGTACTT	2.08	0.00	2.08	0.65	Hs.183475	Homo sapiens clone
							25061 mRNA
							sequence
1194	CCTTGAAATCA	2.08	0.00	2.08	0.65	Hs.183161	ESTs
1195	GCAGTCATACA	2.08	0.00	2.08	0.65	Hs.182626	chromosome 22 open
							reading frame 5
1196	AAAGGTTGGTT	2.08	0.00	2.08	0.65	Hs.182423	ES1 (zebrafish)
							protein, human
							homolog of
1197	GCTCTGTTCAT	2.08	0.00	2.08	0.65	Hs.18192	Ser/Arg-related
							nuclear matrix protein
							(plenty of prolines
							101-like
1198	GCTCAGGTCTG	2.08	0.00	2.08	0.65	Hs.181406	endothelin converting
							enzyme 1
1199	GTGAAAAAAAA	2.08	0.00	2.08	0.65	Hs.181373	accessory proteins
							BAP31/BAP29
1200	TGATGTGATAG	2.08	0.00	2.08	0.65	Hs.181159	Homo sapiens
							mRNA; cDNA
							DKFZp434F0217
							(from clone
							DKFZp434F0217)
1201	TTTCTGTATGT	2.08	0.00	2.08	0.65	Hs.180877	H3 histone, family 3B
							(H3,3B)
1202	AAATCAGGAAC	2.08	0.00	2.08	0.65	Hs.180549	ESTs, Highly similar
							in R26660_1, partial
							CDS [H,sapiens]
1203	AGTTGAAATTC	2.08	0.00	2.08	0.65	Hs.180428	KIAA1181 protein
1204	AGTGCCTTGGG	2.08	0.00	2.08	0.65	Hs.178604	ESTs
1205	GCTTGGCTCCC	2.08	0.00	2.08	0.65	Hs.175260	EST
1206	CACATCCTTAC	2.08	0.00	2.08	0.65	Hs.173717	phosphatidic acid
							phosphatase type 2B
1207	ATAGAGGCAAT	2.08	0.00	2.08	0.65	Hs.173714	MORF-related gene
							X
1208	CCGTTCTGGAT	2.08	0.00	2.08	0.65	Hs.173638	Homo sapiens partial
							TCF-4 gene for T-cell
							transcription factor-4,
							exon 1 and joined
							CDS features
1209	TGCAGGGACCT	2.08	0.00	2.08	0.65	Hs.173043	metastasis-associated
							1-like 1
1210	GAAGGCTTATC	2.08	0.00	2.08	0.65	Hs.172674	nuclear factor of
							activated T-cells,
							cytoplasmic 3
1211	AATGAGCAACT	2.08	0.00	2.08	0.65	Hs.171862	guanylate binding
							protein 2, interferon-inducible
1212	TTTTGCTACAG	2.08	0.00	2.08	0.65	Hs.171545	HIV-1 Rev binding
							protein
1213	TAATTCTTCTC	2.08	0.00	2.08	0.65	Hs.1708	chaperonin
							containing TCP1,
							subunit 3 (gamma)
1214	TTCTAATTTTT	2.08	0.00	2.08	0.65	Hs.170414	paired basic amino
							acid cleaving system
							4
1215	ATGATAATTAA	2.08	0.00	2.08	0.65	Hs.170142	ESTs
1216	TTCTTGCTTAA	2.08	0.00	2.08	0.65	Hs.169895	ubiquitin-conjugating
							enzyme E2L 6
1217	CGAGGGGGGCG	2.08	0.00	2.08	0.65	Hs.169875	thrombospondin 3
1218	CTCCTGTGGTC	2.08	0.00	2.08	0.65	Hs.169851	ESTs
1219	GATCTGTTTCT	2.08	0.00	2.08	0.65	Hs.169743	Homo sapiens clone
							25121 neuronal
							offactomedin related
							ER localized protein
							mRNA sequence,
							complete cds
1220	AAGATTGGGGT	2.08	0.00	2.08	0.65	Hs.169610	CD44 antigen
							(homing function and
							indian blood group
							system)
1221	TAACCAAAAAC	2.08	0.00	2.08	0.65	Hs.169241	ELK4, ETS-domain
							protein (SRF
							accessory protein 1)
1222	GATTCAACCAA	2.08	0.00	2.08	0.65	Hs.168213	ESTs
1223	TTCTGTGCATA	2.08	0.00	2.08	0.65	Hs.16803	hypothetical protein
							FLJ10231
1224	CATAACCTTCC	2.08	0.00	2.08	0.65	Hs.167460	splicing factor,
							arginine/serine-rich 3
1225	ATAAATAAATT	2.08	0.00	2.08	0.65	Hs.16677	hypothetical protein
							FLJ10506
1226	GCTAGGTA1TT	2.08	0.00	2.08	0.65	Hs.165986	testin
1227	CTTTGA11TAT	2.08	0.00	2.08	0.65	Hs.165590	ribosomal protein S13
1228	ACAGCCCTGAT	2.08	0.00	2.08	0.65	Hs.163593	ribosomal protein
							L18a
1229	GCTCACTGCAA	2.08	0.00	2.08	0.65	Hs.163385	EST
1230	TTGAATATTAA	2.08	0.00	2.08	0.65	Hs.161554	hypothetical protein
							FLJ20159
1231	GGGATGGCAGC	2.08	0.00	2.08	0.65	Hs.159637	valyl-tRNA
							synthetase 2
1232	AGCTGGGATGG	2.08	0.00	2.08	0.65	Hs.15898	peroxisomal 2,4-dienoyl-CoA
							reductase
1233	ATCGCATCACT	2.08	0.00	2.08	0.65	Hs.158126	ESTs
1234	ACGCACATTAT	2.08	0.00	2.08	0.65	Hs.156007	Down syndrome
							critical region gene 1-like 1
1235	CCTCACTTTCT	2.08	0.00	2.08	0.65	Hs.155560	calnexin
1236	AAGAAGGCAAG	2.08	0.00	2.08	0.65	Hs.1554020	site of albumin
							promoter (albumin D-box)
							binding protein
1237	GAATCATTTAT	2.08	0.00	2.08	0.65	Hs.154668	KIAA0391 gene
							product
1238	GACTCTGGAGA	2.08	0.00	2.08	0.65	Hs.154567	supervillin
1239	GGCCGCTGCTC	2.08	0.00	2.08	0.65	Hs.151531	protein phosphatase
							3 (formerly 2B),
							catalytic subunit, beta
							isoform (calcineurin A
							beta)
1240	AACTCTGATAT	2.08	0.00	2.08	0.65	Hs.151046	hypothetical protein
							FLJ11193
1241	CTTCTCTTGAG	2.08	0.00	2.08	0.65	Hs.150557	basic transcription
							element binding
							protein 1
1242	CCCCTCCCCAG	2.08	0.00	2.08	0.65	Hs.150540	Homo sapiens
							chromosome 22q13
							BAC clone
							CIT987SK-384D8
							complete sequence
1243	TGAGGACACAG	2.08	0.00	2.08	0.65	Hs.14541	cullin 1
1244	ATGTCTTCGTT	2.08	0.00	2.08	0.65	Hs.144926	ESTs
1245	GTGCCTCGGAG	2.08	0.00	2.08	0.65	Hs.143046	Homo sapiens cDNA
							FLJ20418 fis, clone
							KAT02427
1246	CCTGCAGTCCC	2.08	0.00	2.08	0.65	Hs.141746	ESTs
1247	TTGATAAATAA	2.08	0.00	2.08	0.65	Hs.139226	replication factor C
							(activator 1) 2 (40kD)
1248	CGCCTGTGGTC	2.08	0.00	2.08	0.65	Hs.138263	Homo sapiens clone
							24528 mRNA
							sequence
1249	ACCTCACCTGG	2.08	0.00	2.08	0.65	Hs.137585	UDP
							glycosyltransferase 2
							family, polypeptide
							B11
1250	GTGTCTGTCTC	2.08	0.00	2.08	0.65	Hs.137432	ESTs
1251	TTCAGTAATAA	2.08	0.00	2.08	0.65	Hs.13479	hypothetical protein
							FLJ20847
1252	CTTTAAGAAAG	2.08	0.00	2.08	0.65	Hs.13456	Homo sapiens clone
							24747 mRNA
							sequence
1253	TAAAGTGTCTG	2.08	0.00	2.08	0.65	Hs.132875	Homo sapiens
							HSPC309 mRNA,
							partial cds
1254	GGCCTCTCCGA	2.08	0.00	2.08	0.65	Hs.132834	hematopoietic protein
							1
1255	GCACCTTCTGG	2.08	0.00	2.08	0.65	Hs.132744	hypothetical protein
1256	CATTGAGCTCC	2.08	0.00	2.08	0.65	Hs.12820	SnRNP assembly
							defective 1 homolog
1257	TCAATCAGTGA	2.08	0.00	2.08	0.65	Hs.127270	ESTs
1258	ACCTGCCCCTC	2.08	0.00	2.08	0.65	Hs.125262	DKFZP586G1624
							protein
1259	GCACCTTATTG	2.08	0.00	2.08	0.65	Hs.125078	ornithine
							decarboxylase
							antizyme 1
1260	ACAACATAGAA	2.08	0.00	2.08	0.65	Hs.12436	ESTs
1261	TGCTGCTTGAA	2.08	0.00	2.08	0.65	Hs.12152	APMCF1 protein
1262	TTATTGTTCCC	2.08	0.00	2.08	0.65	Hs.12126	hepatocellular
							carcinoma-associated
							antigen 112
1263	GGTGATGAGGA	2.08	0.00	2.08	0.65	Hs.12107	putative breast
							adenocarcinoma
							marker (32kD)
1264	CTGAACTGTGA	2.08	0.00	2.08	0.65	Hs.121031	ESTs
1265	AACATAGGAAA	2.08	0.00	2.08	0.65	Hs.119663	CDS9 antigen p18-20
							(antigen identified by
							monoclonal
							antibodies 16,3A5,
							EJ16, EJ30, EL32
							and G344)
1266	CTGGTGAGTGC	2.08	0.00	2.08	0.65	Hs.11902	MYLE protein
1267	GCCTGGGAGAC	2.08	0.00	2.08	0.65	Hs.118346	ESTs
1268	AGCTGAGCTAA	2.08	0.00	2.08	0.65	Hs.118243	deoxyribonuclease II,
							lysosomal
1269	CCGGACCTGTG	2.08	0.00	2.08	0.65	Hs.117582	CGI-43 protein
1270	CGGAGCCGGCT	2.08	0.00	2.08	0.65	Hs.117582	CGI-43 protein
1271	GAGAGGTGATT	2.08	0.00	2.08	0.65	Hs.114062	protein tyrosine
							phosphatase-like
							(proline instead of
							catalytic arginine),
							member a
1272	AAGATCCTTGT	2.08	0.00	2.08	0.65	Hs.113503	karyopherin (importin)
							beta 3
1273	AATGAACAATA	2.08	0.00	2.08	0.65	Hs.11342	ninjurin 1
1274	TTGGTCAGGTT	2.08	0.00	2.08	0.65	Hs.113111	Homo sapiens
							familial
							Mediterranean fever
							locus region, mRNA
							sequence
1275	GACTCTGGGAT	2.08	0.00	2.08	0.65	Hs.11282	ESTs, Weakly similar
							to cleft lip and palate
							transmembrane
							protein 1 [H,sapiens]
1276	TACACGTGAGG	2.08	0.00	2.08	0.65	Hs.1 1156	hypothetical protein
1277	AGCACTGCAGC	2.08	0.00	2.08	0.65	Hs.111039	N-myristoyltransferase
							1
1278	AACTCCCAGTT	2.08	0.00	2.08	0.65	Hs.110571	growth arrest and
							DNA-damage-inducible,
							beta
1279	GCATAATGTTT	2.08	0.00	2.08	0.65	Hs.11050	F-box only protein 9
1280	CCCAGGACACC	2.08	0.00	2.08	0.65	Hs.110443	Homo sapiens
							mRNA; cDNA
							DKFZp761O051
							(from clone
							DKFZp761O051)
1281	AAAGGAAAGTC	2.08	0.00	2.08	0.65	Hs.109706	HN1 protein
1282	AATAAATGGAT	2.08	0.00	2.08	0.65	Hs.109052	chromosome 14 open
							reading frame 2
1283	ACCAACACGGG	2.08	0.00	2.08	0.65	Hs.109005	ESTs
1284	CTTCCGGGTAA	2.08	0.00	2.08	0.65	Hs.108924	DKFZP586P1422
							protein
1285	GGAGTCCTAGC	2.08	0.00	2.08	0.65	Hs.108894	hypothetical protein
							FLJ20411
1286	CTTCTGTCTCC	2.08	0.00	2.08	0.65	Hs.108824	ESTs, Weakly similar
							to cDNA EST
							yk415c12,5 comes
							from this gene
							[C,elegans]
1287	TTTAGGGGGAA	2.08	0.00	2.08	0.65	Hs.108319	thyroid hormone
							receptor-associated
							protein, 150 kDa
							subunit
1288	TGTAGCTGCAA	2.08	0.00	2.08	0.65	Hs.107882	hypothetical protein
							FLJ10659
1289	TGAAACTTTTC	2.08	0.00	2.08	0.65	Hs.107528	androgen induced
							protein
1290	TTACAGAGCTT	2.08	0.00	2.08	0.65	Hs.10590	zinc finger protein
							313
1291	TCCTTTAAAAT	2.08	0.00	2.08	0.65	Hs.10587	KIAA0353 protein
1292	GGAACTTGGCT	2.08	0.00	2.08	0.65	Hs.105613	ESTs
1293	GAGAACCGTAG	2.08	0.00	2.08	0.65	Hs.105547	neural proliferation,
							differentiation and
							control, 1
1294	TCATCTGCAAA	2.08	0.00	2.08	0.65	Hs.105189	ESTs, Weakly similar
							to AF148856_2
							unknown [H,sapiens]
1295	CATAATTTCTC	2.08	0.00	2.08	0.65	Hs.104660	eIF-5A2 protein
1296	CAATCTTGTGA	2.08	0.00	2.08	0.65	Hs.104353	ESTs
1297	TTTCCTTCCTT	2.08	0.00	2.08	0.65	Hs.104143	clathrin, light
							polypeptide (Lca)
1298	AGACAGAGTGG	2.08	0.00	2.08	0.65	Hs.103833	ESTs, Weakly similar
							to AF151869_1 CGI-111
							protein
							[H,sapiens]
1299	TGGGGAGAGGA	5.21	10.58	2.03	1.10	Hs.75799	protease, serine, 8
							(prostasin)
1300	CCACCACGCTT	5.21	10.58	2.03	1.10	Hs.285275	ESTs
1301	TGCCTGTGGTC	5.21	10.58	2.03	1.10	Hs.277100	ESTs
1302	ATGGCAGGTGC	5.21	10.58	2.03	1.10	Hs.236479	EST
1303	AAGTTGCTATT	15.62	7.70	2.03	1.38	Hs.78575	prosaposin (variant
							Gaucher disease and
							variant
							metachromatic
							leukodystrophy)
1304	AGCCACTGCAC	15.62	7.70	2.03	1.38	Hs.122126	ESTs
1305	GCAAAAAAAAA	6.25	12.51	2.00	1.19	Hs.76293	thymosin, beta 10
1306	GTGGCACGCGC	6.25	12.51	2.00	1.19	Hs.187346	ESTs

[0225]

TABLE 5
No.	Tag sequence	Young	Old	Quotient	Significance	Annotation	Description
1307	TCTCCATACCC	175.94	0.00	175.94	53.84	manual	Mitochondrial
							polymorphic tag,
							pos:4216
1308	ATGAAACTTCG	63.50	0.96	66.15	17.94	manual	Mitochondrial minor
							tag, pos:14832
1309	CACTACTCACC	2.08	79.85	38.39	20.69	manual	Mitochondrial major
							tag, pos:14902
1310	ACCCTTGGCCA	10.41	109.67	10.54	21.39	manual	Mitochondrial major
							tag, pos:3839
1311	AAACATCCTAT	1.04	4.81	4.63	0.98	manual	Mitochondrial minor
							tag, pos:7249
1312	GTAGGGGTAAA	4.16	0.00	4.16	1.29	manual	Mitochondrial
							antisense tag, pos:-
							6282
1313	TTGGAACAATG	0.00	3.85	3.85	1.15	manual	rRNA major tag
1314	ACCCGCCGGGC	1.04	3.85	3.70	0.77	manual	rRNA major tag
1315	TGGCGTACGGA	1.04	3.85	3.70	0.77	manual	rRNA major tag
1316	CCGACGGGCGC	4.16	15.39	3.70	2.15	manual	rRNA intermediate
							tag
1317	GGTCAGTCGGT	6.25	1.92	3.26	1.05	manual	rRNA major tag
1318	TGCCTAGACCA	3.12	0.96	3.25	0.66	manual	Mitochondrial minor
							tag, pos:12498
1319	AGCTGTCCCCA	0.00	2.89	2.89	0.87	manual	Mitochondrial minor
							tag, pos:8070
1320	ATGGCAGGAGT	0.00	2.89	2.89	0.87	manual	Mitochondrial
							antisense tag, pos:-
							12728
1321	TGAGAAGAAGC	0.00	2.89	2.89	0.87	manual	Mitochondrial
							antisense tag, pos:-
							11703
1322	CATTTGGTATT	8.33	2.89	2.88	1.20	manual	Mitochondrial minor
							tag, pos:44
1323	TACTGCTCGGA	1.04	2.89	2.78	0.59	manual	Mitochondrial
							antisense tag, pos:-
							13715
1324	GCTAGGTTTAT	2.08	5.77	2.77	0.91	manual	Mitochondrial
							antisense tag, pos:-
							7732
1325	TGGTGTATGCA	5.21	1.92	2.71	0.86	manual	Mitochondrial
							antisense tag, pos:-
							9318
1326	AATGGATGAAC	5.21	12.51	2.40	1.37	manual	rRNA intermediate
							tag
1327	GTAATCCTGCT	27.07	61.57	2.27	4.03	manual	rRNA major tag
1328	TTGCTCAGGCT	2.08	0.96	2.17	0.46	manual	rRNA intermediate
							tag, Alu
1329	GAAGTCGGAAT	3.12	6.73	2.16	0.88	manual	rRNA major tag
1330	AGAATCGCTTG	22.90	48.10	2.10	2.98	manual	Alu-repeat
1331	CATTTGTAATA	4.16	8.66	2.08	1.00	manual	Mitochondrial
							intermediate tag,
							pos:6084
1332	CTTACAAGCAA	2.08	0.00	2.08	0.65	manual	Mitochondrial minor
							tag, pos:16193
1333	TTACTTATACT	2.08	0.00	2.08	0.65	manual	Mitochondrial
							antisense tag, pos:-
							14253
1334	GGGGTCAGGGG	5.21	10.58	2.03	1.10	manual	Mitochondrial
							antisense tag, pos:-
							2138
1335	AAAACATTCTC	18.74	37.52	2.00	2.34	manual	Mitochondrial major
							tag, pos:2314

[0226]

TABLE 7
					Unigene
					No.
No.	Tag sequence	Young	Old	Quotient	(NCBI)	Description
1336	TGTGCCAGTGT	1.04	11.54	11.10	331555	Homo sapiens serine protease
						inhibitor, Kazal type, 5
						(SPINK5), mRNA
1337	CATCTGCTGAT	8.33	0	8.33	28338	Homo sapiens mRNA for
						KIAA1546 protein, partial cds
1338	TTCCCCCTTCC	7.29	0.96	7.59	332967	nx11f05.s1 Homo sapiens
						cDNA, 3′ end
1339	CGGCTTTTCTG	7.29	0.96	7.59	324648	Homo sapiens cDNA FLJ13700
						fis, clone PLACE2000216,
						highly similar to SPECTRIN
						BETA CHAIN, BRAIN
1340	CGCCGGGAGCT	1.04	7.7	7.40	61460	Homo sapiens cDNA FLJ14847
						fis, clone PLACE1000401,
						weakly similar to POLIOVIRUS
						RECEPTOR PRECURSOR
1341	CTGTGGGAAAC	0	6.73	6.73	225997	“Homo sapiens mRNA; cDNA
						DKFZp564C0962 (from clone
						DKFZp564C0962)”
1342	GCGTCGGTGCA	6.25	0.96	6.51	155597	Homo sapiens D component of
						complement (adipsin) (DF),
						mRNA
1343	GACCAGCTGGC	6.25	0.96	6.51	74120	Homo sapiens adipose specific
						2 (APM2), mRNA
1344	GTGTGGTGGAG	0	5.77	5.77	177486	Homo sapiens amyloid beta
						(A4) precursor protein
						(protease nexin-II, Alzheimer
						disease) (APP), mRNA
1345	AAAGTCATTGA	5.21	0.96	5.43	77899	Homo sapiens tropomyosin 1
						(alpha) (TPM1), mRNA
1346	ACCTGGAGGGG	3.12	16.35	5.24	135188	602625439F1 Homo sapiens
						cDNA, 5′ end
1347	GGTAATCCGTT	5.21	0	5.21	30942	Homo sapiens ephrin-B2
						(EFNB2), mRNA
1348	GTGGCGGGCTC	0	4.81	4.81	142634	Homo sapiens zinc finger
						protein (AF020591), mRNA
1349	CTGATCTCGAA	0	4.81	4.81	177932	ie10c08.y1 Homo sapiens
						cDNA, 5′ end
1350	CTCGGTACATT	0	4.81	4.81	74316	Homo sapiens desmoplakin
						(DPI, DPII) (DSP), mRNA
1351	CAGCGGCGGGA	0	4.81	4.81	2420	Homo sapiens superoxide
						dismutase 3, extracellular
						(SOD3), mRNA
1352	TAGCTGCTGGT	1.04	4.81	4.63	11482	Homo sapiens splicing factor,
						arginine/serine-rich 11
						(SFRS11), mRNA
1353	GTGGCACATTC	1.04	4.81	4.63	319567	Homo sapiens cDNA FLJ12130
						fis, clone MAMMA1000251
1354	GTCAGTTCCTG	1.04	4.81	4.63	3796	Homo sapiens EphB6 (EPHB6)
						mRNA
1355	GGTGACAGAGA	4.16	0.96	4.33	324611	602370629F1 Homo sapiens
						cDNA, 5′ end
1356	AAACTTTGCCT	4.16	0.96	4.33	194431	Homo sapiens palladin
						(KIAA0992), mRNA
1357	CAGCTCACTGA	4.16	17.32	4.16	738	Homo sapiens ribosomal
						protein L14 (RPL14), mRNA
1358	ATGACAGATGG	2.08	8.66	4.16	13775	Homo sapiens hypothetical
						protein SMAP31 (SMAP31),
						mRNA
1359	GCACTCTAGCC	4.16	0	4.16	306735	Homo sapiens cDNA:
						FLJ21297 fis, clone COL02035
1360	AAATGCTTGGA	4.16	0	4.16	252998	xl80g03.x1 Homo sapiens
						cDNA, 3′ end
1361	CCTCTTTGCAT	5.21	21.17	4.06	707	Homo sapiens keratin 2A
						(epidermal ichthyosis bullosa of
						Siemens) (KRT2A), mRNA
1362	TGGTCCCAGCT	0	3.85	3.85	275481	ni38b03.s1 Homo sapiens
						cDNA, 3′ end
1363	TGAAGGTGGTG	0	3.85	3.85	250528	Homo sapiens, clone
						IMAGE:4098694, mRNA
1364	TCAACTTGAAA	0	3.85	3.85	38891	602385216F1 Homo sapiens
						cDNA, 5′ end
1365	GTTGTCATCAC	0	3.85	3.85	2633	Homo sapiens desmoglein 1
						(DSG1), mRNA
1366	GTGGCGCACGT	0	3.85	3.85	249720	Homo sapiens cDNA, 3′ end
1367	GCACCGTAAGA	0	3.85	3.85	168232	Homo sapiens hypothetical
						protein FLJ13855 (FLJ13855),
						mRNA
1368	GACCCGGGAGG	0	3.85	3.85	41974	Homo sapiens , clone
						IMAGE:4100953, mRNA
1369	CTGCGGAAGAT	0	3.85	3.85	99816	Homo sapiens beta-catenin-
						interacting protein ICAT
						(LOC56998), mRNA
1370	AACAGGCAAGA	0	3.85	3.85	73995	Human DNA sequence from
						clone RP1-14N1 on
						chromosome 1q21.1-21.3
						Contains ESTs, GSSs and
						STSs. Contains the FLG gene
						for profilaggrin and part of a
						gene for a novel S-100/ICaBP
						type calcium binding domain
						protein similar to trichohyalin.n
1371	GGCCGCGAGGT	7.29	1.92	3.80	78344	Homo sapiens myosin, heavy
						polypeptide 11, smooth muscle
						(MYH11), transcript variant
						SM2, mRNA
1372	CTAACGCAGCA	7.29	1.92	3.80	78465	Homo sapiens v-jun avian
						sarcoma virus 17 oncogene
						homolog (JUN), mRNA
1373	TGGCCTCCCCG	1.04	3.85	3.70	159161	Homo sapiens Rho GDP
						dissociation inhibitor (GDI)
						alpha (ARHGDIA), mRNA
1374	GGAGAGAAAAG	1.04	3.85	3.70	158291	Human DNA sequence from
						clone RP1-233K16 on
						chromosome 1p36.21-36.33
						Contains the gene KIAA0444, a
						putative chromodomain
						helicase DNA binding protein 3
						(CHD3), the gene for
						potassium channel beta 2
						subunit (KCNK2), two CpG
						island, ESTs, STSs and GSSs
1375	GGACTCTGCCC	1.04	3.85	3.70	225948	Homo sapiens small inducible
						cytokine subfamily A (Cys-
						Cys), member 27 (SCYA27),
						mRNA
1376	GACGGCGCAGG	1.04	3.85	3.70	73946	Homo sapiens endothelial cell
						growth factor 1 (platelet-
						derived) (ECGF1), mRNA
1377	ATGAGATCCTG	1.04	3.85	3.70	275741	nx39e06.s1 Homo sapiens
						cDNA, 3′ end
1378	ACCTGGAGGGT	1.04	3.85	3.70	127723	“Homo sapiens mRNA; cDNA
						DKFZp586J211 (from clone
						DKFZp586J211)”
1379	GTGGCACGTGA	3.12	0.96	3.25	147996	Homo sapiens protein kinase,
						X-linked (PRKX), mRNA
1380	GTAGCGGGCGC	3.12	0.96	3.25	323114	Homo sapiens cDNA FLJ13784
					fis, clone PLACE4000593
1381	GGGCTGTTTGG	3.12	0.96	3.25	189658	Homo sapiens CGI-149 protein
						(LOC51652), mRNA
1382	GGCCTCTGAGC	3.12	0.96	3.25	69559	Novel human mRNA from
						chromosome 1, which has
						similarities to BAT2 genes
1383	GGCAGTGCCCA	3.12	0.96	3.25	110915	Homo sapiens interleukin 22
						receptor (IL22R), mRNA
1384	GCAGTGCGTGC	3.12	0.96	3.25	202508	601649719F1 Homo sapiens
						cDNA, 5′ end
1385	GCAAAGCCCTG	3.12	0.96	3.25	210509	EST371827 Homo sapiens
						cDNA
1386	GATCCCAACAT	3.12	0.96	3.25	25	Homo sapiens ATP synthase,
						H+ transporting, mitochondrial
						F1 complex, beta polypeptide
						(ATP5B)
1387	GAGAAACACCG	3.12	0.96	3.25	2479	602153463F1 Homo sapiens
						cDNA, 5′ end
1388	GACGATGTATA	3.12	0.96	3.25	1837	Homo sapiens POU domain,
						class 3, transcription factor 1
						(POU3F1), mRNA
1389	CAAGCATTCCC	3.12	0.96	3.25	131620	ov74g10.x1 Homo sapiens
						cDNA, 3′ end
1390	ATGAAGAAGGA	3.12	0.96	3.25	2780	Homo sapiens jun D proto
						oncogene (JUND), mRNA
1391	AGTAGCCGTGA	3.12	0.96	3.25	286360	601655325R1 Homo sapiens
						cDNA, 3′ end
1392	ACTTGATAAAT	3.12	0.96	3.25	344484	tj56h03.x1 Homo sapiens
						cDNA, 3′ end
1393	ACCCGCGAGGA	3.12	0.96	3.25	170294	Homo sapiens , clone
						IMAGE:3637796, mRNA,
						partial cds
1394	AACCAGGGAGG	3.12	0.96	3.25	265317	Homo sapiens hypothetical
						protein MGC2562 (MGC2562),
						mRNA
1395	TAACCAAATCA	3.12	0	3.12	145421	qf27h11.x5 Homo sapiens
						cDNA, 3′ end
						/clone=IMAGE:1751301
1396	GTGGTGGTGCC	3.12	0	3.12	13197	603045818F1 Homo sapiens
						cDNA, 5′ end
1397	GTGAAACTCAG	3.12	0	3.12	178485	Homo sapiens cDNA FLJ13919
						fis, clone Y79AA1000410
1398	GGGCTCGGGGA	3.12	0	3.12	105927	“Homo sapiens stem cell
						growth factor; lymphocyte
						secreted C-type lectin (SCGF),
						mRNA”
1399	GCGGCGGGTGC	3.12	0	3.12	257719	he36a05.x1 Homo sapiens
						cDNA, 3+ end
1400	GCAAAATTCTG	3.12	0	3.12	336728	nk76b08.s1 Homo sapiens
						cDNA, 3′ end
1401	GAAGGAGGCAT	3.12	0	3.12	184771	Homo sapiens nuclear factor
						I/C (CCAAT-binding
						transcription factor) (NFIC),
						mRNA
1402	CTTTTAAGAAA	3.12	0	3.12	86043	Homo sapiens cDNA FLJ13558
						fis, clone PLACE1007743
1403	CTCTACAGTGC	3.12	0	3.12	24322	Homo sapiens ATPase, H+
						transporting, lysosomal
						(vacuolar proton pump) 9kD
						(ATP6H), mRNA
1404	CGTTTTCTGAT	3.12	0	3.12	82911	Homo sapiens BM-008 mRNA,
						complete cds
1405	CCCCGGGCCTC	3.12	0	3.12	89901	Homo sapiens
						phosphodiesterase 4A, cAMP-
						specific (dunce (Drosophila)-
						homolog phosphodiesterase
						E2) (PDE4A), mRNA
1406	CCCCCACCCGG	3.12	0	3.12	78482	Homo sapiens paralemmin
						(PALM), mRNA
1407	CCATCTTGAGG	3.12	0	3.12	110707	Homo sapiens H326 (H326),
						mRNA
1408	CAGACCGGTGC	3.12	0	3.12	118397	Homo sapiens AE-binding
						protein 1 (AEBP1), mRNA
1409	AGTAACAAGAT	3.12	0	3.12	118174	Homo sapiens tetratricopeptide
						repeat domain 3 (TTC3),
						mRNA
1410	AGCCTAGGAGT	3.12	0	3.12	37308	yq9Be10.s1 Homo sapiens
						cDNA, 3′ end
1411	AATTAACTCCG	3.12	0	3.12	169517	Homo sapiens , Similar to
						aldehyde dehydrogenase 5,
						clone MGC:2230
1412	GCTTTATTTGT	28.11	9.62	2.92	288061	Homo sapiens actin, beta
						(ACTB), mRNA
1413	TTTATCTTTTA	0	2.89	2.89	303125	Homo sapiens p53-induced
						protein PIGPC1 (PIGPC1),
						mRNA
1414	TGTTCCTGGAT	0	2.89	2.89	287423	Homo sapiens cDNA FLJ11556
						fis, clone HEMBA1003079
1415	TGCGCTGGCCC	0	2.89	2.89	289019	Homo sapiens latent
						transforming growth factor beta
						binding protein 3 (LTBP3),
						mRNA
1416	TCGGAGCTGCT	0	2.89	2.89	1030	Homo sapiens ras inhibitor
						(RIN1), mRNA
1417	GTTTCCAATGC	0	2.89	2.89	57672	Homo sapiens leucine rich
						repeat (in FLII) interacting
						protein 2 (LRRFIP2), mRNA
1418	GTTCAGCTGTC	0	2.89	2.89	78902	Homo sapiens voltage-
						dependent anion channel 2
						(VDAC2), mRNA
1419	GTGGTGCAAGC	0	2.89	2.89	306411	Homo sapiens cDNA FLJ20846
						fis, clone ADKA01802
1420	GTGGTGAGTAC	0	2.89	2.89	182999	yx41g11.s1 Homo sapiens
						cDNA, 3′ end
1421	GTGAGCCCATT	0	2.89	2.89	74335	Homo sapiens heat shock
						90kD protein 1, beta (HSPCB),
						mRNA
1422	GGCTATGCCAA	0	2.89	2.89	3688	Homo sapiens mRNA for
						cisplatin resistance-associated
						overexpressed protein,
						complete cds
1423	GGCAGCTGGCA	0	2.89	2.89	3487	Homo sapiens hypothetical
						protein FLJ10439 (FLJ10439),
						mRNA
1424	GGCAGACAATC	0	2.89	2.89	335880	601277672F1 Homo sapiens
						cDNA, 5′ end
1425	GCTAAAAACAA	0	2.89	2.89	134590	oy67c11.x1 Homo sapiens
						cDNA, 3′ end
1426	GCAGCTACGGC	0	2.89	2.89	80828	Homo sapiens keratin 1
						(epidermolytic hyperkeratosis)
						(KRT1), mRNA
1427	GATCTTCTCGG	0	2.89	2.89	73995	Human profilaggrin mRNA, 3′
						end
1428	GAGGAGTCCAT	0	2.89	2.89	1432	Homo sapiens protein kinase C
						substrate 80K-H (PRKCSH),
						mRNA
1429	GACCACACACC	0	2.89	2.89	86950	qf57c11.x1 Homo sapiens
						cDNA, 3′ end
1430	CGGTCATTCTC	0	2.89	2.89	154396	Homo sapiens cDNA:
						FLJ22282 fis, clone HRC03861
1431	CCTATGGTCCC	0	2.89	2.89	344536	cong1.P10.E3 Homo sapiens
						cDNA, 3′ end
1432	CCTATAGTCTC	0	2.89	2.89	328052	ty52c06.x1 Homo sapiens
						cDNA, 3′ end
1433	CCCTGTTGATA	0	2.89	2.89	151254	Homo sapiens kallikrein 7
						(chymotryptic, stratum
						corneum) (KLK7), mRNA
1434	CCAGTGAATAG	0	2.89	2.89	146825	qb68e04.x1 Homo sapiens
						cDNA, 3′ end
1435	CCACTGCACCA	0	2.89	2.89	257594	Homo sapiens mRNA for
						KIAA1364 protein, partial cds

[0227]

TABLE 6
	Unigene
	accession	SWISSPROT
No.	No(s).	or TREMBL	EMBL/GENBANK	Description
1	Hs.279604			DESMIN: DESMIN
2	Hs.119571			COLLAGEN ALPHA1(III)
3	Hs.74649			COX6C: CYTOCHROME C OXIDASE
				POLYPEPTIDE VIC [PRECURSOR] EC
				1.9.3.1
4	Hs.102948			ENIGMA
5	Hs.76941			NA K ATPASE B3: NA K ATPASE BETA3
6	Hs.183760			C3: (C3) COMPLEMENT C3 PRECURSOR
7	Hs.75748			PSMB1: (PSMB1 OR PSC5) PROTEASOME
				COMPONENT C5
8	Hs.198427			HK2: HEXOKINASE, TYPE II EC 2.7.1.1 HK
				II
9	Hs.170171			GLNA GLUTAMINE SYNTHETASE (EC
				6.3.1.2) (GLUTAMATE AMMONIA LIGASE)
10	Hs.81328			IKBA: (NFKBIA OR NFKBI OR MAD3) I
				KAPPA B ALPHA, MAJOR
				HISTOCOMPATIBILITY COMPLEX
				ENHANCER BINDING
11	Hs.197345			G22P1: (G22P1) ATP DEPENDENT DNA
				HELICASE II, 70 KDA SUBUNIT (LUPUS KU
				AUTOANTIGEN PROTEIN P70) (KU70) (70 KDA
				SUBUNIT OF KU ANTIGEN)
				(THYROID LUPUS AUTOANTIGEN) (TLAA)
				(CTC BOX BINDING FACTOR 75 KDA
				SUBUNIT) (CTCBF) (CTC75).
12	Hs.155560			CANX: (CANX) CALNEXIN PRECURSOR
				(MAJOR HISTOCOMPATIBILITY COMPLEX
				CLASS I ANTIGEN BINDING PROTEIN P88)
				(P90) (IP90).
13	Hs.119222			HIP: (HIP OR ST13 OR P48) HSC70
				INTERACTING PROTEIN
				(PROGESTERONE RECEPTOR
				ASSOCIATED P48 PROTEIN) (PUTATIVE
				TUMOR SUPPRESSOR ST13).
14	Hs.4055			ZF9: ZINC FINGER PROTEIN 9
15	Hs.179573			COLLAGEN ALPHA2 (I)
16	Hs.74077			PROTEASOME IOTA CHAIN (EC 3.4.99.46)
				(MACROPAIN IOTA CHAIN)
				(MULTICATALYTIC ENDOPEPTIDASE
				COMPLEX IOTA CHAIN) (27 KDA
				PROSOMAL PROTEIN) (PROS 27) (P27K).
				{GENE: PSMA6 OR PROS27}
17	Hs.83077			INTERLEUKIN 18
18	Hs.79387			PSMC5: (PSMC5 OR S8) 26S
				PROTEASOME REGULATORY ATPASE
				SUBUNIT 8 (P45) (TRIP1).
19	Hs.750			FBN1, FIBRILLIN 1 PRECURSOR
20	Hs.173125			CYP3: PEPTIDYL PROLYL CIS TRANS
				ISOMERASE, MITOCHONDRIAL
				[PRECURSOR] EC
21	Hs.131255			UQCRB: UBIQUINOL CYTOCHROME C
				REDUCTASE COMPLEX 14 KDA PROTEIN
				EC 1.10.2.2
22	Hs.75511			CTGF CONNECTIVE TISSUE GROWTH
				FACTOR PRECURSOR
23	Hs.75410			BIP: (HSPA5 OR GRP78) 78 KD GLUCOSE
				REGULATED PROTEIN PRECURSOR
24	Hs.75360			CBPH: CARBOXYPEPTIDASE H
				PRECURSOR (EC 3.4.17.10) (CPH)
				(CARBOXYPEPTIDASE E)(CPE)
				(ENKEPHALIN CONVERTASE)
				(PROHORMONE
				PROCESSINGCARBOXYPEPTIDASE)
25	Hs.6101			BMP6 BONE MORPHOGENETIC PROTEIN
				6 PRECURSOR (BMP 6)
26	Hs.154103			LIM
27	Hs.110802			VWF VON WILLEBRAND FACTOR
				PRECURSOR
28	Hs.111301			MMP2, 72 KD TYPE IV COLLAGENASE
				PRECURSOR (EC 3.4.24.24) (72 KD
				GELATINASE)
29	Hs.172928			COLLAGEN ALPHA1(I)
30	Hs.78225			ANX1: ANNEXIN I (LIPOCORTIN I)
				(CALPACTIN II) (CHROMOBINDIN 9)
				(P35)(PHOSPHOLIPASE A2 INHIBITORY
				PROTEIN)
31	Hs.252189			RYODOCAN, RYUDOCAN CORE PROTEIN
32	Hs.241257			LTBP1, HSTGFB1B ORF FROM
				TGFB_HUMAN
33	Hs.227751			GALECTIN 1: (L14, LGALS1 OR GBP)
				GALECTIN 1
34	Hs.111779			SPARC, SPARC PRECURSOR (SECRETED
				PROTEIN ACIDIC AND RICH IN CYSTEINE)
35	Hs.79368			EMP1: (EMP1 OR TMP OR B4B)
				EPITHELIAL MEMBRANE PROTEIN 1 (EMP
				1) (TUMOR ASSOCIATED MEMBRANE
				PROTEIN) (CL 20) (B4B PROTEIN).
36	Hs.77508			GLUDP1: GLUTAMATE DEHYDROGENASE
				1/2 [PRECURSOR] EC 1.4.1.3 GDH
37	Hs.74471			CXB1 GAP JUNCTION BETA 1 PROTEIN
				(CONNEXIN 32) (CX32) (GAP JUNCTION
				28 KD LIVER PROTEIN)
38	Hs.23598			CREBBP: (CREBBP OR CBP) CREB
				BINDING PROTEIN.
39	Hs.184601			MPE16 INTEGRAL MEMBRANE PROTEIN
				E16
40	Hs.180532			HSP86 = HSP90 ALPHA HSPCA
41	Hs.149846			INTEGRIN BETA5
42	Hs.79732			FIBULIN1, HS2444 ORF FROM
				FBLD_HUMAN
43	Hs.79070			CMYC: (MYC) MYC PROTO ONCOGENE
				PROTEIN (C MYC)
44	Hs.75847			ESTB2.2:
45	Hs.89761			ATP5D: ATP SYNTHASE DELTA CHAIN,
				MITOCHONDRIAL [PRECURSOR]
46	Hs.85289			CD34
47	Hs.83004			INTERLEUKIN 14
48	Hs.80475			POLR2J: (POLR2J) DNA DIRECTED RNA
				POLYMERASE II 13.3 KDA POLYPEPTIDE
				(EC 2.7.7.6) (RPB11).
49	Hs.73965			MRF1: SFRS10, SRFA, MYELIN
				REGULATORY FACTOR 1 (PROBABLY
				IDENTICAL TO SFRS2/SC 35)
50	Hs.199160			MLL: (MLL OR HRX OR ALL1 OR TRX1 OR
				HTRX) ZINC FINGER PROTEIN HRX (ALL
				1) (TRITHORAX LIKE PROTEIN).
51	Hs.180714			COX6A1: CYTOCHROME C OXIDASE
				POLYPEPTIDE VIA LIVER [PRECURSOR]
				EC 1.9.3.1
52	Hs.155433			ATP5C1: (ATP5C1 OR ATP5C) ATP
				SYNTHASE GAMMA CHAIN,
53	Hs.75445			HEVIN (= SC1, ECM, HEVIN LIKE PROTEIN
				!?)
54	Hs.180532			HSP86 = HSP90 ALPHA HSPCA
55	Hs.83190			FAS: FATTY ACID SYNTHASE (EC
				2.3.1.85) [INCLUDES: EC 2.3.1.38; EC
				2.3.1.39; EC 2.3.1.41; EC 1.1.1.100; EC
				4.2.1.61; EC 1.3.1.10; EC 3.1.2.14].
56	Hs.9589			PLIC 1: (PLIC 1 OR UBIQUILIN) UBIQUILIN
57	Hs.80986			ATP5G1: ATP SYNTHASE LIPID BINDING
				PROTEIN P1 PRECURSOR (EC 3.6.1.34)
				(ATPASE
58	Hs.78781			VEGB VASCULAR ENDOTHELIAL
				GROWTH FACTOR B PRECURSOR (VEGF
				B) (VEGF RELATED FACTOR)
59	Hs.78409			COLLAGEN ALPHA1(XVIII)
60	Hs.76753			CD105/ENDOGLIN
61	Hs.75516			TYK2: (TYK2) NON RECEPTOR TYROSINE
				PROTEIN KINASE TYK2 (EC 2.7.1.112).
62	Hs.268571			APC1: APOLIPOPROTEIN C I
				PRECURSOR (APO C1)
63	Hs.23960			CYCLIN B1 G2/MITOTIC SPECIFIC CYCLIN
				B1 (CCNB1 OR CCNB)
64	Hs.211579			CD146/CELL SURFACE GLYCOPROTEIN
				MUC18
65	Hs.197114			KIAA0324
66	Hs.181028			COX5A: CYTOCHROME C OXIDASE
				POLYPEPTIDE VA, MITOCHONDRIAL
				PRECURSOR (EC
67	Hs.148495			PSMD4: (PSMD4 OR MCB1) 26S
				PROTEASOME REGULATORY SUBUNIT
				S5A (AF) (ASF).
68	Hs.125359			CD90/THY 1
69	Hs.1139			DBPA: DBPA_HUMAN (CSDA OR DBPA)
				DNA BINDING PROTEIN A (COLD SHOCK
				DOMAIN
70	Hs.111076			MDH2: MALATE DEHYDROGENASE,
				MITOCHONDRIAL [PRECURSOR] EC
				1.1.1.37
71	Hs.106673			EIF3S6: (EIF3S6 OR INT6) EUKARYOTIC
				TRANSLATION INITIATION FACTOR 3
				SUBUNIT 6 (EIF 3 P48) (MAMMARY
				TUMOR ASSOCIATED PROTEIN INT 6)
				(VIRAL INTEGMOUSEION SITE PROTEIN
				INT 6).
72	Hs.89649			EPOHY MI EPOXIDE HYDROXYLASE,
				MICROSOMAL (EPHX1)
73	Hs.88474			PGH1: PROSTAGLANDIN G/H SYNTHASE
				1 PRECURSOR (EC 1.14.99.1)
				(CYCLOOXYGENASE 1) (COX 1)
				(PROSTAGLANDIN ENDOPEROXIDE
				SYNTHASE 1) (PROSTAGLANDIN
				H2SYNTHASE 1) (PGH SYNTHASE 1)
				(PGHS 1) (PHS 1)(PTGS1)
74	Hs.79172			ANT2: ADP, ATP CARRIER PROTEIN,
				FIBROBLAST ISOFORM ADP/ATP
				TRANSLOCASE 2
75	Hs.429			ATP5G3: ATP SYNTHASE LIPID BINDING
				PROTEIN P3 [PRECURSOR] EC 3.6.1.34
				ATPASE
76	Hs.8867			CYR6 CYR61 PROTEIN PRECURSOR
				(GIG1 PROTEIN) (INSULIN LIKE GROWTH
				FACTOR BINDING PROTEIN 10)
77	Hs.861			MITOGEN ACTIVATED PROTEIN KINASE 3
				(EC 2.7.1.) (EXTRACELLULAR SIGNAL
				REGULATED KINASE 1) (ERK1) (INSULIN
				STIMULATED MAP2 KINASE) (MAP
				KINASE 1) (MAPK 1) (P44 ERK1) (ERT2)
				(P44 MAPK) (MICROTUBULE ASSOCIATED
				PROTEIN 2 KINASE) (MAPK3 OR PRKM3
				OR ERK1)
78	Hs.82112			CD121A/INTERLEUKIN 1 RECEPTOR,
				TYPE 1
79	Hs.80645			IRF1: INTERFERON REGULATORY
				FACTOR
80	Hs.75617			COLLAGEN ALPHA2(IV)
81	Hs.75608			X104
82	Hs.75428			SOD 1 CU ZN SUPEROXIDASE
				DISMUTASE (SOD 1) GENE
83	Hs.75334			EXT2: (EXT2) EXOSTOSIN 2 (PUTATIVE
				TUMOR SUPPRESSOR PROTEIN EXT2)
				(MULTIPLE EXOSTOSES PROTEIN 2).
84	Hs.46468			CKR6 C C CHEMOKINE RECEPTOR TYPE
				6 (C C CKR 6) (CC CKR 6) (CCR 6) (LARC
				RECEPTOR) (GPR CY4) (GPRCY4)
				(CHEMOKINE RECEPTOR LIKE 3) (CKR
				L3) (DRY6)
85	Hs.245188			TIMP3, METALLOPROTEINASE INHIBITOR
				3 PRECURSOR (TIMP 3) (TISSUE
				INHIBITOR OF METALLOPROTEINASES 3)
86	Hs.237356			CXCL12: SDF1_HUMAN (SDF1) STROMAL
				CELL DERIVED FACTOR 1 PRECURSOR
				(SDF 1) (PRE B CELL GROWTH
				STIMULATING FACTOR) (PBSF)
87	Hs.183			DUFF DUFFY ANTIGEN (FY
				GLYCOPROTEIN) (GLYCOPROTEIN D)
				(GPFY)
88	Hs.172180			KIAA0440
89	Hs.171825			DEC1: DEC1 (STRA13) (STRA14)
90	Hs.146428			COLLAGEN ALPHA1(V)
91	Hs.105700			FRPHE FRPHE
92	Hs.75736			APD: APOLIPOPROTEIN D PRECURSOR
				APOD
93	Hs.83551			MAGP1, HUMAN MICROFIBRIL
				ASSOCIATED GLYCOPROTEIN (MFAP2)
94	Hs.75431			FGG: (FGG) FIBRINOGEN GAMMA CHAIN
				PRECURSOR.
95	Hs.75356			TCF4: (TCF4 OR ITF2 OR
				SEF2)(IMMUNOGLOBULIN
				TRANSCRIPTION FACTOR 2) (ITF 2)
96	Hs.63236			SNCG OR BCSG1 SYU3 (GAMMA
				SYNUCLEIN) (PERSYN) (BREAST
				CANCER SPECIFIC GENE 1 PROTEIN)
97	Hs.25313			MSP58 NUCLEOLAR PROTEIN
98	Hs.167835			CAOP: ACYL COENZYME A OXIDASE,
				PEROXISOMAL (EC 1.3.3.6) (PALMITOYL
				COAOXIDASE) (AOX)
99	Hs.119475			CIRBP: (CIRBP OR CIRP OR A18HNRNP)
				COLD INDUCIBLE RNA BINDING PROTEIN
				(GLYCINE RICH RNA BINDING PROTEIN
				CIRP) (A18 HNRNP).
100	Hs.116577			MIC 1 HOMO SAPIENS MACROPHAGE
				INHIBITORY CYTOKINE 1 (MIC 1) MRNA
101	Hs.105097			TK1: (TK1) THYMIDINE KINASE,
				CYTOSOLIC (EC 2.7.1.21).
102	Hs.81097			COX8: CYTOCHROME C OXIDASE
				POLYPEPTIDE VIII LIVER/HEART
				[PRECURSOR] EC 1.9.3.1
103	Hs.75106			CLU: (CLU) CLUSTERIN PRECURSOR
				(COMPLEMENT ASSOCIATED PROTEIN
				SP 40, 40) (COMPLEMENT CYTOLYSIS
				INHIBITOR) (CLI) (NA1 AND NA2)
				(APOLIPOPROTEIN J) (APO J) (TRPM 2).
104	Hs.83623			NR1I3: (NR1I3) ORPHAN NUCLEAR
				RECEPTOR NR1I3 (CONSTITUTIVE
				ANDROSTANE RECEPTOR) (CAR)
				(ORPHAN NUCLEAR RECEPTOR MB67).
105	Hs.76722			CEBPD: (NE IL6 BETA) CCAAT/ENHANCER
				BINDING PROTEIN DELTA
106	Hs.76136			TXN: (TXN OR TRDX OR TRX)
				THIOREDOXIN (ATL DERIVED FACTOR)
				(ADF) (SURFACE ASSOCIATED
				SULPHYDRYL PROTEIN) (SASP).
107	Hs.278614			LON: MITOCHONDRIAL LON PROTEASE
				HOMOLOG PRECURSOR (EC 3.4.21.)
108	Hs.278242			ALPHA TUBULIN
109	Hs.277401			BAZ2B2: (BAZ2B) BROMODOMAIN
				ADJACENT TO ZINC FINGER DOMAIN 2B
				KIAA0314
110	Hs.184161			EXT1: (EXT1) EXOSTOSIN 1 (PUTATIVE
				TUMOR SUPPRESSOR PROTEIN EXT1)
				(MULTIPLE EXOSTOSES PROTEIN 1).
111	Hs.182429			CABP1: (CABP1 OR ERP5) PROBABLE
				PROTEIN DISULFIDE ISOMERASE P5
				PRECURSOR (EC 5.3.4.1).
112	Hs.173664			ERBB2: RECEPTOR PROTEIN TYROSINE
				KINASE ERBB 2
113	Hs.1244			CD9
114	Hs.79516			BASP1 MYRISTOYLATED PROTEINS
				ABUNDANT IN AXONAL TERMINI
115	Hs.169476			(GAPDH) GLYCERALDEHYDE 3
				PHOSPHATE DEHYDROGENASE, LIVER
				(EC 1.2.1.12) (GAPD)
116	Hs.23582			M1S1: (M1S1 OR GA733 1 OR TROP2)
				PANCREATIC CARCINOMA MARKER
				PROTEIN GA733 1 PRECURSOR (CELL
				SURFACE GLYCOPROTEIN TROP 2).
117	Hs.195850			KRT5: (KRT5) KERATIN, TYPE II
				CYTOSKELETAL 5 (CYTOKERATIN 5) (K5)
				(CK 5) (58 KDA CYTOKERATIN)
118	Hs.15977			NDUFB9: NADH UBIQUINONE
				OXIDOREDUCTASE B22 SUBUNIT EC
				1.6.5.3 EC 1.6.99.3
119	Hs.150580			SUI1KURZ: SUI1TRANSLATION
				INITIATION FACTOR
120	Hs.76307			DAN ZINC FINGER PROTEIN DAN (N03)
121	Hs.177486			APP ALZHEIMER PRECURSOR PROTEIN
				A4
122	Hs.57929			MEGF5 MRNA FOR MEGF5 SLIT 3
123	Hs.155101			ATPA ATP SYNTHASE ALPHA CHAIN,
				MITOCHONDRIAL PRECURSOR
124	Hs.8762			FKBP63: (FKBP63) FK506 BINDING
				PROTEIN (FRAGMENT) FKBP9.
125	Hs.848			FKBP4: (FKBP4) P59 PROTEIN (HSP
				BINDING IMMUNOPHILIN) (HBI)
				(POSSIBLE PEPTIDYL PROLYL CIS
				TRANS ISOMERASE) (EC 5.2.1.8) (PPIASE)
				(ROTAMASE) (FKBP52 PROTEIN) (52 KDA
				FK506 BINDING PROTEIN) (P52) (FKBP59)
				(HSP56).
126	Hs.54457			CD81/AAPA1
127	Hs.230			FIBROMODULIN
128	Hs.173902			PPP2R1A: (PPP2R1A)
				SERINE/THREONINE PROTEIN
				PHOSPHATASE 2A, 65 KDA REGULATORY
				SUBUNIT A, ALPHA ISOFORM (PP2A,
				SUBUNIT A, PR65 ALPHA ISOFORM)
				(PP2A, SUBUNIT A, R1 ALPHA ISOFORM)
				(MEDIUM TUMOR ANTIGEN ASSOCIATED
				61 KDA PROTEIN)
129	Hs.9194			GBDR1: (GBDR1) PUTATIVE
				GLIALBLASTOMA CELL
				DIFFERENTIATION RELATED PROTEIN.
130	Hs.83469			NRF1: (NFE2L1 OR NRF1 OR TCF11 OR
				HBZ17) NFE2 RELATED FACTOR 1
131	Hs.82120			NR4A2: (NR4A2 OR NURR1 OR TINUR OR
				NOT) ORPHAN NUCLEAR RECEPTOR
				NURR1
132	Hs.77171			MCM5: (MCM5 OR CDC46) DNA
				REPLICATION LICENSING FACTOR MCM5
				(CDC46 HOMOLOG) (P1 CDC46).
133	Hs.77054			BTG1: (BTG1) BTG1 PROTEIN (B CELL
				TRANSLOCATION GENE 1 PROTEIN).
134	Hs.76686			GPX1 GLUTATHIONE PEROXIDASE 1
135	Hs.69745			FDXR: NADPH: ADRENODOXIN
				OXIDOREDUCTASE [PRECURSOR] EC
				1.18.1.2 ADRENODOXIN
136	Hs.279554			PSMD13: (PSMD13) 26S PROTEASOME
				SUBUNIT S11 (P40.5)
137	Hs.239663			AFX1: (AFX1 OR AFX OR MLLT7)
				PUTATIVE FORK HEAD DOMAIN
				TRANSCRIPTION FACTOR AFX1
138	Hs.199067			ERBB3: ERBB 3 RECEPTOR PROTEIN
				TYROSINE KINASE PRECURSOR (EC
				2.7.1.112) (TYROSINE KINASE TYPE CELL
				SURFACE RECEPTOR HER3)
139	Hs.182937			CYCLOPHILIN 1 PEPTIDYL PROLYL CIS
				TRANS ISOMERASE A (EC 5.2.1.8)
				(PPIASE) (ROTAMASE) (CYCLOPHILIN A)
				(CYCLOSPORIN A BINDING PROTEIN)
				{PPIA OR CYPA}
140	Hs.178658			RAD23B: (RAD23B) UV EXCISION REPAIR
				PROTEIN PROTEIN RAD23 HOMOLOG B
				(HHR23B) (XP C REPAIR
				COMPLEMENTING COMPLEX 58 KDA
				PROTEIN) (P58).
141	Hs.155543			PSMD7: (PSMD7 OR MOV34L) 26S
				PROTEASOME REGULATORY SUBUNIT
				S12 (MOV34 PROTEIN).
142	Hs.15071			CCT8: (CCT8 OR CCTQ) T COMPLEX
				PROTEIN 1, THETA SUBUNIT (TCP 1
				THETA) (CCT THETA) (KIAA0002).
143	Hs.149923			XBP1: (XBP1 OR XBP2 OR TREB5) X BOX
				BINDING PROTEIN 1
144	Hs.142258			STAT3: (STAT3 OR APRF) SIGNAL
				TRANSDUCER AND ACTIVATOR OF
				TRANSCRIPTION 3 (ACUTE PHASE
				RESPONSE FACTOR)
145	Hs.129943			KIAA0545
146	Hs.12068			CACP: CARNITINE O
				ACETYLTRANSFERASE (EC 2.3.1.7)
				(CARNITINE ACETYLASE)(CAT)
				(FRAGMENT)
147	Hs.118174			TPRD: TETRATRICOPEPTIDREPEAT
				PROTEIN
148	Hs.11669			LAMININ ALPHA 5
149	Hs.1119			NR4A1: (NR4A1 OR HMR OR NAK1 OR
				GFRP1) ORPHAN NUCLEAR RECEPTOR
				HMR (EARLY RESPONSE PROTEIN NAK1)
				(TR3 ORPHAN RECEPTOR)
150	Hs.108809			CCT7: (CCT7 OR CCTH OR NIP7 1) T
				COMPLEX PROTEIN 1, ETA SUBUNIT
				(TCP 1 ETA) (CCT ETA) (HIV 1 NEF
				INTERACTING PROTEIN).
151	Hs.106070			CDKN1C: (CDKN1C OR KIP2) CYCLIN
				DEPENDENT KINASE INHIBITOR 1C
				(CYCLIN DEPENDENT KINASE INHIBITOR
				P57) (P57KIP2).
152	Hs.738			EGR1: (EGR1 OR ZNF225) EARLY
				GROWTH RESPONSE PROTEIN 1 (EGR 1)
				(KROX24) (ZIF268) (TRANSCRIPTION
				FACTOR ETR103) (ZINC FINGER PROTEIN
				225) (AT225).
153	Hs.250723			FRAP: (FRAP) FKBP RAPAMYCIN
				ASSOCIATED PROTEIN (FRAP)
				(RAPAMYCIN TARGET
154	Hs.226795			GSTP1 GLUTATHIONE S TRANSFERASE,
				PI FORM
155	Hs.82646			HSPF1: (HSPF1 OR DNAJ1 OR HDJ1)
				HEAT SHOCK 40 KDA PROTEIN 1 (HEAT
				SHOCK PROTEIN 40) (HSP40) (DNAJ
				PROTEIN HOMOLOG 1) (HDJ 1).
156	Hs.153179			FABE: FATTY ACID BINDING PROTEIN,
				EPIDERMAL (E FABP) (PSORIASIS
				ASSOCIATED FATTY ACID BINDING
				PROTEIN HOMOLOG) (PA FABP)(FABP5)
157	Hs.99936			KRT10: (KRT10) KERATIN, TYPE I
				CYTOSKELETAL 10 (CYTOKERATIN 10)
				(K10)
158	Hs.149609			CD49E/INTEGRIN ALPHA 5
159	Hs.9736			PSMD3: (PSMD3) 26S PROTEASOME
				REGULATORY SUBUNIT S3
				(PROTEASOME SUBUNIT P58).
160	Hs.97203			CCL22: SY22_HUMAN (SCYA22 OR MDC
				OR A 152E5.1) SMALL INDUCIBLE
				CYTOKINE A22 PRECURSOR
				(MACROPHAGE DERIVED CHEMOKINE)
				(STIMULATED T CELL CHEMOTACTIC
				PROTEIN 1) (CC CHEMOKINE STCP 1)
161	Hs.89466			D3D2: 3,2 TRANS ENOYL COA
				ISOMERASE, MITOCHONDRIAL
				PRECURSOR (EC 5.3.3.8)(DODECENOYL
				COA DELTA ISOMERASE)
162	Hs.87539			ALDH8: (ALDH8) ALDEHYDE
				DEHYDROGENASE 8 (EC 1.2.1.5).
163	Hs.75424			ID1: (ID1 OR ID) DNA BINDING PROTEIN
				INHIBITOR ID 1 (ID)
164	Hs.75379			EAT1 (SLC1A3 OR EAAT1) EXCITATORY
				AMINO ACID TRANSPORTER 1 (SODIUM
				DEPENDENT GLUTAMATE/ASPARTATE
				TRANSPORTER 1) (GLIAL GLUTAMATE
				TRANSPORTER) (GLAST1)
165	Hs.75212			ODC1: (ODC1) ORNITHINE
				DECARBOXYLASE (EC 4.1.1.17) (ODC).
166	Hs.74631			CD147/BASIGIN
167	Hs.74619			PSMD2: (PSMD2 OR TRAP2) 26S
				PROTEASOME REGULATORY SUBUNIT
				S2 (P97) (TUMOR NECROSIS FACTOR
				TYPE 1 RECEPTOR ASSOCIATED
				PROTEIN 2).
168	Hs.724			NR1D1: (NR1D1 OR THRAL OR EAR1 OR
				HREV) ORPHAN NUCLEAR RECEPTOR
				NR1D1 (V ERBA RELATED PROTEIN EAR
				1) (REV ERBA ALPHA).
169	Hs.63290			2HPCL: 2 HYDROXYPHYTANOYL COA
				LYASE
170	Hs.6216			TID1: (TID1 OR TID 1) TUMOROUS
				IMAGINAL DISCS HOMOLOG
				PRECURSOR (HTID 1).
171	Hs.56874			CVHSP: (CVHSP) CARDIOVASCULAR
				HEAT SHOCK PROTEIN.
172	Hs.5566			CXB2 GAP JUNCTION BETA 2 PROTEIN
				(CONNEXIN 26) (CX26)
173	Hs.52081			KIAA0867: (KIAA0867) KIAA0867 PROTEIN
174	Hs.206097			RRAS2
175	Hs.19545			FZD4 FRIZZLED HOMOLOG 4
				(TRANSMEMBRANE RECEPTOR)
176	Hs.182423			KNP I: ES1 PROTEIN HOMOLOG,
				MITOCHONDRIAL [PRECURSOR]
				PROTEIN KNP I GT335 HES1
177	Hs.181373			CDM: CDM PROTEIN (6C6 AG TUMOR
				ASSOCIATED ANTIGEN) (DXS1357E)
				BAP31
178	Hs.172674			NFATX4: (A 67A1.1) TRANSCRIPTION
				FACTOR NFATX4.
179	Hs.1708			CCT3: (CCT3 OR CCTG OR TRIC5) T
				COMPLEX PROTEIN 1, GAMMA SUBUNIT
				(TCP 1 GAMMA) (CCT GAMMA).
180	Hs.169610			CD44
181	Hs.156007			ZAKI4 THYROID HORMONE RESPONSIVE
				GENE ZAKI 4
182	Hs.155402			DBP: D BINDING PROTEIN (DBP)
183	Hs.13456			OASIS: (OASIS) OASIS PROTEIN, BZIP
				TRANSCRIPTION FACTOR
184	Hs.119663			CD59
185	Hs.111039			NMYRIST N MYRISTOYLTRANSFERASE 1
				MRNA
186	Hs.78575			SGP1: SULFATED GLYCOPROTEIN 1,
				PROSAPOSIN
187	Hs.79432			FBN2, FIBRILLIN 2 PRECURSOR
188	Hs.118162			FN, FIBRONECTIN PRECURSOR (FN)
				(FRAGMENTS).
189	Hs.80828			Keratin 1
190			XM_008578	Keratin 14
191		X58531		LAMININ ALPHA 1
192	Hs.75279			LAMININ ALPHA 2 (MEROSIN)
193	Hs.83450			LAMININ ALPHA 3 (EPILIGRIN 170 KD
				SUBUNIT)
194	Hs.78672			LAMININ ALPHA 4
195	Hs.82124			LAMININ BETA 1
196	Hs.90291			LAMININ BETA 2
197	Hs.75517			LAMININ BETA 3
198	Hs.214982			LAMININ GAMMA 1
199	Hs.69954			LAMININ GAMMA 3 LAMC3
200	Hs.83169			MMP1, INTERSTITIAL COLLAGENASE
201	Hs.1695			MMP12, MACROPHAGE
				METALLOELASTASE PRECURSOR
				(MATRIX METALLOPROTEINASE 12)
202	Hs.99863			NELASTASE: NEUTROPHIL ELASTASE
203	Hs.62041			NIDOGEN, NIDOGEN PRECURSOR
				(ENTACTIN)
204	Hs.76152			PGS2, BONE PROTEOGLYCAN II
				PRECURSOR (PG S2) (DECORIN) (PG40)
205	Hs.177781			SOD2: SUPEROXIDE DISMUTASE [MN],
				MITOCHONDRIAL PRECURSOR (EC
				1.15.1.1)
206	Hs.5831			TIMP1, METALLOPROTEINASE INHIBITOR
				1 PRECURSOR (TIMP 1)
207	Hs.6441			TIMP2, METALLOPROTEINASE INHIBITOR
				2 PRECURSOR (TIMP 2) (TISSUE
				INHIBITOR OF METALLOPROTEINASES 2)
208	Hs.190787			TIMP4
		P12718		(ACTG2 OR ACTA3 OR ACTSG) ACTIN,
				GAMMA-ENTERIC SMOOTH MUSCLE
				(ALPHA-ACTIN 3).
209		P20290		(BTF3) TRANSCRIPTION FACTOR BTF3
				(RNA POLYMERASE B TRANSCRIPTION
				FACTOR 3).
210		P40121		(CAPG OR MCP) MACROPHAGE CAPPING
				PROTEIN (ACTIN-REGULATORY PROTEIN
				CAP-G).
211		Q9UMW5		(CCAM) CEREBRAL CELL ADHESION
				MOLECULE (RELATED TO LYSINE
				OXIDASES).
212		P12277		(CKB OR CKBB) CREATINE KINASE, B
				CHAIN (EC 2.7.3.2) (B-CK).
213		P51911		(CNN1) CALPONIN H1, SMOOTH MUSCLE
				(BASIC CALPONIN) (CALPONIN 1).
214		Q99439		(CNN2) CALPONIN H2, SMOOTH MUSCLE
				(NEUTRAL CALPONIN).
215		P21291		(CSRP1 OR CSRP OR CYRP) CYSTEINE-
				RICH PROTEIN 1 (CRP1) (CRP).
216		O00571		(DDX3 OR DBX) DEAD-BOX PROTEIN 3
				(HELICASE-LIKE PROTEIN 2) (HLP2)
				(DEAD-BOX, X ISOFORM).
217			AL137555	unknown cDNA DKFZp434H0820 (from
				clone DKFZp434H0820).
218		Q08554		(DSC1) DESMOCOLLIN 1A/1B
				PRECURSOR (DESMOSOMAL
				GLYCOPROTEIN 2/3) (DG2/DG3).
219		Q15056		(EIF4H OR WBSCR1 OR WSCR1)
				EUKARYOTIC TRANSLATION INITIATION
				FACTOR 4H (EIF-4H) (KIAA0038).
220		O15197		(EPHB6) EPHRIN TYPE-B RECEPTOR 6
				PRECURSOR (TYROSINE-PROTEIN
				KINASE-DEFECTIVE RECEPTOR EPH-6)
				(HEP).
221		P22607		(FGFR3 OR JTK4) FIBROBLAST GROWTH
				FACTOR RECEPTOR 3 PRECURSOR
				(FGFR-3) (EC 2.7.1.112).
222		P21333		(FLN1 OR FLN) ENDOTHELIAL ACTIN-
				BINDING PROTEIN (ABP-280)
				(NONMUSCLE FILAMIN) (FILAMIN 1).
223		P01100		(FOS) P55-C-FOS PROTO-ONCOGENE
				PROTEIN (CELLULAR ONCOGENE C-FOS)
				(G0S7 PROTEIN).
224		Q16186		(GP110) 110 KDA CELL MEMBRANE
				GLYCOPROTEIN.
225		P22352		(GPX3 OR GPXP) PLASMA GLUTATHIONE
				PEROXIDASE PRECURSOR (EC 1.11.1.9)
				(GSHPX-P).
226		O95819		(HGK) HPK/GCK-LIKE KINASE HGK.
227		O75166		(KIAA0679) KIAA0679 PROTEIN
				(FRAGMENT).
228		O94979		(KIAA0905) KIAA0905 PROTEIN (SEC31
				PROTEIN).
229		Q9Y2J6		(KIAA0992) KIAA0992 PROTEIN
				(FRAGMENT).
230		P33176		(KIF5B OR KNS1 OR KNS) KINESIN HEAVY
				CHAIN (UBIQUITOUS KINESIN HEAVY
				CHAIN) (UKHC).
231		O00301		(KSRP) KSRP.
232		Q15012		(MTRP) GOLGI 4-TRANSMEMBRANE
				SPANNING TRANSPORTER MTP
				(KIAA0108).
233		P35749		(MYH11) MYOSIN HEAVY CHAIN,
				SMOOTH MUSCLE ISOFORM (SMMHC)
				(FRAGMENT).
234		Q15746		(MYLK OR MLCK) MYOSIN LIGHT CHAIN
				KINASE, SMOOTH MUSCLE AND NON-
				MUSCLE ISOZYMES (EC 2.7.1.117) (MLCK)
235		Q9UGL9		(NICE-1) NICE-1 PROTEIN.
236		P30086		(PEBP OR PBP)
				PHOSPHATIDYLETHANOLAMINE-BINDING
				PROTEIN (PEBP) (NEUROPOLYPEPTIDE
				H3).
237		P36955		(PEDF) PIGMENT EPITHELIUM-DERIVED
				FACTOR PRECURSOR (PEDF) (EPC-1).
238		P14786		(PKM2 OR PKM) PYRUVATE KINASE, M2
				ISOZYME (EC 2.7.1.40).
239		P41222		(PTGDS OR PDS) PROSTAGLANDIN-H2 D-
				ISOMERASE PRECURSOR (EC 5.3.99.2)
				(PROSTAGLANDIN-D SYNTHASE)
				(GLUTATHIONE-INDEPENDENT PGD
				SYNTHETASE) (PROSTAGLANDIN D2
				SYNTHASE) (PGD2 SYNTHASE) (PGDS2)
				(PGDS) (BETA-TRACE PROTEIN).
240			AL365373	hypothetical protein R33729_1
241		P39030		(RPL15) 60S RIBOSOMAL PROTEIN L15.
242		P31151		(S100A7 OR PSOR1) S100 CALCIUM-
				BINDING PROTEIN A7 (PSORIASIN).
243		O14778		(SARP1) SECRETED APOPTOSIS
				RELATED PROTEIN 1 (FRAGMENT).
244		P31947		(SFN OR HME1) 14-3-3 PROTEIN SIGMA
				(STRATIFIN) (EPITHELIAL CELL MARKER
				PROTEIN 1).
245		O75368		(SH3BGRL) SH3 DOMAIN BINDING
				GLUTAMIC ACID-RICH-LIKE PROTEIN.
246		P11166		(SLC2A1 OR GLUT1) GLUCOSE
				TRANSPORTER TYPE 1,
				ERYTHROCYTE/BRAIN.
247		P37108		(SRP14) SIGNAL RECOGNITION
				PARTICLE 14 KDA PROTEIN (SRP14) (18 KDA
				ALU RNA BINDING PROTEIN).
248		Q01995		(TAGLN OR SM22 OR WS3-10)
				TRANSGELIN (SMOOTH MUSCLE
				PROTEIN 22-ALPHA) (SM22-ALPHA) (WS3-
				10) (22 KDA ACTIN-BINDING PROTEIN).
249		P11387		(TOP1) DNA TOPOISOMERASE I (EC
				5.99.1.2).
250		P07951		(TPM2 OR TMSB) TROPOMYOSIN BETA
				CHAIN, SKELETAL MUSCLE.
251		P07919		(UQCRH) UBIQUINOL-CYTOCHROME C
				REDUCTASE COMPLEX 11 KDA PROTEIN
				PRECURSOR (EC 1.10.2.2)
				(MITOCHONDRIAL HINGE PROTEIN)
				(CYTOCHROME C1, NONHEME 11 KDA
				PROTEIN) (COMPLEX III SUBUNIT VIII).
252		P15311		(VIL2) EZRIN (P81) (CYTOVILLIN) (VILLIN-
				2).
253		P31946		(YWHAB) 14-3-3 PROTEIN BETA/ALPHA
				(PROTEIN KINASE C INHIBITOR PROTEIN-
				1) (KCIP-1) (PROTEIN 1054).

[0228]

TABLE 8
	UniGene
	accession	SWISSPROT
No.:	No.	or TREMBL	Name of gene/Description
1			- ESTB2.2: PTD014 (C15ORF3).
2	Hs.63290	Q9UJ83	2HPCL: 2-HYDROXYPHYTANOYL-COA LYASE.
3	Hs.195851	P03996	ACTA2: (ACTA2 OR ACTSA OR ACTVS) AORTIC
			SMOOTH MUSCLE (ALPHA-ACTIN 2).
4	Hs.239663	Q13720	AFX1: (AFX1 OR AFX OR MLLT7) PUTATIVE FORK HEAD
			DOMAIN TRANSCRIPTION FACTOR AFX1.
5	Hs.87539	P48448	ALDH8: (ALDH8) ALDEHYDE DEHYDROGENASE 8 (EC
			1.2.1.5).
6	Hs.79172	P05141	ANT2: (SLC25A5 OR ANT2) ADP, ATP CARRIER
			PROTEIN, FIBROBLAST ISOFORM (ADP/ATP
			TRANSLOCASE 2) (ADENINE NUCLEOTIDE
			TRANSLOCATOR 2) (ANT 2).
7	Hs.78225	P04083	ANX1: (ANXA1 OR ANX1 OR LPC1) ANNEXIN I
			(LIPOCORTIN I) (CALPACTIN II) (CHROMOBINDIN 9)
			(P35)(PHOSPHOLIPASE A2 INHIBITORY PROTEIN).
8	Hs.182778	P02654	APC1: (APOC1) APOLIPOPROTEIN C-I PRECURSOR
			(APO-C1).
9	Hs.75736	P05090	APD: (APOD) APOLIPOPROTEIN D PRECURSOR.
10	Hs.177486	P05067	APP: (APP OR A4 OR CVAP OR AD1) ALZHEIMER'S
			DISEASE AMYLOID A4 PROTEIN PRECURSOR
			(PROTEASE NEXIN-II) (PN-II) (APPI) [CONTAINS: BETA-
			AMYLOID PROTEIN (BETA-APP) (A-BETA)].
11	Hs.155101	P25705	ATP5A1: (ATP5A1) ATP SYNTHASE ALPHA CHAIN,
			MITOCHONDRIAL PRECURSOR (EC 3.6.1.34).
12	Hs.155433	P36542	ATP5C1: (ATP5C1 OR ATP5C) ATP SYNTHASE GAMMA
			CHAIN, MITOCHONDRIAL PRECURSOR (EC 3.6.1.34).
13	Hs.80986	P05496	ATP5G1: (ATP5G1) ATP SYNTHASE LIPID-BINDING
			PROTEIN P1 PRECURSOR (EC 3.6.1.34) (ATPASE
			PROTEIN 9) (SUBUNIT C).
14	Hs.429	P48201	ATP5G3: (ATP5G3) ATP SYNTHASE LIPID-BINDING
			PROTEIN P3 PRECURSOR (EC 3.6.1.34) (ATPASE
			PROTEIN 9) (SUBUNIT C).
15	Hs.79516	P80723	BASP1: (BASP1 OR NAP22) BRAIN ACID SOLUBLE
			PROTEIN 1 (BASP1 PROTEIN) (NEURONAL AXONAL
			MEMBRANE PROTEIN NAP-22) (NEURONAL TISSUE-
			ENRICHED ACIDIC PROTEIN).
16	Hs.229405	Q9UIF9	BAZ2B2: (BAZ2B) BROMODOMAIN ADJACENT TO ZINC
			FINGER DOMAIN 2B KIAA0314
17	Hs.75410	P11021	BIP: (HSPA5 OR GRP78) 78 KDA GLUCOSE-REGULATED
			PROTEIN PRECURSOR (GRP 78) (IMMUNOGLOBULIN
			HEAVY CHAIN BINDING PROTEIN) (BIP).
18	Hs.6101	P22004	BMP6: (BMP6 OR BMP-6 OR VGR1) BONE
			MORPHOGENETIC PROTEIN 6 PRECURSOR (BMP 6).
19	Hs.74631	P35613	BSG: (BSG) BASIGIN PRECURSOR (LEUKOCYTE
			ACTIVATION ANTIGEN M6) (COLLAGENASE
			STIMULATORY FACTOR) (EXTRACELLULAR MATRIX
			METALLOPROTEINASE INDUCER) (EMMPRIN) (5F7)
			(CD147 ANTIGEN).
20	Hs.77054	P31607	BTG1: (BTG1) BTG1 PROTEIN (B-CELL
			TRANSLOCATION GENE 1 PROTEIN).
21		P01024	C3: (C3) COMPLEMENT C3 PRECURSOR
22	Hs.12068	P43155	CACP: (CRAT OR CAT1) CARNITINE O-
			ACETYLTRANSFERASE (EC 2.3.1.7) (CARNITINE
			ACETYLASE) (CAT) (FRAGMENT).
23	Hs.155560	P27824	CANX: (CANX) CALNEXIN PRECURSOR (MAJOR
			HISTOCOMPATIBILITY COMPLEX CLASS I ANTIGEN-
			BINDING PROTEIN P88) (P90) (IP90).
24	Hs.167835	Q15067	CAOP: (ACOX1 OR ACOX) ACYL-COENZYME A
			OXIDASE 1, PEROXISOMAL (EC 1.3.3.6) (PALMITOYL-
			COAOXIDASE) (AOX) MUSPAOX.
25	Hs.75360	P16870	CBPH: (CPE) CARBOXYPEPTIDASE H PRECURSOR (EC
			3.4.17.10) (CPH) (CARBOXYPEPTIDASE E) (CPE)
			(ENKEPHALIN CONVERTASE) (PROHORMONE
			PROCESSING CARBOXYPEPTIDASE).
26	Hs.340	P13500	CCL2_HUMAN: (SCYA2 OR MCP1) SMALL INDUCIBLE
			CYTOKINE A2 PRECURSOR (MONOCYTE
			CHEMOTACTIC PROTEIN 1) (MCP-1) (MONOCYTE
			CHEMOATTRACTANT PROTEIN-1) (MONOCYTE
			CHEMOTACTIC AND ACTIVATING FACTOR) (MCAF)
			(MONOCYTE SECRETORY PROTEIN JE) (HC11).
27	Hs.97203	O00626	CCL22: (SCYA22 OR MDC OR A-152E5.1) SMALL
			INDUCIBLE CYTOKINE A22 PRECURSOR
			(MACROPHAGE-DERIVED CHEMOKINE) (STIMULATED
			T CELL CHEMOTACTIC PROTEIN 1) (CC CHEMOKINE
			STCP-1).
28	Hs.46468	P51684	CCR6: (CCR6 OR CMKBR6 OR STRL22 OR GPR29 OR
			CKRL3) C-C CHEMOKINE RECEPTOR TYPE 6 (C-C CKR-
			6) (CC-CKR-6) (CCR-6) (LARC RECEPTOR) (GPR-CY4)
			(GPRCY4) (CHEMOKINE RECEPTOR-LIKE 3) (CKR-L3)
			(DRY6).
29	Hs.1708	P49368	CCT3: (CCT3 OR CCTG OR TRIC5) T-COMPLEX
			PROTEIN 1, GAMMA SUBUNIT (TCP-1-GAMMA) (CCT-
			GAMMA).
30	Hs.108809	Q99832	CCT7: (CCT7 OR CCTH OR NIP7-1) T-COMPLEX
			PROTEIN 1, ETA SUBUNIT (TCP-1-ETA) (CCT-ETA) (HIV-1
			NEF INTERACTING PROTEIN).
31	Hs.15071	P50990	CCT8: (CCT8 OR CCTQ) T-COMPLEX PROTEIN 1,
			THETA SUBUNIT (TCP-1-THETA) (CCT-THETA)
			(KIAA0002).
32	Hs.85289	P28906	CD34: (CD34) HEMATOPOIETIC PROGENITOR CELL
			ANTIGEN CD34 PRECURSOR.
33	Hs.169610	P16070	CD44_EX10-12: (CD44 OR LHR) CD44 ANTIGEN
			PRECURSOR (PHAGOCYTIC GLYCOPROTEIN I)(PGP-
			1)(HUTCH-I)(EXTRACELLULAR MATRIX RECEPTOR-
			III)(GP90 LYMPHOCYTE HOMING/ADHESION
			RECEPTOR)(HERMES ANTIGEN)(HYALURONATE
			RECEPTOR)(HEPARAN SULFATE
			PROTEOGLYCAN)(EPICAN).
34	Hs.170121	P08575	CD45_EX29-31: (PTPRC OR CD45) LEUKOCYTE
			COMMON ANTIGEN PRECURSOR (EC 3.1.3.48) (L-CA)
			(CD45 ANTIGEN) (T200).
35	Hs.119663	P13987	CD59: (CD59) CD59 GLYCOPROTEIN PRECURSOR
			(MEMBRANE ATTACK COMPLEX INHIBITION FACTOR)
			(MACIF) (MAC-INHIBITORY PROTEIN) (MAC-IP) (MEM43
			ANTIGEN) (PROTECTIN) (MEMBRANE INHIBITOR OF
			REACTIVE LYSIS) (MIRL) (HRF-20) (1F5 ANTIGEN).
36	Hs.54457	P18582	CD81: (CD81 OR TAPA1) CD81 ANTIGEN (26 KDA CELL
			SURFACE PROTEIN TAPA-1).
37	Hs.1244	P21926	CD9: (CD9 OR MIC3) CD9 ANTIGEN (P24) (LEUKOCYTE
			ANTIGEN MIC3) (MOTILITY-RELATED PROTEIN) (MRP-
			1).
38	Hs.106070	P49918	CDKN1C: (CDKN1C OR KIP2) CYCLIN-DEPENDENT
			KINASE INHIBITOR 1C (CYCLIN-DEPENDENT KINASE
			INHIBITOR P57) (P57KIP2).
39	Hs.181373	P51572	CDM: (BCAP31 OR BAP31) B-CELL RECEPTOR-
			ASSOCIATED PROTEIN 31 (CDM PROTEIN) (6C6-AG
			TUMOR-ASSOCIATED ANTIGEN) (DXS1357E).
40	Hs.119475	Q14011	CIRBP: (CIRBP OR CIRP OR A18HNRNP) COLD-
			INDUCIBLE RNA-BINDING PROTEIN (GLYCINE-RICH
			RNA-BINDING PROTEIN CIRP) (A18 HNRNP).
41	Hs.79070	P01107	CMYC: (MYC) MYC PROTO-ONCOGENE PROTEIN (C-
			MYC).
42	Hs.78409	P39060	COL18A1_2: (COL18A1) COLLAGEN ALPHA 1(XVIII)
			CHAIN [CONTAINS: ENDOSTATIN].
43	Hs.172928	P02452	COL1A1: (COL1A1) COLLAGEN ALPHA 1(I) CHAIN
			PRECURSOR.
44	Hs.179573	P08123	COL1A2: (COL1A2) COLLAGEN ALPHA 2(I) CHAIN
			PRECURSOR.
45	Hs.119571	P02461	COL3A1: (COL3A1) COLLAGEN ALPHA 1(III) CHAIN
			PRECURSOR.
46	Hs.75617	P08572	COL4A2: (COL4A2) COLLAGEN ALPHA 2(IV) CHAIN
			PRECURSOR.
47	Hs.146428	P20908	COL5A1: (COL5A1) PRO-ALPHA-1 TYPE V COLLAGEN.
48	Hs.181028	P20674	COX5A: (COX5A) CYTOCHROME C OXIDASE
			POLYPEPTIDE VA, MITOCHONDRIAL PRECURSOR (EC
			1.9.3.1).
49	Hs.180714	P12074	COX6A1: (COX6A1 OR COX6AL) CYTOCHROME C
			OXIDASE POLYPEPTIDE VIA-LIVER PRECURSOR (EC
			1.9.3.1).
50	Hs.74649	P09669	COX6C: (COX6C) CYTOCHROME C OXIDASE
			POLYPEPTIDE VIC PRECURSOR (EC 1.9.3.1).
51	Hs.23598	Q92793	CREBBP: (CREBBP OR CBP) CREB-BINDING PROTEIN.
52	Hs.75511	P29279	CTGF: (CTGF) CONNECTIVE TISSUE GROWTH FACTOR
			PRECURSOR.
53	Hs.56874	Q9UBY9	CVHSP: (CVHSP) CARDIOVASCULAR HEAT SHOCK
			PROTEIN.
54	Hs.237356	P48061	CXCL12: (SDF1) STROMAL CELL-DERIVED FACTOR 1
			PRECURSOR (SDF-1) (PRE-B CELL GROWTH
			STIMULATING FACTOR) (PBSF)
55	Hs.182937	P05092	CYPA: (PPIA OR CYPA) CYCLOPHILIN 1 PEPTIDYL-
			PROLYL CIS-TRANS ISOMERASE A (EC 5.2.1.8)
			(PPIASE) (ROTAMASE) (CYCLOPHILIN A)
			(CYCLOSPORIN A-BINDING PROTEIN).
56	Hs.8867	O00622	CYR61: (CYR61 OR IGFBP10 OR GIG1) CYR61 PROTEIN
			PRECURSOR (GIG1 PROTEIN) (INSULIN-LIKE GROWTH
			FACTOR-BINDING PROTEIN 10).
57	Hs.89466	P42126	D3D2: (DCI) 3,2-TRANS-ENOYL-COA ISOMERASE,
			MITOCHONDRIAL PRECURSOR (EC 5.3.3.8)
			(DODECENOYL-COA DELTA-ISOMERASE).
58	Hs.155402	Q10586	DBP: (DBP) D-SITE-BINDING PROTEIN (ALBUMIN D
			BOX-BINDING PROTEIN) (TAXREB302).
59	Hs.1139	P16989	DBPA: (CSDA OR DBPA) DNA-BINDING PROTEIN A
			(COLD SHOCK DOMAIN
60	Hs.171825	O14503	DEC1: (BHLHB2 OR SHARP-2 OR STRA14) STIMULATED
			BY RETINOIC ACID 14 (BASIC-HELIX-LOOP-HELIX
			PROTEIN) (FRAGMENT) STRA13 (SHARP-2)
			ENHANCER-OF-SPLIT AND HAIRY-RELATED PROTEIN
			2.
61		P43003	EAAT1: (SLC1A3 OR EAAT1) EXCITATORY AMINO ACID
			TRANSPORTER 1 (SODIUM-DEPENDENT
			GLUTAMATE/ASPARTATE TRANSPORTER 1) (GLIAL
			GLUTAMATE TRANSPORTER) (GLAST1)
62	Hs.738	P18146	EGR1: (EGR1 OR ZNF225) EARLY GROWTH RESPONSE
			PROTEIN 1 (EGR-1) (KROX-24 PROTEIN) (ZIF268)
			(NERVE GROWTH FACTOR-INDUCED PROTEIN A)
			(NGFI-A) (TRANSCRIPTION FACTOR ETR103) (ZINC
			FINGER PROTEIN 225) (AT225).
63	Hs.106673	Q64252	EIF3S6: (EIF3S6 OR INT6) EUKARYOTIC TRANSLATION
			INITIATION FACTOR 3 SUBUNIT 6 (EIF-3 P48)
			(MAMMARY TUMOR-ASSOCIATED PROTEIN INT-6)
			(VIRAL INTEGMOUSEION SITE PROTEIN INT-6).
64		P54849	EMP1: (EMP1 OR TMP OR B4B) EPITHELIAL MEMBRANE
			PROTEIN-1 (EMP-1) (TUMOR-ASSOCIATED MEMBRANE
			PROTEIN) (CL-20) (B4B PROTEIN).
65	Hs.76753	Q14248	ENG: (ENG OR END) ENDOGLIN PRECURSOR (CD105
			ANTIGEN).
66	Hs.102948	Q14250	ENIGMA: ENIGMA PROTEIN (LIM-DOMAIN PROTEIN
			LMP-1).
67	Hs.89649	P07099	EPHX1: (EPHX1 OR EPHX OR EPOX) EPOXIDE
			HYDROLASE (EC 3.3.2.3) (MICROSOMAL EPOXIDE
			HYDROLASE) (EPOXIDE HYDRATASE).
68	Hs.173664	P04626	ERBB2: (ERBB2 OR HER2 OR NGL OR NEU) RECEPTOR
			PROTEIN-TYROSINE KINASE ERBB-2 PRECURSOR (EC
			2.7.1.112) (P185ERBB2) (NEU PROTO-ONCOGENE) (C-
			ERBB-2) (TYROSINE KINASE-TYPE CELL SURFACE
			RECEPTOR HER2) (MLN 19).
69	Hs.199067	P21860	ERBB3: (ERBB3 OR HER3) ERBB-3 RECEPTOR
			PROTEIN-TYROSINE KINASE PRECURSOR (EC
			2.7.1.112) (TYROSINE KINASE-TYPE CELL SURFACE
			RECEPTOR HER3).
70	Hs.182429	Q15084	ERP5: (CABP1 OR ERP5) PROBABLE PROTEIN
			DISULFIDE ISOMERASE P5 PRECURSOR (EC 5.3.4.1).
71	Hs.75334	Q93063	EXT2: (EXT2) EXOSTOSIN-2 (PUTATIVE TUMOR
			SUPPRESSOR PROTEIN EXT2) (MULTIPLE EXOSTOSES
			PROTEIN 2).
72	Hs.153179	Q01469	FABE: (FABP5) FATTY ACID-BINDING PROTEIN,
			EPIDERMAL (E-FABP) (PSORIASIS-ASSOCIATED FATTY
			ACID-BINDING PROTEIN HOMOLOG) (PA-FABP).
73	Hs.83190	P49327	“FAS: (FASN OR FAS) FATTY ACID SYNTHASE (EC
			2.3.1.85) [INCLUDES: EC 2.3.1.38; EC 2.3.1.39; EC
			2.3.1.41; EC 1.1.1.100; EC 4.2.1.61; EC 1.3.1.10; EC
			3.1.2.14].”
74	Hs.69745	P22570	FDXR: (FDXR OR ADXR) NADPH: ADRENODOXIN
			OXIDOREDUCTASE PRECURSOR (EC 1.18.1.2)
			(ADRENODOXIN REDUCTASE) (FERREDOXIN-NADP(+)
			REDUCTASE).
75	Hs.75431	P04469	FGG: (FGG) FIBRINOGEN GAMMA CHAIN PRECURSOR.
76	Hs.750	P35555	FIBRILLIN1: (FBN1 OR FBN) FIBRILLIN 1 PRECURSOR.
77	Hs.79432	P35556	FIBRILLIN2: (FBN2) FIBRILLIN 2 PRECURSOR.
78	Hs.230	Q06828	FIBROMODULIN: (FMOD OR FM) FIBROMODULIN
			PRECURSOR (FM) (COLLAGEN-BINDING 59 KDA
			PROTEIN).
79	Hs.118162	P02751	FIBRONECTIN: (FN1 OR FN) FIBRONECTIN
			PRECURSOR (FN).
80	Hs.79732	P37888	FIBULIN1: (FBLN1) FIBULIN-1, ISOFORM D
			PRECURSOR.
81	Hs.848	Q02790	FKBP4: (FKBP4) P59 PROTEIN (HSP BINDING
			IMMUNOPHILIN) (HBI) (POSSIBLE PEPTIDYL-PROLYL
			CIS-TRANS ISOMERASE) (EC 5.2.1.8) (PPIASE)
			(ROTAMASE) (FKBP52 PROTEIN) (52 KDA FK506
			BINDING PROTEIN) (P52) (FKBP59) (HSP56).
82	Hs.8762	O95302	FKBP63: (FKBP9 OR FKBP63) FK506-BINDING PROTEIN
			(FRAGMENT) FKBP9.
83	Hs.155952	P42345	FRAP: (FRAP) FKBP-RAPAMYCIN ASSOCIATED
			PROTEIN (FRAP) (RAPAMYCIN TARGET PROTEIN).
84	Hs.105700	O14877	FRPHE_1: (SFRP4) SECRETED FRIZZLED-RELATED
			SEQUENCE PROTEIN 4 FRPHE FRPAP.
85	Hs.183	Q16570	FY: (FY OR GPD OR DARC) DUFFY ANTIGEN (FY
			GLYCOPROTEIN) (GLYCOPROTEIN D) (GPFY)
86	Hs.19545	Q9ULV1	FZD4: (FZD4) WNT RECEPTOR FRIZZLED-4.
87	Hs.197345	P12956	G22P1: (G22P1) ATP-DEPENDENT DNA HELICASE II, 70
			KDA SUBUNIT (LUPUS KU AUTOANTIGEN PROTEIN
			P70) (KU70) (70 KDA SUBUNIT OF KU ANTIGEN)
			(THYROID-LUPUS AUTOANTIGEN) (TLAA) (CTC BOX
			BINDING FACTOR 75 KDA SUBUNIT) (CTCBF) (CTC75).
88	Hs.227751	P09382	GALECTIN-1: (LGALS1) GALECTIN-1 (BETA-
			GALACTOSIDE-BINDING LECTIN L-14-I) (LACTOSE-
			BINDING LECTIN 1) (S-LAC LECTIN 1) (GALAPTIN) (14 KDA
			LECTIN) (HPL) (HBL).
89	Hs.169476	P04406	GAPD: (GAPD) (GAPDH) GLYCERALDEHYDE 3-
			PHOSPHATE DEHYDROGENASE, LIVER (EC 1.2.1.12).
90	Hs.9194	Q9UMW7	GBDR1: (GBDR1) PUTATIVE GLIALBLASTOMA CELL
			DIFFERENTIATION-RELATED PROTEIN.
91	Hs.74471	P17302	GJA1_2: (GJA1) GAP JUNCTION ALPHA-1 PROTEIN
			(CONNEXIN 43) (CX43) (GAP JUNCTION 43 KDA HEART
			PROTEIN).
92		P29033	GJB2: (GJB2) GAP JUNCTION BETA-2 PROTEIN
			(CONNEXIN 26) (CX26)
93	Hs.77508	P49448	GLUDP1: (GLUD2 OR GLUDP1) GLUTAMATE
			DEHYDROGENASE 2 PRECURSOR (EC 1.4.1.3) (GDH).
94	Hs.170171	P15104	GLUL: (GLUL OR GLNS) GLUTAMINE SYNTHETASE (EC
			6.3.1.2) (GLUTAMATE —AMMONIA LIGASE).
95	Hs.76686	P07203	GPX1: (GPX1) GLUTATHIONE PEROXIDASE (EC
			1.11.1.9) (GSHPX-1) (CELLULAR GLUTATHIONE
			PEROXIDASE).
96	Hs.226795	P09211	GSTP1: (GSTP1 OR GST3) GLUTATHIONE S-
			TRANSFERASE P (EC 2.5.1.18) (GST CLASS-PI) (GSTP1-
			1).
97	Hs.75445	Q14515	HEVIN: (HEVIN) HIGH ENDOTHELIAL VENULE
			PRECURSOR. (MAST 9) HEVIN-LIKE PROTEIN.
98	Hs.119222	P50502	HIP: (HIP OR ST13 OR P48) HSC70-INTERACTING
			PROTEIN (PROGESTERONE RECEPTOR-ASSOCIATED
			P48 PROTEIN) (PUTATIVE TUMOR SUPPRESSOR ST13).
99	Hs.198427	P52789	HK2: (HK2) HEXOKINASE, TYPE II (EC 2.7.1.1) (HK II).
100	Hs.82314	P00492	HPRT: (HPRT1 OR HPRT) HYPOXANTHINE-GUANINE
			PHOSPHORIBOSYLTRANSFERASE (EC 2.4.2.8)
			(HGPRT) (HGPRTASE).
101	Hs.180414	P11142	HSC73: (HSPA8 OR HSPA10 OR HSC70 OR HSP73)
			HEAT SHOCK COGNATE 71 KD PROTEIN.
102	Hs.180532	P07900	HSPCA: (HSPCA OR HSPC1 OR HSP90A) HEAT SHOCK
			PROTEIN HSP 90-ALPHA (HSP 86).
103	Hs.82646	P25685	HSPF1: (HSPF1 OR DNAJ1 OR HDJ1) HEAT SHOCK 40 KDA
			PROTEIN 1 (HEAT SHOCK PROTEIN 40) (HSP40)
			DNAJ PROTEIN HOMOLOG 1) (HDJ-1).
104	Hs.81328	P25963	IKBA: (NFKBIA OR NFKBI OR MAD3) MAJOR
			HISTOCOMPATIBILITY COMPLEX ENHANCER-BINDING
			PROTEIN MAD3 (NUCLEAR FACTOR KAPPA-B
			INHIBITOR) (I-KAPPA-B-ALPHA) (IKBA).
105	Hs.83004	P40222	IL14: (IL14) INTERLEUKIN-14 PRECURSOR (IL-14) (HIGH
			MOLECULAR WEIGHT B-CELL GROWTH FACTOR)
			(HMW-BCGF).
106	Hs.83077	Q14116	IL18: (IL18 OR IGIF) INTERLEUKIN-18 PRECURSOR (IL-
			18) (INTERFERON-GAMMA INDUCING FACTOR) (IFN-
			GAMMA-INDUCING FACTOR) INTERLEUKIN-1 GAMMA)
			(IL-1 GAMMA).
107	Hs.1722	P01583	IL1A: (IL1A) INTERLEUKIN-1 ALPHA PRECURSOR (IL-1
			ALPHA) (HEMATOPOIETIN-1).
108	Hs.126256	P01584	IL1B: (IL1B) INTERLEUKIN-1 BETA PRECURSOR (IL-1
			BETA) (CATABOLIN).
109	Hs.82112	P14778	IL1R1: (IL1R1 OR IL1RA OR IL1R) INTERLEUKIN-1
			RECEPTOR, TYPE I PRECURSOR (IL-1R-1) (IL-1R-
			ALPHA) (P80) (ANTIGEN CD121A).
110	Hs.93913	P05231	IL6: (1L6 OR IFNB2) INTERLEUKIN-6 PRECURSOR (IL-6)
			(B-CELL STIMULATORY FACTOR 2) (BSF-2)
			(INTERFERON BETA-2) (HYBRIDOMA GROWTH
			FACTOR).
111	Hs.624	P10145	IL8: (IL8) INTERLEUKIN-8 PRECURSOR (IL-8)
			(MONOCYTE-DERIVED NEUTROPHIL CHEMOTACTIC
			FACTOR) (MDNCF) (T-CELL CHEMOTACTIC FACTOR)
			(NEUTROPHIL-ACTIVATING PROTEIN 1) (NAP-1)
			(LYMPHOCYTE-DERIVED NEUTROPHIL-ACTIVATING
			FACTOR) (LYNAP) (PROTEIN 3-10C).
112	Hs.149846	P18084	INTEGRINB5: (ITGB5) INTEGRIN BETA-5 PRECURSOR.
113	Hs.149609	P08648	ITGA5: (ITGA5 OR FNRA) INTEGRIN ALPHA-5
			PRECURSOR (FIBRONECTIN RECEPTOR ALPHA
			SUBUNIT) (INTEGRIN ALPHA-F) (VLA-5) (CD49E).
114	Hs.172180	O43166	KIAA0440: (KIAA0440) KIAA0440 (FRAGMENT). SPA-1
			LIKE PROTEIN P1294. PUTATIVE GAP PROTEIN ALPHA.
			HIGH-RISK HUMAN PAPILLOMA VIRUSES E6
			ONCOPROTEINS TARGETED PROTEIN E6TP1 BETA.
115	Hs.129943	O60292	KIAA0545: (KIAA0545) KIAA0545 PROTEIN (FRAGMENT).
116	Hs.52081	O94945	KIAA0867: (KIAA0867) KIAA0867 PROTEIN
117	Hs.182423	P30042	KNP-I: (C21ORF33 OR HES1 OR KNPI) ES1 PROTEIN
			HOMOLOG, MITOCHONDRIAL PRECURSOR (PROTEIN
			KNP-I) (GT335 PROTEIN).
118	Hs.80828	P04264	KRT1: (KRT1 OR KRTA) KERATIN, TYPE II
			CYTOSKELETAL 1 (CYTOKERATIN 1) (K1) (CK 1) (67 KDA
			CYTOKERATIN) (HAIR ALPHA PROTEIN).
119	Hs.99936	P13645	KRT10: (KRT10) KERATIN, TYPE I CYTOSKELETAL 10
			(CYTOKERATIN 10) (K10) (CK 10).
120	Hs.117729	P02533	KRT14: (KRT14) KERATIN, TYPE I CYTOSKELETAL 14
			(CYTOKERATIN 14) (K14) (CK 14).
121	Hs.195850	P13647	KRT5: (KRT5) KERATIN, TYPE II CYTOSKELETAL 5
			(CYTOKERATIN 5) (K5) (CK 5) (58 KDA CYTOKERATIN).
122		P25391	LAMA1: (LAMA1 OR LAMA) LAMININ ALPHA-1 CHAIN
			PRECURSOR (LAMININ A CHAIN).
123	Hs.75279	Q14736	LAMA2: (LAMA2 OR LAMM) LAMININ ALPHA-2 CHAIN
			PRECURSOR (LAMININ M CHAIN) (MEROSIN HEAVY
			CHAIN).
124	Hs.83450	Q16787	LAMA3: (LAMA3) LAMININ ALPHA-3 CHAIN PRECURSOR
			(EPILIGRIN 170 KDA SUBUNIT) (E170).
125	Hs.78672	Q16363	LAMA4: (LAMA4) LAMININ ALPHA-4 CHAIN
			PRECURSOR.
126	Hs.11669	O15230	LAMA5: (KIAA0533 OR LAMA5) KIAA0533 PROTEIN
			(LAMININ ALPHA 5 CHAIN) (FRAGMENT).
127	Hs.82124	P07942	LAMB1: (LAMB1) LAMININ BETA-1 CHAIN PRECURSOR
			(LAMININ B1 CHAIN).
128	Hs.75517	Q13751	LAMB3: (LAMB3) LAMININ BETA-3 CHAIN PRECURSOR
			(LAMININ B1K CHAIN) (KALININ B1 CHAIN).
129	Hs.214982	P11047	LAMG1: (LAMC1 OR LAMB2) LAMININ GAMMA-1 CHAIN
			PRECURSOR (LAMININ B2 CHAIN).
130	Hs.69954	Q9Y6N6	LAMG3: (LAMC3) LAMININ GAMMA 3 CHAIN
			PRECURSOR.
131	Hs.223014	P36777	LON: (PRSS15) MITOCHONDRIAL LON PROTEASE
			HOMOLOG PRECURSOR (EC 3.4.21.—).
132	Hs.241257	P22064	LTBP1: (LTBP1) LATENT TRANSFORMING GROWTH
			FACTOR BETA BINDING PROTEIN 1 PRECURSOR
			(TRANSFORMING GROWTH FACTOR BETA-1 BINDING
			PROTEIN 1) (TGF-BETA1-BP-1).
133	Hs.23582	P09758	M1S1: (M1S1 OR GA733-1 OR TROP2) PANCREATIC
			CARCINOMA MARKER PROTEIN GA733-1 PRECURSOR
			(CELL SURFACE GLYCOPROTEIN TROP-2).
134	Hs.83551	P55001	MAGP1: (MFAP2 OR MAGP1) MICROFIBRIL-
			ASSOCIATED GLYCOPROTEIN PRECURSOR (MAGP)
			(MAGP-1).
135	Hs.861	P27361	MAPK3: (MAPK3 OR PRKM3 OR ERK1) MITOGEN-
			ACTIVATED PROTEIN KINASE 3 (EC 2.7.1.—)
			(EXTRACELLULAR SIGNAL-REGULATED KINASE 1)
			(ERK-1) (INSULIN-STIMULATED MAP2 KINASE) (MAP
			KINASE 1) (MAPK 1) (P44-ERK1) (ERT2)(P44-
			MAPK)(MICROTUBULE-ASSOCIATED PROTEIN-2
			KINASE)
136	Hs.211579	P43121	MCAM: (MCAM OR MUC18) CELL SURFACE
			GLYCOPROTEIN MUC18 PRECURSOR (MELANOMA-
			ASSOCIATED ANTIGEN MUC18) (MELANOMA-
			ASSOCIATED ANTIGEN A32) (S-ENDO 1 ENDOTHELIAL-
			ASSOCIATED ANTIGEN) (CD146 ANTIGEN) (MELANOMA
			ADHESION MOLECULE).
137	Hs.77171	P33992	MCM5: (MCM5 OR CDC46) DNA REPLICATION
			LICENSING FACTOR MCM5 (CDC46 HOMOLOG) (P1-
			CDC46).
138	Hs.111076	P40926	MDH2: (MDH2) MALATE DEHYDROGENASE,
			MITOCHONDRIAL PRECURSOR (EC 1.1.1.37).
139	Hs.199160	Q03164	MLL: (MLL OR HRX OR ALL1 OR TRX1 OR HTRX) ZINC
			FINGER PROTEIN HRX (ALL-1) (TRITHORAX-LIKE
			PROTEIN).
140	Hs.83169	P03956	MMP1: (MMP1 OR CLG) INTERSTITIAL COLLAGENASE
			PRECURSOR (EC 3.4.24.7) (MATRIX
			METALLOPROTEINASE-1) (MMP-1) (FIBROBLAST
			COLLAGENASE).
141	Hs.1695	P39900	MMP12: (MMP12 OR HME) MACROPHAGE
			METALLOELASTASE PRECURSOR (EC 3.4.24.65) (HME)
			(MATRIX METALLOPROTEINASE-12) (MMP-12).
142	Hs.111301	P08253	MMP2: (MMP2 OR CLG4A) 72 KDA TYPE IV
			COLLAGENASE PRECURSOR (EC 3.4.24.24) (72 KDA
			GELATINASE) (MATRIX METALLOPROTEINASE-2)
			(MMP-2) (GELATINASE A) (TBE-1).
143	Hs.184601	Q01650	MPE16: (MPE16) INTEGRAL MEMBRANE PROTEIN E16.
			(HLAT1 OR CD98LC) L-TYPE AMINO ACID
			TRANSPORTER 1. (4F2 LC) 4F2 LIGHT CHAIN. (SLC7A5).
144	Hs.73965	Q01130	MRF1: (SFRS2) SPLICING FACTOR, ARGININE/SERINE-
			RICH 2 (SPLICING FACTOR SC35) (SC-35) (SPLICING
			COMPONENT, 35 KDA) (PR264 PROTEIN).
145	Hs.25313	O14742	MSP58: (MSP58) NUCLEOLAR PROTEIN CELL CYCLE-
			REGULATED FACTOR P78.
146	Hs.76941	P54709	NA-K-ATPASE-B3: (ATP1B3) SODIUM/POTASSIUM-
			TRANSPORTING ATPASE BETA-3 CHAIN
			(SODIUM/POTASSIUM-DEPENDENT ATPASE BETA-3
			SUBUNIT) (ATPB-3).
147	Hs.15977	Q9Y6M9	NDUFB9: (NDUFB9 OR UQOR22) NADH-UBIQUINONE
			OXIDOREDUCTASE B22 SUBUNIT (EC 1.6.5.3) (EC
			1.6.99.3) (COMPLEX I-B22) (CI-B22).
148	Hs.172674	Q99842	NFATX4: (NFATC3 OR NFAT4) NUCLEAR FACTOR OF
			ACTIVATED T-CELLS, CYTOPLASMIC 3 (T CELL
			TRANSCRIPTION FACTOR NFAT4) (NF-ATC3) (NF-AT4)
			(NFATX).
149	Hs.62041	P14543	NIDOGEN: (NID) NIDOGEN PRECURSOR (ENTACTIN).
150	Hs.111039	P30419	NMT1: (NMT1 OR NMT) GLYCYLPEPTIDE N-
			TETRADECANOYLTRANSFERASE 1 (EC 2.3.1.97)
			(PEPTIDE N-MYRISTOYLTRANSFERASE 1)
			(MYRISTOYL-COA: PROTEIN N-
			MYRISTOYLTRANSFERASE 1) (NMT 1).
151	Hs.724	P20393	NR1D1: (NR1D1 OR THRAL OR EAR1 OR HREV)
			ORPHAN NUCLEAR RECEPTOR NR1D1 (V-ERBA
			RELATED PROTEIN EAR-1) (REV-ERBA-ALPHA).
152	Hs.1119	P22736	NR4A1: (NR4A1 OR HMR OR NAK1 OR GFRP1) ORPHAN
			NUCLEAR RECEPTOR HMR (EARLY RESPONSE
			PROTEIN NAK1) (TR3 ORPHAN RECEPTOR)
153	Hs.82120	P43354	NR4A2: (NR4A2 OR NURR1 OR TINUR OR NOT)
			ORPHAN NUCLEAR RECEPTOR NURR1
154	Hs.83469	Q14494	NRF1: (NFE2L1 OR NRF1 OR TCF11 OR HBZ17)
			NUCLEAR FACTOR ERYTHROID 2 RELATED FACTOR 1
			(NF-E2 RELATED FACTOR 1) (NFE2-RELATED FACTOR
			1) (NUCLEAR FACTOR, ERYTHROID DERIVED 2, LIKE 1)
			(TRANSCRIPTION FACTOR 11) (TRANSCRIPTION
			FACTOR HBZ17)
155	Hs.75212	P11926	ODC1: (ODC1) ORNITHINE DECARBOXYLASE (EC
			4.1.1.17) (ODC).
156	Hs.88474	P23219	PGH1: (PTGS1 OR COX1) PROSTAGLANDIN G/H
			SYNTHASE 1 PRECURSOR (EC 1.14.99.1)
			(CYCLOOXYGENASE-1) (COX-1) (PROSTAGLANDIN-
			ENDOPEROXIDE SYNTHASE 1) (PROSTAGLANDIN
			H2SYNTHASE 1) (PGH SYNTHASE 1) (PGHS-1) (PHS 1).
157	Hs.76152	P07585	PGS2: (DCN) BONE PROTEOGLYCAN II PRECURSOR
			(PG-S2) (DECORIN) (PG40).
158	Hs.9589	Q9UMX0	PLIC-1: (UBQLN1) PLIC-1 UBIQUILIN. (DA41)
159	Hs.173902	P30153	PPP2R1A: (PPP2R1A) SERINE/THREONINE PROTEIN
			PHOSPHATASE 2A, 65 KDA REGULATORY SUBUNIT A,
			ALPHA ISOFORM (PP2A, SUBUNIT A, PR65-ALPHA
			ISOFORM) (PP2A, SUBUNIT A, R1-ALPHA ISOFORM)
			(MEDIUM TUMOR ANTIGEN-ASSOCIATED 61 KDA
			PROTEIN)
160		P34062	PSMA6: (PSMA6 OR PROS27) PROTEASOME IOTA
			CHAIN (EC 3.4.99.46) (MACROPAIN IOTA CHAIN)
			(MULTICATALYTIC ENDOPEPTIDASE COMPLEX IOTA
			CHAIN) (27 KDA PROSOMAL PROTEIN) (PROS-27)
			(P27K).
161	Hs.75748	P20618	PSMB1: (PSMB1 OR PSC5) PROTEASOME COMPONENT
			C5
162	Hs.79387	P47210	PSMC5: (PSMC5 OR S8) 26S PROTEASOME
			REGULATORY ATPASE SUBUNIT 8 (P45) (TRIP1).
163	Hs.18700	O75831	PSMD13: (PSMD13) 26S PROTEASOME SUBUNIT S11
			(P40.5)
164	Hs.74619	Q13200	PSMD2: (PSMD2 OR TRAP2) 26S PROTEASOME
			REGULATORY SUBUNIT S2 (P97) (TUMOR NECROSIS
			FACTOR TYPE 1 RECEPTOR ASSOCIATED PROTEIN 2).
165	Hs.9736	O43242	PSMD3: (PSMD3) 26S PROTEASOME REGULATORY
			SUBUNIT S3 (PROTEASOME SUBUNIT P58).
166	Hs.148495	P55036	PSMD4: (PSMD4 OR MCB1) 26S PROTEASOME
			REGULATORY SUBUNIT S5A (AF) (ASF).
167	Hs.155543	P51665	PSMD7: (PSMD7 OR MOV34L) 26S PROTEASOME
			REGULATORY SUBUNIT S12 (MOV34 PROTEIN).
168	Hs.178658	P54727	RAD23B: (RAD23B) UV EXCISION REPAIR PROTEIN
			PROTEIN RAD23 HOMOLOG B (HHR23B) (XP-C REPAIR
			COMPLEMENTING COMPLEX 58 KDA PROTEIN) (P58).
169	Hs.206097	P17082	RRAS2: (RRAS2) RAS-RELATED PROTEIN R-RAS2
			(RAS-LIKE PROTEIN TC21) (TERATOCARCINOMA
			ONCOGENE).
170	Hs.252189	P31431	RYODOCAN: (SDC4) SYNDECAN-4 PRECURSOR
			(AMPHIGLYCAN) (SYND4) (RYUDOCAN CORE
			PROTEIN).
171	Hs.78575	P07602	“SGP1: (PSAP) PROACTIVATOR POLYPEPTIDE
			PRECURSOR [CONTAINS: SAPOSIN A (PROTEIN A);
			SAPOSIN B (SPHINGOLIPID ACTIVATOR PROTEIN 1)
			(SAP-1) (DISPERSIN) (SULFATIDE/GM1 ACTIVATOR);
			SAPOSIN C (CO-BETA-GLUCOSIDASE) (A1 ACTIVATOR)
			(GLUCOSYLCERAMIDASE ACTIVATOR)...”
172	Hs.63236	O76070	SNCG: (SNCG OR BCSG1) GAMMA-SYNUCLEIN
			(PERSYN) (BREAST CANCER-SPECIFIC GENE 1
			PROTEIN).
173	Hs.75428	P00441	SOD1: (SOD1) SUPEROXIDE DISMUTASE [CU-ZN] (EC
			1.15.1.1).
174	Hs.177781	P04179	SOD2: (SOD2 OR SOD-2) SUPEROXIDE DISMUTASE
			[MN], MITOCHONDRIAL PRECURSOR (EC 1.15.1.1).
175	Hs.111779	P09486	SPARC: (SPARC OR ON) SPARC PRECURSOR
			(SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE)
			(OSTEONECTIN) (ON) (BASEMENT MEMBRANE
			PROTEIN BM-40).
176	Hs.142258	P40763	STAT3: (STAT3 OR APRF) SIGNAL TRANSDUCER AND
			ACTIVATOR OF TRANSCRIPTION 3 (ACUTE-PHASE
			RESPONSE FACTOR).
177	Hs.150580	P41567	SUI1: (SUI1) PROTEIN TRANSLATION FACTOR SUI1
			HOMOLOG (SUI1ISO1).
178	Hs.75356	P15884	TCF4: (TCF4 OR ITF2 OR SEF2) TRANSCRIPTION
			FACTOR 4 (IMMUNOGLOBULIN TRANSCRIPTION
			FACTOR 2) (ITF-2) (SL3-3 ENHANCER FACTOR 2) (SEF-
			2).
179	Hs.125359	P04216	THY1: (THY1) THY-1 MEMBRANE GLYCOPROTEIN
			PRECURSOR (THY-1 ANTIGEN) (CDW90) (CD90
			ANTIGEN).
180	Hs.6216	O75472	TID1: (TID1 OR TID-1) TUMOROUS IMAGINAL DISCS
			HOMOLOG PRECURSOR (HTID-1).
181	Hs.5831	P01033	TIMP1: (TIMP1 OR TIMP OR CLGI)
			METALLOPROTEINASE INHIBITOR 1 PRECURSOR
			(TIMP-1) (ERYTHROID POTENTIATING ACTIVITY) (EPA)
			(TISSUE INHIBITOR OF METALLOPROTEINASES)
			(FIBROBLAST COLLAGENASE INHIBITOR)
			(COLLAGENASE INHIBITOR).
182	Hs.6441	P16035	TIMP2: (TIMP2) METALLOPROTEINASE INHIBITOR 2
			PRECURSOR (TIMP-2) (TISSUE INHIBITOR OF
			METALLOPROTEINASES-2) (CSC-21 K).
183	Hs.245188	P35625	TIMP3: (TIMP3) METALLOPROTEINASE INHIBITOR 3
			PRECURSOR (TIMP-3) (TISSUE INHIBITOR OF
			METALLOPROTEINASES-3) (MIG-5 PROTEIN).
184	Hs.190787	Q99727	TIMP4: (TIMP4) METALLOPROTEINASE INHIBITOR 4
			PRECURSOR (TIMP-4) (TISSUE INHIBITOR OF
			METALLOPROTEINASES-4).
185	Hs.105097	P04183	TK1: (TK1) THYMIDINE KINASE, CYTOSOLIC (EC
			2.7.1.21).
186	Hs.118174	P53804	TPRD: (TTC3 OR TPRD) TETRATRICOPEPTIDE REPEAT
			PROTEIN 3 (TPR REPEAT PROTEIN D) MTPRD.
187	Hs.278242	P04687	TUBA: (TUBA1) TUBULIN ALPHA-1 CHAIN.
188	Hs.179661	P07437	TUBB: (TUBB1) TUBULIN BETA-1 CHAIN.
189	Hs.76136	P10599	TXN: (TXN OR TRDX OR TRX) THIOREDOXIN (ATL-
			DERIVED FACTOR) (ADF) (SURFACE ASSOCIATED
			SULPHYDRYL PROTEIN (SASP).
190	Hs.110802	P04275	VWF: (F8VWF OR VWF) VON WILLEBRAND FACTOR
			PRECURSOR.
191	Hs.75608	Q15883	X104: (X104 OR ZO-2) X104 (TIGHT JUNCTION PROTEIN
			ZO-2 ISOFORM A) (TIGHT JUNCTION PROTEIN ZO-2
			ISOFORM C) (TIGHT JUNCTION PROTEIN ZO-2)
192	Hs.149923	P17861	XBP1: (XBP1 OR XBP2 OR TREB5) X BOX BINDING
			PROTEIN-1 (XBP-1) (TREB5 PROTEIN). (HTF)
			HEPATOCARCINOGENESIS-RELATED TRANSCRIPTION
			FACTOR (HTF).
193	Hs.4055	Q99612	ZF9: (COPEB OR BCD1 OR CPBP) CORE PROMOTER
			ELEMENT-BINDING PROTEIN (B-CELL DERIVED
			PROTEIN 1) (PROTO-ONCOGENE BCD1) (KRUEPPEL-
			LIKE FACTOR ZF9) (TRANSCRIPTION FACTOR ZF9)
			(GC-RICH SITES BINDING FACTOR GBF).

[0229]

TABLE 9
	UniGene
	Accession	SWISSPROT
No.:	No.	or TREMBL	Name of gene/Description
1			ACTA1_HUMAN: (ACTA1 OR ACTA) ACTIN, ALPHA
			SKELETAL MUSCLE (ALPHA-ACTIN 1).
2			ACTA1_MOUSE: (ACTA1 OR ACTA) ACTIN, ALPHA
			SKELETAL MUSCLE (ALPHA-ACTIN 1).
3			ADD3: (ADD3 OR ADDL) GAMMA ADDUCIN (ADDUCIN-
			LIKE PROTEIN 70).
4			AHCYL1: (AHCYL1 OR XPVKONA) PUTATIVE
			ADENOSYLHOMOCYSTEINASE (EC 3.3.1.1) (S-
			ADENOSYL-L-HOMOCYSTEINE HYDROLASE)
			(ADOHCYASE).
5			AK025194: AK025194
6			APM2: (APM2) ADIPOSE MOST ABUNDANT GENE
			TRANSCRIPT 2.
7			ARHGAP1: (ARHGAP1 OR RHOGAP1 OR CDC42GAP)
			RHO-GTPASE-ACTIVATING PROTEIN 1 (GTPASE-
			ACTIVATING PROTEIN RHOOGAP) (RHO-RELATED
			SMALL GTPASE PROTEIN ACTIVATOR) (CDC42
			GTPASE-ACTIVATING PROTEIN) (P50-RHOGAP).
8			ARPC4: (ARPC4 OR ARC20) ARP2/3 COMPLEX 20 KDA
			SUBUNIT (P20-ARC) (ACTIN-RELATED PROTEIN 2/3
			COMPLEX SUBUNIT 4).
9			ATP1A1: (ATP1A1) SODIUM/POTASSIUM-
			TRANSPORTING ATPASE ALPHA-1 CHAIN PRECURSOR
			(EC 3.6.3.9) (SODIUM PUMP) (NA+/K+ ATPASE).
10			ATP6S14: (ATP6S14 OR VATF) VACUOLAR ATP
			SYNTHASE SUBUNIT F (EC 3.6.1.34) (V-ATPASE F
			SUBUNIT) (VACUOLAR PROTON PUMP F SUBUNIT) (V-
			ATPASE 14 KDA SUBUNIT).
11			B4-2: B4-2 PROTEIN.
12			BA217H1.1: (BA217H1.1) BA217H1.1 (SIMILAR TO N33
			PROTEIN) (FRAGMENT). (DKFZP564K142). (IAG2)
			IMPLANTATION-ASSOCIATED PROTEIN.
13			BHMT2: (BHMT2) BETAINE-HOMOCYSTEINE
			METHYLTRANSFERASE 2.
14			BLP: (BLP OR KM23) BITHORAXOID-LIKE PROTEIN
			(HSPC162) (DYNEIN-ASSOCIATED PROTEIN HKM23)
			(HSPC162 PROTEIN).
15			BM-002: BM-002 (HYPOTHETICAL 9.1 KDA PROTEIN).
16			BM045: UNCHARACTERIZED BONE MARROW PROTEIN
			BM045.
17			C11ORF24: (C11ORF24) DM4E3.
18			C1QA: (C1QA) COMPLEMENT C1Q SUBCOMPONENT, A
			CHAIN PRECURSOR.
19			CG8989: (CG8989)) ((H3F3A OR HIS3.3A OR CG5825)
			AND (H3F3B OR HISH3-3Q OR HIS3) HISTONE H3.3
			(H3.A) (H3.B) (H3.3Q).
20			CGBP: (CGBP) CPG BINDING PROTEIN.
21			CGI-149: CGI-149 PROTEIN.
22			CTSH: (CTSH) CATHEPSIN H PRECURSOR (EC
			3.4.22.16).
23			CYBA_HUMAN: (CYBA) CYTOCHROME B-245 LIGHT
			CHAIN (P22 PHAGOCYTE B-CYTOCHROME)
			(NEUTROPHIL CYTOCHROME B, 22 KDA POLYPEPTIDE)
			(P22-PHOX) (CYTOCHROME B(558) ALPHA CHAIN)
			(SUPEROXIDE-GENERATING NADPH OXIDASE LIGHT
			CHAIN SUBUNIT).
24			CYBA_MOUSE: (CYBA) CYTOCHROME B-245 LIGHT
			CHAIN (P22 PHAGOCYTE B-CYTOCHROME)
			(NEUTROPHIL CYTOCHROME B, 22 KDA POLYPEPTIDE)
			(P22-PHOX) (CYTOCHROME B(558) ALPHA CHAIN)
			(SUPEROXIDE-GENERATING NADPH OXIDASE LIGHT
			CHAIN SUBUNIT).
25			DAXX: FAS-BINDING PROTEIN DAXX.
26			DJ1009E24.7: (DJ1009E24.7) DJ1009E24.7.
27			DJ159A19.3: (DJ159A19.3) DJ159A19.3 (NOVEL PROTEIN)
			(HYPOTHETICAL 26.4 KDA PROTEIN).
28			DKFZP434B044: (DKFZP434B044) HYPOTHETICAL 55.9 KDA
			PROTEIN.
29			DKFZP434M242: DKFZP434M242
30			DKFZP547A023: (DKFZP547A023) HYPOTHETICAL 19.5 KDA
			PROTEIN (FRAGMENT).
31			DKFZP566B193: DKFZP566B193
32			DKFZP761D0211: (DKFZP761D0211) HYPOTHETICAL 59.7 KDA
			PROTEIN.
33			DNCI2: (DNCI2 OR DNCIC2) DYNEIN INTERMEDIATE
			CHAIN 2, CYTOSOLIC (DH IC-2) (CYTOPLASMIC DYNEIN
			INTERMEDIATE CHAIN 2) (FRAGMENT).
34			DPM2: (DPM2) DOLICHOL PHOSPHATE-MANNOSE
			BIOSYNTHESIS REGULATORY PROTEIN.
35			DQ2A: HLA CLASS II HISTOCOMPATIBILITY ANTIGEN,
			DQ(2) ALPHA CHAIN PRECURSOR. H-2 CLASS II
			HISTOCOMPATIBILITY ANTIGEN, ALPHA CHAIN.
36			DSP: (DSP) DESMOPLAKIN (DP) (250/210 KDA
			PARANEOPLASTIC PEMPHIGUS ANTIGEN).
37			ECGF1: (ECGF1) THYMIDINE PHOSPHORYLASE
			PRECURSOR (EC 2.4.2.4) (TDRPASE) (TP) (PLATELET-
			DERIVED ENDOTHELIAL CELL GROWTH FACTOR) (PD-
			ECGF) (GLIOSTATIN).
38			EDAG: (EDAG) EDAG-1 -LIKE PROTEIN (HEMOGEN-1).
39			EFEMP2: (EFEMP2 OR FBLN4) EGF-CONTAINING
			FIBULIN-LIKE EXTRACELLULAR MATRIX PROTEIN 2
			PRECURSOR (FIBULIN-4) (FIBL-4) (UPH1 PROTEIN).
40			EIF4G1: (EIF4G1 OR EIF4G) EUKARYOTIC TRANSLATION
			INITIATION FACTOR 4 GAMMA (EIF-4-GAMMA) (EIF-4G)
			(EIF4G) (P220).
41			EMI: (EMI) EMILIN PRECURSOR.
42			FB19: (FB19) FB19 PROTEIN (PNUTS).
43			FLJ11346: FLJ11346
44			GTAR: (GTAR) GENE TRAP ANKYRIN REPEAT
			CONTAINING PROTEIN.
45			HSD17B7: (HSD17B7) ESTRADIOL 17 BETA-
			DEHYDROGENASE 7 (EC 1.1.1.62) (17-BETA-HSD 7) (17-
			BETA-HYDROXYSTEROID DEHYDROGENASE 7).
46			ICAT: (ICAT) BETA-CATENIN-INTERACTING PROTEIN
			ICAT.
47			KLF5: (KLF5 OR IKLF OR CKLF OR BTEB2) KRUEPPEL-
			LIKE FACTOR 5 (INTESTINAL-ENRICHED KRUEPPEL-
			LIKE FACTOR) (COLON KRUEPPEL-LIKE FACTOR)
			(TRANSCRIPTION FACTOR BTEB2) (BASIC
			TRANSCRIPTION ELEMENT BINDING PROTEIN 2) (GC
			BOX BINDING PROTEIN 2).
48			LAP: (LAP) CYTOSOL AMINOPEPTIDASE (EC 3.4.11.1)
			(LEUCINE AMINOPEPTIDASE) (LAP) (LEUCYL
			AMINOPEPTIDASE) (PROLINE AMINOPEPTIDASE) (EC
			3.4.11.5) (PROLYL AMINOPEPTIDASE).
49			LMOD1: (LMOD1) LEIOMODIN 1 (LEIOMODIN, MUSCLE
			FORM) (64 KDA AUTOANTIGEN D1) (64 KDA
			AUTOANTIGEN 1D) (64 KDA AUTOANTIGEN 1D3)
			(THYROID-ASSOCIATED OPHTHALMOPATHY
			AUTOANTIGEN) (SMOOTH MUSCLE LEIOMODIN) (SM-
			LMOD).
50			LNV: (LNV) LNV.
51			MAP17: (MAP17) 17 KDA MEMBRANE ASSOCIATED
			PROTEIN (DD96 PROTEIN).
52			MLN51: (MLN51) MLN 51 PROTEIN.
53			NAF1: (NAF1 BETA) NAF1 BETA PROTEIN (HUMAN
			FETAL CRANIOFACIAL MRNA, PARTIAL CDS).
54			NCBP1: (NCBP1 OR NCBP OR CBP80) 80 KDA NUCLEAR
			CAP BINDING PROTEIN (NCBP 80 KDA SUBUNIT)
			(CBP80).
55			NUCKS: (NUCKS) NUCLEAR UBIQUITOUS CASEIN AND
			CYCLIN-DEPENDENT KINASES SUBSTRATE.
56			OS9: (OS9) PROTEIN OS-9 PRECURSOR.
57			Q16465: HYPOTHETICAL PROTEIN (FRAGMENT).
			(RPL41) HOMOLOGUE TO YEAST RIBOSOMAL PROTEIN
			L41.
58			Q9BSM6: SIMILAR TO RIKEN CDNA 2310040G17 GENE
			(FRAGMENT).
59			R32184_3: R32184_3.
60			RAN: (RAN) GTP-BINDING NUCLEAR PROTEIN RAN
			(TC4).
61			RPL13: (RPL13 OR BBC1) 60S RIBOSOMAL PROTEIN L13
			(BREAST BASIC CONSERVED PROTEIN 1).
62			RPLP2: (RPLP2) 60S ACIDIC RIBOSOMAL PROTEIN P2.
63			RPS16: (RPS16) 40S RIBOSOMAL PROTEIN S16.
64			RPS19: (RPS19) 40S RIBOSOMAL PROTEIN S19.
65			RTN-X: (KIAA0886 OR RTN-X) KIAA0886 PROTEIN (RTN-
			XL) (RETICULON 4A). TESTIS SPECIFIC RETICULON 5
			PROTEIN. BRAIN MY043 PROTEIN. (NOGO OR RTN-X)
			FOOCEN-M (NOGO-B PROTEIN) (RTN-XS) (RETICULON
			4B). (ASY) ASY PROTEIN. (NOGO) FOOCEN-S (NOGO-C
			PROTEIN) (HYPOTHET
66			S100A10: (S100A10 OR CAL1L OR ANX2LG OR CLP11)
			CALPACTIN I LIGHT CHAIN (P10 PROTEIN) (P11)
			(CELLULAR LIGAND OF ANNEXIN II).
67			S100A2: (S100A2 OR S100L) S100 CALCIUM-BINDING
			PROTEIN A2 (S-100L PROTEIN) (CAN19).
68			SEMA3C: (SEMA3C OR SEMAE) SEMAPHORIN 3C
			PRECURSOR (SEMAPHORIN E) (SEMA E).
69			SEPT2: (SEPT2 OR NEDD5 OR DIFF6 OR KIAA0158)
			SEPTIN 2 (NEDD5 PROTEIN HOMOLOG).
70			SET: (SET) SET PROTEIN (HLA-DR ASSOCIATED
			PROTEIN II) (PHAPII) (PHOSPHATASE 2A INHIBITOR
			I2PP2A).
71			SFRS11: (SFRS11) SPLICING FACTOR
			ARGININE/SERINE-RICH 11 (ARGININE-RICH 54 KDA
			NUCLEAR PROTEIN) (P54).
72			SIR2L: (SIR2L OR SIRT2 OR SIR2L2) SILENCING
			INFORMATION REGULATOR 2-LIKE PROTEIN (SIR2
			(SILENT MATING TYPE INFORMATION REGULATION 2,
			S. CEREVISIAE, HOMOLOG)-LIKE).
73			SLC9A1: (SLC9A1 OR NHE1 OR APNH1)
			SODIUM/HYDROGEN EXCHANGER 1 (NA(+)/H(+)
			EXCHANGER 1) (NHE-1) (NA+/H+ ANTIPORTER,
			AMILORIDE-SENSITIVE) (APNH).
74			SLU7: STEP II SPLICING FACTOR SLU7.
75			SMT3H2: (SMT3H2 OR SMT3B) UBIQUITIN-LIKE PROTEIN
			SMT3B (SENTRIN 2).
76			SORD: (SORD OR SDH1) SORBITOL DEHYDROGENASE
			(EC 1.1.1.14) (L-IDITOL 2-DEHYDROGENASE).
77			SOX20: (SOX20 OR SOX15 OR SOX-15) SOX-20
			PROTEIN.
78			SRP9: (SRP9) SIGNAL RECOGNITION PARTICLE 9 KDA
			PROTEIN (SRP9).
79			SSRP1: (SSRP1 OR CIIDBP) STRUCTURE-SPECIFIC
			RECOGNITION PROTEIN 1 (SSRP1) (RECOMBINATION
			SIGNAL SEQUENCE RECOGNITION PROTEIN) (T160)
			(CHROMATIN-SPECIFIC TRANSCRIPTION ELONGATION
			FACTOR 80 KDA SUBUNIT) (FACT 80 KDA SUBUNIT).
80			STAB1: (STAB1) STABILIN-1.
81			SUV3: (SUV3) PUTATIVE ATP-DEPENDENT
			MITOCHONDRIAL RNA HELICASE.
82			TE2: (TE2 OR ARD1) N-TERMINAL
			ACETYLTRANSFERASE COMPLEX ARD1 SUBUNIT
			HOMOLOG.
83			TGFBI: (TGFBI OR BIGH3) TRANSFORMING GROWTH
			FACTOR-BETA INDUCED PROTEIN IG-H3 PRECURSOR
			(BETA IG-H3) (KERATO-EPITHELIN) (RGD-CONTAINING
			COLLAGEN ASSOCIATED PROTEIN) (RGD-CAP).
84			TPMT: (TPMT) THIOPURINE S-METHYLTRANSFERASE
			(EC 2.1.1.67) (THIOPURINE METHYL TRANSFERASE).
85			TRIM29A: ATAXIA-TELANGIECTASIA GROUP D-
			ASSOCIATED PROTEIN (TRIPARTITE MOTIF PROTEIN
			TRIM29 ALPHA).
86			TSTA3: (TSTA3 OR TSTAP35B OR P35B) GDP-FUCOSE
			SYNTHETASE (FX PROTEIN) (RED CELL NADP(H)-
			BINDING PROTEIN.
87			TTF-I-IP12: (FKSG13 OR PTRF) LEUCINE-ZIPPER
			PROTEIN FKSG13 (TTF-I INTERACTING PEPTIDE 12)
			(POLYMERASE I-TRANSCRIPT RELEASE FACTOR).
88			TUBA4: (TUBA4) TUBULIN ALPHA-4 CHAIN.
89			TUFT1: (TUFT1 OR DKFZP586G2219) TUFTELIN 1
			(HYPOTHETICAL 44.3 KDA PROTEIN).
90			CHST5_MOUSE: (CHST5 OR I-GLCNAC-6-ST) N-
			ACETYLGLUCOSAMINE 6-O-SULFOTRANSFERASE.
91			EEF1A1: (EEF1A1 OR EEF1A OR EF1A) ELONGATION
			FACTOR 1-ALPHA 1 (EF-1-ALPHA-1) (ELONGATION
			FACTOR 1 A-1) (EEF1A-1) (ELONGATION FACTOR TU)
			(EF-TU).
92			EMBL_AL133429: EMBL_AL133429
93			EMBL_BC009757: EMBL_BC009757
94			EST00098: (EST00098) EST00098 PROTEIN
			(FRAGMENT).
95			EST_AA548686: EST_AA548686
96			EST_AA552025: EST_AA552025
97			EST_AA584843: EST_AA584843
98			EST_AA640108: EST_AA640108
99			EST_AA649141: EST_AA649141
100			EST_AA725246: EST_AA725246
101			EST_AA804235: EST_AA804235
102			EST_AA913191: EST_AA913191
103			EST_AI075228: EST_AI075228
104			EST_AI089822: EST_AI089822
105			EST_AI242082: EST_AI242082
106			EST_AI354540: EST_AI354540
107			EST_AI418576: EST_AI418576
108			EST_AI732274: EST_AI732274
109			EST_AL045661: EST_AL045661
110			EST_AV735432: EST_AV735432
111			EST_AW016700: EST_AW016700
112			EST_AW137203: EST_AW137203
113			EST_AW205184: EST_AW205184
114			EST_AW296183: EST_AW296183
115			EST_AW970604: EST_AW970604
116			FER1L3: (FER1L3) FER-1 LIKE PROTEIN 3.
117			FLJ00075: (FLJ00075) FLJ00075 PROTEIN (FRAGMENT).
118			FLJ12408: CDNA FLJ12408 FIS, CLONE MAMMA1002869,
			HIGHLY SIMILAR TO PINCH PROTEIN.
119			FLJ12671: CDNA FLJ12671 FIS, CLONE NT2RM4002323,
			WEAKLY SIMILAR TO ANTIGEN GOR (SIMILAR TO
			HYPOTHETICAL PROTEIN FLJ12484).
120			FLJ12750: CDNA FLJ12750 FIS, CLONE NT2RP2001168,
			WEAKLY SIMILAR TO VERPROLIN (HYPOTHETICAL 31.3 KDA
			PROTEIN).
121			FLJ12875: CDNA FLJ12875 FIS, CLONE NT2RP2003777.
122			FLJ13110: CDNA FLJ13110 FIS, CLONE NT2RP3002549,
			MODERATELY SIMILAR TO HYPOTHETICAL 26.6 KD
			PROTEIN T19C3.4 IN CHROMOSOME III.
123			FLJ13388: FLJ13388
124			“FLJ13631: CDNA FLJ13631 FIS, CLONE PLACE1011090,
			HIGHLY SIMILAR TO HOMO SAPIENS MRNA; CDNA
			DKFZP586A0522 (FROM CLONE DKFZP586A0522)
			(UNKNOWN) (PROTEIN FOR MGC: 11081).”
125			FLJ13855: CDNA FLJ13855 FIS, CLONE THYRO1000983,
			WEAKLY SIMILAR TO UBIQUITIN-CONJUGATING
			ENZYME E2-17 KD 9 (EC 6.3.2.19), FLJ 13968, CLONE
			Y9AA1001493.
126			FLJ14318: FLJ14318
127			FLJ20037: CDNA FLJ20037 FIS, CLONE COL00314.
128			FLJ20288: CDNA FLJ20288 FIS, CLONE HEP04414
			(FRAGMENT).
129			FLJ20297: CDNA FLJ20297 FIS, CLONE HEP05942.
130			FLJ20321: CDNA FLJ20321 FIS, CLONE HEP09380.
131			FLJ20396: CDNA FLJ20396 FIS, CLONE KAT00561
			(HYPOTHETICAL 20.4 KDA PROTEIN).
132			FLJ20895: FLJ20895
133			FLJ21120: CDNA: FLJ21120 FIS, CLONE CAS05691.
134			FLJ21289: FLJ21289
135			FLJ21296: FLJ21296
136			FLJ21839: CDNA: FLJ21839 FIS, CLONE HEP01794.
137			FLJ22428: (FBXW5) CDNA: FLJ22428 FIS, CLONE
			HRC09055 (WD REPEAT-CONTAINING F-BOX PROTEIN
			FBW5) (F-BOX AND WD-40 DOMAINPROTEIN 5).
138			FLJ22955: CDNA: FLJ22955 FIS, CLONE KAT09907.
139			FLJ23558: CDNA: FLJ23558 FIS, CLONE LNG09703.
140			GJB3_HUMAN: (GJB3 OR CX31) GAP JUNCTION BETA-3
			PROTEIN (CONNEXIN 31) (CX31).
141			GLIPR: (GLIPR OR RTVP1) GLIOMA PATHOGENESIS-
			RELATED PROTEIN (RTVP-1 PROTEIN).
142			GNAS1: (GNAS1 OR GNAS OR GSP) GUANINE
			NUCLEOTIDE-BINDING PROTEIN G(S), ALPHA SUBUNIT
			(ADENYLATE CYCLASE-STIMULATING G ALPHA
			PROTEIN). (XLAS) G-PROTEIN XLAS.
143			GNB1: (GNB1) GUANINE NUCLEOTIDE-BINDING
			PROTEIN G(I)/G(S)/G(T) BETA SUBUNIT 1 (TRANSDUCIN
			BETA CHAIN 1).
144			GST4BETA_HUMAN: (GST4BETA OR CHST6) N-
			ACETYLGLUCOSAMINE 6-O-SULFOTRANSFERASE GST-
			4BETA (CORNEAL N-ACETYLGLUCOSAMINE-6-O-
			SULFOTRANSFERASE).
145			GSTM2: (GSTM2 OR GST4) GLUTATHIONE S-
			TRANSFERASE MU 2 (EC 2.5.1.18) (GSTM2-2) (GST
			CLASS-MU).
146			GTF2F1: (GTF2F1 OR RAP74) TRANSCRIPTION
			INITIATION FACTOR IIF, ALPHA SUBUNIT (TFIIF-ALPHA)
			(TRANSCRIPTION INITIATION FACTOR RAP74).
147			H-SP1: (H-SP1) PANTOPHYSIN.
148			HASPP28: (HASPP28) 28 KDA HEAT-AND ACID-STABLE
			PHOSPHOPROTEIN (PDGF-ASSOCIATED PROTEIN).
149			HNRPL: (HNRPL) HETEROGENEOUS NUCLEAR
			RIBONUCLEOPROTEIN L (HNRNP L).
150			HSPC170: ADRENAL GLAND PROTEIN AD-001 (HSPC170
			PROTEIN) (HSPC152).
151			HSPC195: HSPC195.
152			HSPC254: HSPC254 (FRAGMENT).
153			HSPC300: HSPC300 (FRAGMENT).
154			HSPC330: HSPC330 (FRAGMENT).
155			IGFBP4: (IGFBP4 OR IBP4) INSULIN-LIKE GROWTH
			FACTOR BINDING PROTEIN 4 PRECURSOR (IGFBP-4)
			(IBP-4) (IGF-BINDING PROTEIN 4).
156			IGHA1: (IGHA1) IG ALPHA-1 CHAIN C REGION.
157			IL22R: (IL22R) IL-22 RECEPTOR.
158			ITM2B: (ITM2B OR BRI) INTEGRAL MEMBRANE PROTEIN
			2B (TRANSMEMBRANE PROTEIN BRI).
159			ITPKB: (ITPKB) 1D-MYO-INOSITOL-TRISPHOSPHATE 3-
			KINASE B (EC 2.7.1.127) (INOSITOL 1,4,5-
			TRISPHOSPHATE 3-KINASE) (IP3K) (IP3 3-KINASE)
			(FRAGMENT).
160			JANUS-A: SEX-REGULATED PROTEIN JANUS-A (CGI-
			202).
161			KCNK6: (KCNK6 OR TWIK2 OR TOSS) POTASSIUM
			CHANNEL SUBFAMILY K MEMBER 6 (INWARD
			RECTIFYING POTASSIUM CHANNEL PROTEIN TWIK-2)
			(TWIK-ORIGINATED SIMILARITY SEQUENCE).
162			KIAA0127: (KIAA0127) HYPOTHETICAL PROTEIN
			KIAA0127.
163			KIAA0252: (KIAA0252) MYELOBLAST KIAA0252
			(FRAGMENT).
164			KIAA0302: (KIAA0302 OR SPTBN2) BETA-SPECTRIN III
			(FNTA III SPECTRIN).
165			KIAA0346: (KIAA0346) KIAA0346 PROTEIN (FRAGMENT).
166			KIAA0661: (KIAA0661) KIAA0661 PROTEIN (95 KDA
			RETINOBLASTOMA PROTEIN BINDING
			PROTEIN, KIAA0661 GENE PRODUCT).
167			KIAA0720: (KIAA0720) KIAA0720 PROTEIN (FRAGMENT).
168			KIAA0731: (KIAA0731) KIAA0731 PROTEIN (FRAGMENT).
169			KIAA0876: (KIAA0876) KIAA0876 PROTEIN (FRAGMENT).
170			KIAA0911: (KIAA0911) KIAA0911 PROTEIN.(CSTN1 OR
			CALSYNTENIN-1) CALSYNTENIN-1
171			KIAA1063: (KIAA1063) KIAA1063 PROTEIN (FRAGMENT).
172			KIAA1096: (KIAA1096) KIAA1096 PROTEIN (FRAGMENT).
173			KIAA1175: (KIAA1175) KIAA1175 PROTEIN (FRAGMENT).
174			KIAA1440: (KIAA1440) KIAA1440 PROTEIN (FRAGMENT).
175			KIAA1564: (KIAA1564) KIAA1564 PROTEIN (FRAGMENT).
176			KIAA1753: (KIAA1753) KIAA1753 PROTEIN (FRAGMENT).
177			KIAA1841: KIAA1841 PROTEIN.
178			LDHA: (LDHA) L-LACTATE DEHYDROGENASE M CHAIN
			(EC 1.1.1.27) (LDH-A).
179			LIPHB: (LIPHB) LIPOPHILIN B PRECURSOR.
180			MAZ: (MAZ) MYC-ASSOCIATED ZINC FINGER PROTEIN
			(MAZI) (PURINE-BINDING TRANSCRIPTION FACTOR)
			(PUR-1) (ZF87) (ZIF87).
181			MDH1: (MDH1 OR MDHA) MALATE DEHYDROGENASE,
			CYTOPLASMIC (EC 1.1.1.37).
182			MEN1: MEN1
183			MGC2532: UNKNOWN (PROTEIN FOR MGC: 5178)
			(PROTEIN FOR MGC:2532).
184			MGC2749: HYPOTHETICAL 19.6 KDA PROTEIN
			(UNKNOWN) (PROTEIN FOR MGC:2749).
185			MIG-2: MIG-2 PROTEIN (FRAGMENT).
186			MT2A_HUMAN: (MT2A OR MT2) METALLOTHIONEIN-II
			(MT-II).
187			NAPA: (NAPA) ALPHA-SOLUBLE NSF ATTACHMENT
			PROTEIN (SNAP-ALPHA).
188			NCL: (NCL) NUCLEOLIN (PROTEIN C23).
189			NDUFA3: (NDUFA3) NADH-UBIQUINONE
			OXIDOREDUCTASE B9 SUBUNIT (EC 1.6.5.3) (EC
			1.6.99.3) (COMPLEX I-B9) (CI-B9).
190			O75394: RIBOSOMAL PROTEIN L33-LIKE PROTEIN.
191			PABP2: (PABP2) POLY(A) BINDING PROTEIN II.
192			PALLID: PALLID (PALLID (MOUSE) HOMOLOG,
			PALLIDIN).
193			PARPL: (PARPL) PUTATIVE POLY(ADP-RIBOSYL)
			TRANSFERASE PRECURSOR. VAULT PROTEIN.
			(ADPRTL1) BA169O17.3 (ADP-RIBOSYLTRANSFERASE
			(NAD+, POLY (ADP-RIBOSE) POLYMERASE)-LIKE 1).
			(KIAA0177) KIAA0177 PROTEIN (FRAGMENT).
194			PCOLCE: (PCOLCE) PROCOLLAGEN C-PROTEINASE
			ENHANCER PROTEIN PRECURSOR (PCPE) (TYPE I
			PROCOLLAGEN COOH-TERMINAL PROTEINASE
			ENHANCER) (TYPE 1 PROCOLLAGEN C-PROTEINASE
			ENHANCER PROTEIN).
195			PFKL: (PFKL) 6-PHOSPHOFRUCTOKINASE, LIVER TYPE
			(EC 2.7.1.11) (PHOSPHOFRUCTOKINASE 1)
			(PHOSPHOHEXOKINASE) (PHOSPHOFRUCTO-1-KINASE
			ISOZYME B) (PFK-B).
196			PI4KB: (PI4KB) PHOSPHATIDYLINOSITOL 4-KINASE.
197			PIR: (PIR) PIRIN.
198			PLASMOLIPIN: PLASMOLIPIN.
199			PNAS-110: PNAS-110.
200			PPL: (PPL OR KIAA0568) PERIPLAKIN (195 KDA
			CORNIFIED ENVELOPE PRECURSOR) (190 KDA
			PARANEOPLASTIC PEMPHIGUS ANTIGEN).
201			PQBP-1: (PQBP-1 OR JM26 OR NPW38)
			POLYGLUTAMINE BINDING PROTEIN 1 (JM26 PROTEIN)
			(PQBP-1).
202			PSMF1: (PSMF1) DJ545L17.3 (PROTEASOME
			(PROSOME, MACROPAIN) INHIBITOR SUBUNIT 1 (PI31)).
203			Q04323: HYPOTHETICAL 33.4 KDA PROTEIN.
204			Q9BRK3: SIMILAR TO RIKEN CDNA 1200013A08 GENE.
205			Q9BRX8: SIMILAR TO RIKEN CDNA 5730469M10 GENE.
206			Q9BV68: HYPOTHETICAL 35.6 KDA PROTEIN.
207			Q9BWN5: SIMILAR TO ILVB (BACTERIAL
			ACETOLACTATE SYNTHASE)-LIKE.
208			Q9Y475: INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE
			ISOENZYME (EC 2.7.1.127) (FRAGMENT).
209			RAB11A: (RAB11A OR RAB11) RAS-RELATED PROTEIN
			RAB-11A (RAB-11) (24KG) (YL8).
210			RAB2: (RAB2) RAS-RELATED PROTEIN RAB-2.
211			RALGDS: (RALGDS OR RGF) RAL GUANINE
			NUCLEOTIDE DISSOCIATION STIMULATOR (RALGEF)
			(RALGDS).
212			RBM6: (RBM6 OR DEF3) RNA-BINDING PROTEIN 6 (RNA
			BINDING MOTIF PROTEIN 6) (RNA-BINDING PROTEIN
			DEF-3) (LUNG CANCER ANTIGEN NY-LU-12) (PROTEIN
			G16).
213			RGS10: (RGS10) REGULATOR OF G-PROTEIN
			SIGNALING 10 (RGS10).
214			RHOIP3: (RHOIP3) RHO-INTERACTING PROTEIN 3
			(P116RIP) (RIP3). (KIAA0864) KIAA0864 PROTEIN
			(FRAGMENT).
215			RIS: (RIS) RIS.
216			RLIP76: (RIP1) RLIP76 PROTEIN, RAL-INTERACTING
			PROTEIN 1 (RIP1 PROTEIN) RALBP1.
217			RNPS1: (RNPS1) SR PROTEIN (RIBONUCLEIC ACID
			BINDING PROTEIN S1 (RNA/DNA-BINDING PROTEIN)).
218			RPL14: (RPL14) 60S RIBOSOMAL PROTEIN L14 (CAG-ISL7).
219			SB135: (MYADM OR MUG) MYELOID-ASSOCIATED
			DIFFERENTIATION MARKER (MYELOID UPREGULATED
			PROTEIN) (SB135).
220			SEPP1: (SEPP1 OR SELP) SELENOPROTEIN P
			PRECURSOR (SEP).
221			SF3B2: (SF3B2 OR SAP145) SPLICING FACTOR 3B
			PROTEIN, SUBUNIT 2 (SF3B150) (SPLICEOSOME
			ASSOCIATED PROTEIN 145) (SAP 145).
222			SOD3: (SOD3) EXTRACELLULAR SUPEROXIDE
			DISMUTASE PRECURSOR (EC 1.15.1.1) (EC-SOD).
223			SQSTM1_HUMAN: (SQSTM1 OR OSI) OXIDATIVE
			STRESS INDUCED PHOSPHOTYROSINE INDEPENDENT
			LIGAND FOR THE LCK SH2 DOMAIN P62
			(SEQUESTOSOME 1). EBI3-ASSOCIATED PROTEIN P60.
			PKC-ZETA-INTERACTING PROTEIN (ZIP).
224			SQSTM1_MOUSE: (SQSTM1 OR OSI) OXIDATIVE
			STRESS INDUCED PHOSPHOTYROSINE INDEPENDENT
			LIGAND FOR THE LCK SH2 DOMAIN P62
			(SEQUESTOSOME 1). EBI3-ASSOCIATED PROTEIN P60.
			PKC-ZETA-INTERACTING PROTEIN (ZIP).
225			SUN2: (SUN2) SAD1 UNC-84 DOMAIN PROTEIN 2
			(FRAGMENT). (KIAA0668 OR DJ508115.4) KIAA0668
			PROTEIN (FRAGMENT).
226			TM4SF2: (TM4SF2 OR MXS1 OR A15) TRANSMEMBRANE
			4 SUPERFAMILY, MEMBER 2 (CELL SURFACE
			GLYCOPROTEIN A15) (T-CELL ACUTE LYMPHOBLASTIC
			LEUKEMIA ASSOCIATED ANTIGEN 1) (TALLA-1)
			(MEMBRANE COMPONENT, X CHROMOSOME,
			SURFACE MARKER 1).
227			UGP2: (UGP2) UTP —GLUCOSE-1-PHOSPHATE
			URIDYLYLTRANSFERASE 2 (EC 2.7.7.9) (UDP-GLUCOSE
			PYROPHOSPHORYLASE 2) (UDPGP 2) (UGPASE 2).
228			VAMP5: (VAMP5) VESICULE-ASSOCIATED MEMBRANE
			PROTEIN 5 (VAMP-5) (MYOBREVIN) (HSPC191).
229			WDR1: (WDR1) WD-REPEAT PROTEIN 1 (ACTIN
			INTERACTING PROTEIN 1) (NORI-1).
230			XAB2: (XAB2) XAB2.
231			ZB42D04: ZB42D04
232			ZNF220: (ZNF220 OR MOZ) MONOCYTIC LEUKEMIA ZINC
			FINGER PROTEIN (ZINC FINGER PROTEIN 220).
233			ZNF6: (ZNF6) ZINC FINGER TRANSCRIPTION FACTOR.
234			ZNFN2A1: (ZNFN2A1) DOUBLE FYVE-CONTAINING
			PROTEIN 1.

[0230]

Claims

1. A process for the in vitro identification of the genes relevant to ageing of the skin and/or to skin stress in human beings or animals, characterized in that a) a first mixture of genetically coded factors expressed, i.e. transcribed and optionally translated, in human or animal skin, i.e. a mixture of proteins, mRNA molecules or fragments of proteins or mRNA molecules, is isolated from young human or animal skin, b) a second mixture of genetically coded factors expressed, i.e. transcribed and optionally translated, in human or animal skin, i.e. a mixture of proteins, mRNA molecules or fragments of proteins or mRNA molecules, is isolated from old human or animal skin, c) the mixtures isolated in a) and b) are subjected to a serial analysis of gene expression (SAGE) so that the genes expressed to different extents (differentially) in old and young skin are identified.

2. A process for the in vitro determination of skin stress and/or ageing of the skin in human beings or animals, characterized in that a) a mixture of proteins, mRNA molecules or fragments of proteins or mRNA molecules is isolated from human or animal skin, b) the mixture isolated is tested for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules identified as expressed differentially in old and young skin by serial analysis of gene expression (SAGE), c) the test results from b) are compared with the expression patterns identified by serial analysis of gene expression (SAGE) and d) the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed more strongly in old or stressed skin than in young or unstressed skin or the mixture tested in b) is assigned to young or unstressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed more strongly in young or unstressed skin than in old or stressed skin.

3. A process as claimed in claim 2, characterized in that, in step b), the mixture isolated is tested for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules defined by their UniGene Accession Number in Tables 1 to 4, column 7; in step c), the test results from b) are compared with the relative expression frequencies shown in Tables 1 to 4, columns 3 and 4, and the expression quotients indicated in column 5; and in step d), the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least twice as strongly in old or stressed skin as in young or unstressed skin or the mixture tested in b) is assigned to young or unstressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least twice as strongly in young or unstressed skin as in old or stressed skin.

4. A process as claimed in claim 2 or 3, characterized in that, in step b), the mixture isolated is tested for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules defined by their UniGene Accession Number in Tables 2 to 4, column 7; in step c), the test results from b) are compared with the relative expression frequencies shown in Tables 2 to 4, columns 3 and 4, and the expression quotients indicated in column 5; and in step d), the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least five times as strongly in old or stressed skin as in young or unstressed skin or the mixture tested in b) is assigned to young or unstressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least five times as strongly in young or unstressed skin as in old or stressed skin.

5. A process as claimed in any of claims 2 to 4, characterized in that, in step b), the mixture isolated is tested for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules defined by their UniGene Accession Number in Tables 3 and 4, column 7; in step c), the test results from b) are compared with the relative expression frequencies shown in Tables 3 and 4, columns 3 and 4, and the expression quotients indicated in column 5; and in step d), the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least seven times as strongly in old or stressed skin as in young or unstressed skin or the mixture tested in b) is assigned to young or unstressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least seven times as strongly in young or unstressed skin as in old or stressed skin.

6. A process as claimed in any of claims 2 to 5, characterized in that, in step b), the mixture isolated is tested for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules defined by their UniGene Accession Number in Table 4, column 7; in step c), the test results from b) are compared with the relative expression frequencies shown in Table 4, columns 3 and 4, and the expression quotients indicated in column 5; and in step d), the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least ten times as strongly in old or stressed skin as in young or unstressed skin or the mixture tested in b) is assigned to young or unstressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least ten times as strongly in young or unstressed skin as in old or stressed skin.

7. A process as claimed in claim 2, characterized in that, in step b), the mixture isolated is tested for the presence and optionally the quantity of at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules defined by their 11-base tag sequence in Table 5 or in Table 7, column 2; in step c), the test results from b) are compared with the relative expression frequencies shown in Table 5 or in Table 7, columns 3 and 4, and the expression quotients indicated in column 5; and in step d), the mixture tested in b) is assigned to old or stressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least twice, more particularly five times, preferably seven times and more preferably ten times as strongly in old or stressed skin as in young or unstressed skin or the mixture tested in b) is assigned to young or unstressed skin if it predominantly contains proteins, mRNA molecules or fragments of proteins or mRNA molecules which are expressed at least twice, more particularly five times, preferably seven times and more preferably ten times as strongly in young or unstressed skin as in old or stressed skin.

8. A process for the in vitro determination of skin stress and/or ageing of the skin in human beings or animals, characterized in that a) a mixture of proteins, mRNA molecules or fragments of proteins or mRNA molecules is isolated from human or animal skin, b) in the mixture isolated, at least two of the proteins, mRNA molecules or fragments of proteins or mRNA molecules identified as important to skin ageing and/or skin stress by the process claimed in claim 1 are quantified, c) the expression ratios of the at least two proteins, mRNA molecules or fragments of proteins or mRNA molecules to one another are determined, d) the expression ratios from c) are compared with the expression ratios typically present in young skin or in old skin for the molecules quantified in b), more particularly with the expression ratios shown in Tables 1 to 5 and 7, columns 3 and 4 and e) the mixture isolated in a) is assigned to old or stressed skin if the expression ratios of the skin under analysis correspond to the expression ratios in old skin or the mixture isolated in a) is assigned to young or unstressed skin if the expression ratios of the skin under analysis correspond to from the expression ratios in young skin.

9. A process as claimed in any of claims 1 to 8, characterized in that, in step a), the mixture is isolated from a skin sample, more particularly from a whole skin sample or from an epidermis sample.

10. A process as claimed in any of claims 2 to 8, characterized in that, in step a), the mixture is obtained by microdialysis.

11. A process as claimed in any of claims 2 to 7, 9 and 10, characterized in that, in step b), testing for the presence and optionally the quantity of at least one of the proteins or protein fragments is carried out by a method selected from i. one- or two-dimensional gel electrophoresis ii. affinity chromatography iii. protein/protein complexing in solution iv. mass spectrometry, more particularly Matrix Assisted Laser Desorption Ionization (MALDI) and, more particularly, v. the use of protein chips, or suitable combinations of these methods.

12. A process as claimed in any of claims 8 to 10, characterized in that, in step b), the quantification of at least two proteins or protein fragments is carried out by a method selected from i. one- or two-dimensional gel electrophoresis ii. affinity chromatography iii. protein/protein complexing in solution iv. mass spectrometry, more particularly Matrix Assisted Laser Desorption Ionization (MALDI) and, more particularly, v. the use of protein chips, or suitable combinations of these methods.

13. A process as claimed in any of claims 2 to 7, 9 and 10, characterized in that, in step b), testing for the presence and optionally the quantity of at least one of the mRNA molecules or mRNA molecule fragments is carried out by a method selected from i. northern blots, ii. reverse transcriptase polymerase chain reaction (RT-PCR), iii. RNase protection experiments, iv. dot blots, v. cDNA sequencing, vi. clone hybridization, vii. differential display, viii. subtractive hybridization, ix. cDNA fragment fingerprinting, x. total gene expression analysis (TOGA) xi. serial analysis of gene expression (SAGE) and, more particularly, xii. the use of nucleic acid chips or suitable combinations of these methods.

14. A process as claimed in any of claims 8 to 10, characterized in that in step b), the quantification of at least two mRNA molecules or mRNA molecule fragments is carried out by a method selected from i. northern blots, ii. reverse transcriptase polymerase chain reaction (RT-PCR), iii. RNase protection experiments, iv. dot blots, v. cDNA sequencing, vi. clone hybridization, vii. differential display, viii. subtractive hybridization, ix. cDNA fragment fingerprinting, x. total gene expression analysis (TOGA) xi. serial analysis of gene expression (SAGE) and, more particularly, xii. the use of nucleic acid chips or suitable combinations of these methods.

15. A process as claimed in any of claims 2 to 7, 9, 10, 11 and 13, characterized in that step b) comprises testing for the presence and optionally the quantity of 1 to about 5,000, preferably 1 to about 1,000, more preferably about 10 to about 500, most preferably about 10 to about 250, more particularly about 10 to about 100 and most particularly about 10 to about 50 of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are defined i. by their Unigene Accession Number in Tables 1 to 4, column 7, or ii. by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9 or iii. by their 11-base tag sequence in Table 5 or in Table 7, column 2.

16. A process as claimed in any of claims 8 to 10, 12 and 14, characterized in that 1 to about 5,000, preferably 1 to about 1,000, more preferably about 10 to about 500, most preferably about 10 to about 250, more particularly about 10 to about 100 and most particularly about 10 to about 50 of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are defined i. by their Unigene Accession Number in Tables 1 to 4, column 7, or ii. by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9 or iii. by their 11-base tag sequence in Table 5 or in Table 7, column 2 are quantified in step b).

17. A test kit for the in vitro determination of skin stress and/or ageing of the skin in human beings or animals comprising means for carrying out the process claimed in any of claims 2 to 16.

18. A biochip for the in vitro determination of skin stress and/or ageing of the skin in human beings or animals comprising i. a support and, ii. immobilized thereon, probes which are capable of binding specifically to at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are defined by their UniGene Accession Number in Tables 1 to 4, column 7, or by their 11-base tag sequence in Table 5 or in Table 7, column 2.

19. A biochip as claimed in claim 18 comprising 1 to about 5,000, preferably 1 to about 1,000, more preferably about 10 to about 500, most preferably about 10 to about 250, more particularly about 10 to about 100 and most particularly about 10 to about 50 different probes.

20. A biochip as claimed in claim 18 or 19 comprising nucleic acid probes, more particularly RNA or PNA probes and most particularly DNA probes.

21. A biochip as claimed in claim 20 comprising probes with a length of about 10 to about 1,000, more preferably with a length of about 10 to about 800, most preferably with a length of about 100 to about 600 and, in one most particularly preferred embodiment, with a length of about 200 to about 400 nucleotides.

22. A biochip as claimed in claim 18 or 19 comprising peptide or protein probes, more particularly antibodies.

23. A biochip as claimed in any of claims 18 to 22 comprising probes which are capable of binding specifically to at least one of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are identified by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9.

24. The use of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are defined i. by their Unigene Accession Number in Tables 1 to 4, column 7, or ii. by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9 or iii. by their 11-base tag sequence in Table 5 or in Table 7, column 2, as skin stress and/or skin ageing markers in human beings or animals.

25. A test for demonstrating the effectiveness of cosmetic or pharmaceutical active substances against skin stress and/or ageing of the skin in vitro, characterized in that a) the status of the skin is determined by the process claimed in any of claims 2 to 16 or with the aid of a test kit claimed in claim 17 or with the aid of the biochip claimed in any of claims 18 to 23, b) an active substance against skin stress and/or ageing of the skin is applied one or more times to the skin, c) the status of the skin is re-determined by the process claimed in any of claims 2 to 16 or with the aid of a test kit claimed in claim 17 or with the aid of the biochip claimed in any of claims 18 to 23 and d) the effectiveness of the active substance is determined by comparing the results from a) and c).

26. A test kit for demonstrating the effectiveness of cosmetic or pharmaceutical active substances against skin stress and/or ageing of the skin in vitro comprising means for carrying out the test claimed in claim 25.

27. The use of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are defined i. by their Unigene Accession Number in Tables 1 to 4, column 7, or ii. by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9 or iii. by their 11-base tag sequence in Table 5 or in Table 7, column 2, for demonstrating the effectiveness of cosmetic or pharmaceutical active substances against skin stress and/or ageing of the skin.

28. A screening process for identifying cosmetic or pharmaceutical active substances against skin stress and/or ageing of the skin in vitro, characterized in that a) the status of the skin is determined by the process claimed in any of claims 2 to 16 or with the aid of a test kit claimed in claim 17 or with the aid of the biochip claimed in any of claims 18 to 23, b) a potential active substance against skin stress and/or ageing of the skin is applied one or more times to the skin, c) the status of the skin is re-determined by the process claimed in any of claims 2 to 16 or with the aid of a test kit claimed in claim 17 or with the aid of the biochip claimed in any of claims 18 to 23 and d) effective active substances are determined by comparing the results from a) and c).

29. The use of the proteins, mRNA molecules or fragments of proteins or mRNA molecules which are defined i. by their Unigene Accession Number in Tables 1 to 4, column 7, or ii. by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9 or iii. by their 11-base tag sequence in Table 5 or in Table 7, column 2, for identifying cosmetic or pharmaceutical active substances against skin stress and/or ageing of the skin.

30. A process for the production of a cosmetic or pharmaceutical preparation against skin stress and/or ageing of the skin, characterized in that a) active substances are determined by the process claimed in claim 28 or by the use claimed in claim 29 and b) active substances found to be effective are mixed with cosmetically and pharmacologically suitable and compatible carriers.

31. A cosmetic or pharmaceutical preparation against skin stress and/or ageing of the skin containing at least one nucleic acid construct which is capable of suppressing or reducing the activity of at least one of the proteins that are expressed more strongly in old or stressed skin than in young or unstressed skin or of inducing or strengthening the activity of at least one of the proteins that are expressed more strongly in young or unstressed skin than in old or stressed skin.

32. A preparation as claimed in claim 31, characterized in that the proteins(s) is/are preferably selected from those which are defined a) by their Unigene Accession Number in Tables 1 to 4, column 7, or b) by their UniGene Accession Number in Table 6 or 8, column 2, or by their Swissprot or TREMBL number in column 3 or by their EMBL/Genbank number in column 4 or by the name of the gene in Table 9 or c) by their 11-base tag sequence in Table 5 or in Table 7, column 2.

33. A preparation as claimed in claim 31 or 32, characterized in that the nucleic acid construct is selected from DNA, RNA or PNA.

34. A preparation as claimed in any of claims 31 to 33, characterized in that it contains about 1,000, more particularly about 10 to about 500, preferably about 10 to about 250, more preferably about 10 to about 100 and most preferably about 10 to about 50 different nucleic acid constructs.

35. A preparation as claimed in any of claims 31 to 34, characterized in that the nucleic acid construct is selected from protein-coding sequences, ribozymes, antisense nucleic acids, triple helix formers and rRNA.

36. A preparation as claimed in any of claims 31 to 35, characterized in that the nucleic acid construct is encapsulated in lipid vesicles, for example in liposomes, niosomes or transfersomes, preferably in liposomes.